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Resumo  
Uma das questões fulcrais da biologia do desenvolvimento continua a ser como 
é que uma única célula, o oócito fecundado, se desenvolve num ser tão 
complexo e especializado, com os tecidos e órgãos diferenciados e 
organizados em torno de três eixos, o anterior-posterior (AP), dorso-ventral 
(DV) e esquerdo-direito (LR).  
De um modo geral, o desenvolvimento embrionário humano pode ser dividido 
em três períodos: o primeiro, chamado de período zigótico, inicia-se com a 
fusão dos gametas masculino e feminino, formação do zigoto e termina com a 
implantação do blastocisto na parede do útero duas semanas após a 
fecundação. Durante o segundo período, ou período embrionário, que vai 
desde a terceira até à oitava semana de gestação, ocorre a gastrulação, com a 
formação e diferenciação dos folhetos embrionários (ectoderme, mesoderme e 
endoderme), e a formação dos órgãos e sistemas fisiológicos. O ultimo 
período, chamado fetal, vai desde o terceiro mês de gestação até ao 
nascimento e é caracterizado pelo crescimento do embrião, maturação e 
funcionalização das estruturas e órgãos.  
Durante o desenvolvimento do embrião, o coração é o primeiro órgão interno a 
ser formado e a tornar-se funcional de modo a bombear sangue por volta das 
três semanas de gestação, suprindo as necessidades do embrião e garantindo 
a sua sobrevivência. Na maioria dos vertebrados o desenvolvimento cardíaco 
segue o mesmo padrão de formação. O coração forma-se a partir de duas 
regiões cardíacas bilaterais que advêm de uma região progenitora comum na 
gastrulação, a mesoderme cardíaca. A mesoderme cardíaca recebe informação 
posicional dos três eixos embrionários, porém o efeito do eixo Esquerda-Direita 
(ED) tem recebido particular atenção. Os dois “pools” bilaterais de células 
precursoras cardíacas mesodermais migram para a linha média onde se juntam 
e dão origem ao crescente cardíaco. Este crescente cardíaco vai formar 
posteriormente um tubo cardíaco linear primordial. De seguida, este tubo 
alonga e sofre um processo de “looping” para a direita levando à formação dos 
ventrículos e aurículas. Subsequentemente, ocorre a diferenciação, 
especialização e septação das quatro camaras cardíacas e válvulas 
 x 
 
proporcionando as paredes necessárias para a separação física da circulação 
sistémica e pulmonar de sangue. Por último a formação do sistema de 
condução cardíaco e maturação dos cardiomiócitos, culminam na formação de 
um coração inteiramente funcional. 
As doenças cardíacas congénitas (DCC) são a manifestação clínica de 
problemas durante o desenvolvimento embrionário do coração. Esta doença é 
a forma mais comum de defeito à nascença, ocorrendo em cerca de 8 em 1000 
nados vivos, bem como a principal causa não-infeciosa de morte no primeiro 
ano de vida. Na maioria dos casos (80%), esta doença tem origem 
desconhecida e manifesta-se isoladamente em doentes não sindrómicos e não 
seguindo os padrões de hereditariedade definidos por Mendel, sendo 
considerada uma doença complexa com origem multifatorial. Esta 
complexidade advém do facto de a doença em muitos casos se apresentar 
geneticamente heterogenica, com penetrância reduzida e expressividade 
genética variável. Para além disso, fatores de risco ambientais foram também 
identificados como contribuído para o risco de desenvolver a doença. Nos dias 
de hoje, um modelo envolvendo tanto fatores genéticos como a interação 
genes-ambiente, é a explicação mais plausível para as altas frequências 
verificadas para a doença cardíaca congénita. 
Nos últimos anos, vários esforços foram feitos de modo a se compreender os 
mecanismos moleculares que levam a uma má formação do coração. Estes 
estudos, usando principalmente animais modelo e genética molecular humana, 
da morfogénese do coração e dos primeiros passos da determinação do eixo 
de simetria esquerdo-direito durante a embriogénese, indicam que na maioria 
dos casos de distúrbios de lateralidade é observada uma malformação 
cardíaca complexa, sugerindo que as DCC podem dever-se a defeitos de 
lateralidade na morfogénese do coração.  
Uma das redes regulatórias por detrás do estabelecimento do eixo esquerdo-
direito é a via de sinalização Nodal, um fator de crescimento da família TGF-b, 
que é expresso assimetricamente do lado esquerdo do nó e placa lateral 
esquerda da mesoderme de ratinho. Os fenótipos cardíacos de ratinhos 
geneticamente modificados para desativar a sinalização de nodal ou a sua 
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regulação, demonstraram que o desenvolvimento cardíaco depende vivamente 
do estabelecimento do eixo E-D embrionário. Para além disso, foram 
identificadas variantes genéticas em genes envolvidos na via de sinalização 
Nodal em doentes com DCC. 
O nosso laboratório identificou um membro da família Cerberus/DAN, o gene 
Cerberus-like2 (Cerl2), que é assimetricamente expresso no lado direito do nó 
em ratinho. O gene Cerl2 codifica para uma proteína secretada capaz de se 
liga diretamente a Nodal, inibindo a sua via de sinalização. Na presença de 
Cerl2 a atividade da via de sinalização Nodal restringe-se apenas ao lado 
esquerdo do embrião, o que culmina com uma morfogénese normal dos órgãos 
do abdómem. Ratinhos knock-out para o gene Cerl2, em que o gene Nodal 
passa a poder ser expresso e induzir a sua cascata de sinalização em ambos 
os lados da placa lateral da mesoderme, revelaram uma ampla gama de 
defeitos de lateralidade - situs inversus, isomerismos e heterotaxia - e 
malformações cardíacas - formação incompleta das aurículas, defeitos no 
septo ventricular, falha na rotação das principais artérias (transposição das 
grandes artérias, ventrículo direito de dupla saída), looping cardíaco anormal 
(randomizado), posicionamento do ápex cardíaco e hipertrofia ventricular - o 
que nos levou a suspeitar que alterações neste gene poderiam estar 
associadas a doenças de lateralidade e/ou casos isolados de doenças 
cardíacas congénitas. 
Dado que as vias genéticas que regulam o desenvolvimento cardíaco em 
ratinhos e humanos são conservadas, o principal objetivo desta tese foi o 
estudo de alguns dos genes homólogos humanos envolvidos na via de 
sinalização Nodal, com principal foco no gene DAND5, homólogo humano de 
Cerl2, mapeado no cromossoma 19, região 19p13.2, mas também verificando a 
existência de variantes nos genes NODAL, PITX2C e CFC1 numa cohort de 
doentes com defeitos cardíacos congénitos com origem em perturbações do 
eixo esquerdo-direito.   
A análise dos resultados da sequenciação de DNA do gene DAND5 permitiu-
nos identificar dois doentes com a mesma variação. Clinicamente, um dos 
doentes apresenta um fenótipo de defeito no septo ventricular com aorta 
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conectada aos dois ventrículos, atresia pulmonar e isomerismo esquerdo. O 
outro doente apresenta um caso extremo de tetralogia de Fallot (defeito no 
septo ventricular com aorta conectada aos dois ventrículos, hipertrofia do 
ventrículo esquerdo e atresia pulmonar). A variante, identificada nos dois 
doentes como heterozigótica, leva à substituição de um nucleótido guanina por 
uma adenina na posição 455 do exão 2, resultando na substituição de um 
aminoácido arginina por uma histidina (p.R152H) numa região altamente 
conservada e funcionalmente importante da proteína DAND5. De modo a 
entendermos o potencial efeito da alteração p.R152H na proteína DAND5, 
fizemos um estudo in silico recorrendo a vários programas bioinformáticos. Os 
resultados dessas predições foram inconclusivos uma vez que 3 programas 
apontam para um possível efeito nefasto enquanto que outro programa sugere 
que a variante não tem qualquer efeito na proteína. Para clarificarmos a função 
desta proteína variante, avaliámos o seu efeito na regulação da via de 
sinalização Nodal recorrendo a um ensaio funcional de luciferase. O resultado 
obtido mostra uma diminuição substancial da função da proteína mutante 
comparada com a proteína wild-type.  
Embora os fenótipos dos doentes sejam muito semelhantes, não podemos 
fazer uma clara correlação do genótipo com o fenótipo pois a variante 
c.455G>A foi reportada em bases de dados publicas como variante de 
nucleótido único (rs45513495). Além disso, a mãe de um dos doentes é 
portadora da variante sem apresentar indícios de doença, sugerindo uma 
penetrância incompleta, expressividade genética variável ou o efeito de fatores 
ambientais. Estas observações estão de acordo com a complexidade das 
doenças cardíacas congénitas e/ou defeitos de lateralidade e podem refletir a 
acção de variantes modificadoras ou outras variantes genéticas na via de 
sinalização que podem exacerbar ou atenuar o efeito da variante p.R152H na 
proteína DAND5 e nos fenótipos dos doentes. Portanto, nós propomos que 
esta variação no gene DAND5 pode ser um alelo de risco para o 
desenvolvimento de DCC e/ou defeitos de lateralidade.  
Por esta razão, decidimos levar a cabo uma busca de possíveis alterações em 
genes que fazem parte desta cascata Nodal. Foram assim identificadas uma 
nova alteração na zona codificante do gene CFC1, sem efeito funcional 
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aparente, e quatro polimorfismos, um na zona codificante e outro no intrão do 
gene NODAL e dois na zona não codificante do gene PITX2C em doentes com 
uma vasta gama de defeitos. Tendo em conta a análise levada a cabo por um 
programa bioinformático que permite analisar se alterações genéticas podem 
afetar o processo de splicing, nós verificamos que de facto, as variantes 
genómicas encontradas fora das zonas codificantes dos genes NODAL e 
PITX2C podem resultar em moléculas de RNA mensageiro anormais, 
principalmente devido à criação ou disrupção de locais para a ligação da 
maquinaria de splicing. Quanto à variante na zona codificante do gene NODAL, 
esta encontra-se no exão 2, e leva à substituição do aminoácido Histidina por 
uma Arginina na posição 165 (p.H165R). Esta variante já tinha sido reportada 
em dois estudos de 2008/2009 nos quais os autores verificaram, recorrendo a 
um ensaio funcional de lucifarese, que a variante leva à redução da atividade 
da proteína NODAL e parece atuar como variante modificadora e como fator de 
risco quando associada a outras possíbeis alterações em genes da via Nodal, 
com os quais este normalmente interage. 
Para além disto, e com o objetivo de modelar a doença e estudar os 
mecanismos moleculares por de trás de uma simples variação num nucleótido, 
geramos células estaminais induzidas de um dos doentes com a variante no 
gene DAND5. Estas células foram caracterizadas, apresentado uma 
morfologia, expressão de marcadores pluripotentes e cariotipo normais.   
Em conclusão, embora não possamos fazer uma correlação dos genótipo-
fenótipo, nem classificar as alterações identificadas neste estudo como alelos 
associadas a doença por si, estas variantes, podem, no entanto, aumentar a 
suscetibilidade para o desenvolvimento de DCC e/ou defeitos de lateralidade. 
Uma vez que a maioria dos doentes apresenta mais do que uma das variantes 
no seu genoma, o efeito cumulativo de cada variante na via parece aumentar 
ainda mais o risco para desenvolver doença. Portanto, o desequilíbrio dos 
níveis adequados da via de sinalização Nodal, em ambos os lados da placa 
lateral da mesoderme, devido a uma ou várias variantes nos seus 
componentes, é um denominador comum para defeitos de lateralidade e/ou 
doenças cardíacas congénitas. 
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Abstract  
The majority of congenital heart disease (CHD) is sporadic, with a minority of 
cases associated with a known genetic abnormality. Combinations of genetic-
environmental factors are implicated in the etiology of the disease. Recently, 
several studies, using mostly animal models, unraveled that perturbations in the 
molecular processes that precede the beginning of heart development might 
also be at the origin of CHD. In fact, some of the most complex CHDs are found 
associated with laterality defects, a disorder resulting from abnormal Left-Right 
axis formation. In our laboratory, the identified mouse Cerberus-like2 (Cerl2 – 
human DAND5), a protein that inhibit Nodal signaling, prompt us to study 
cardiac and laterality diseases, since the generated Cerl2 KO mice display a 
wide range of laterality defects and CHD. Considering the high conservation of 
genetic pathways regulating cardiac development in mouse and human, the 
main objective of the present thesis was the study of human genes involved in 
the Nodal pathway, focusing mostly in DAND5, in a CHD and/or laterality 
defects patients cohort. The sequence analysis of DAND5 revealed two patients 
displaying the same p.R152H variant, resulting in a substantial decreased in the 
function of the protein. We propose that p.R152H acts as a risk allele for CHD 
and/or laterality defects. In addition, we found two alterations in NODAL, two 
alterations in PITX2C and one alteration in CFC1. We hypothesized that the 
NODAL p.H165R variant can act as a common modifier and the intronic 
variants in NODAL and PITX2C might cause alterations in the splicing pattern of 
the mRNA molecules. Moreover, we generated patient-specific iPSCs to 
understand the molecular mechanisms of disease behind the DAND5 
nucleotide variant. Although we cannot make a clearly genotype-phenotype 
correlation, the variants here identified probably increase the disease 
susceptibility due to the resulting abnormal Nodal signaling. Because most of 
the patients presented more than one alteration, the cumulative effect of each 
variant within the pathway seems to enhance even more these risk. Therefore, 
the imbalance in dosage-sensitive Nodal signaling is a common denominator for 
laterality defects and associated CHDs.  
Keywords: DAND5, Congenital Heart Diseases, Laterality defects, Nodal 
signaling, allelic variations, Disease modeling, iPSCs. 
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1. The primordium of life 
Human prenatal development starts at the time of fertilization and can be 
divided into three different periods, blastocyst or zygotic period; embryonic 
period and fetal period (Cochard & Netter, 2002). The zygotic period, which 
comprises the first two weeks of gestation, is a period of cell proliferation and 
leads to implantation of the blastocyst into the uterine wall. Through the 
embryonic period (third to the eighth week of gestation), the gastrulation occurs 
and most of the important organs and physiological systems develop. At this 
time, the embryo assumes a human appearance. The fetal period extends from 
the third month until birth. It is a period of growth, maturation and 
functionalization of the structures and organs. During these time course periods, 
the initial fertilized egg undergoes a systematic series of sequential changes to 
become increasingly complex, differentiated and ultimately giving rise to a fully 
developed human organism.  
 
1.1. Early embryogenesis 
Conception or fertilization is the fusion of a male spermatozoid with a female 
oocyte.  This process, which normally occurs in the upper part of the uterine 
tube, marks the beginning of the human development and leads to the 
formation of a genetically unique and specialized cell, the zygote (Moore, 
Persaud, & Torchia). Immediately after fertilization, this newly formed totipotent 
cell makes its way to the uterus, a journey that takes five to seven days in 
humans. As it travels, the zygote undergoes a series of repeated mitotic 
divisions, called cleavages. Cleavage divisions result in a rapid increase in the 
number of cells that also become smaller with each division and are at this time 
called blastomeres. The blastomeres continue to divide and as the developing 
human enters in the uterus, by approximately three days after fertilization, it 
undergoes a compaction phenomenon leading to the formation of a 16-cell 
morula (Carlson, 2014; Moore et al.).  
Posteriorly, by day four, a fluid starts to penetrate into the intercellular spaces of 
the morula and progressively forms a single blastocyst cavity. As the fluid 
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continues to increase into the blastocyst cavity, it separates the blastomeres 
and we can differentiate two groups of cells (Moore et al.). At this time, the 
embryo is a hollow ball of hundreds of cells, called blastocyst, with an internal 
mass of cells, the inner cell mass (ICM) or embryoblast, at one pole of the 
blastocyst, and an outer cell layer that forms the epithelial wall of the blastocyst, 
the trophoblast. The trophoblast will form the extraembryonic structures and the 
fetal component of the placenta whereas the cells of the ICM are pluripotent 
stem cells that can give rise to all cell types of the three embryonic germ layers, 
i.e., Ectoderm, Mesoderm, and Endoderm, and the Germ Cell Lineage, as well 
as to the non-trophoblast tissues (Yolk sac, Allantois, and Amnion) that support 
the developing embryo (Carlson, 2014; Moore et al.; Schoenwolf et al.).  
Around day six of development, the 150 micrometers sized embryo starts to 
invade the endometrial epithelium and by the end of the second week of human 
gestation the blastocyst is completely implanted in the endometrium (Cochard & 
Netter, 2002; Moore et al.). As implantation proceeds, the trophoblast 
proliferates quickly and differentiates into the cytotrophoblast, an inner actively 
proliferating layer, and into the syncytiotrophoblast, which erodes the 
endometrial tissues, whereas the blastocyst changes morphologically resulting 
in a flat bilaminar plate of epithelial cells, the embryonic disc. This bilaminar 
embryonic disc consists of an upper layer of columnar cells, the epiblast, and a 
lower layer of cuboidal cell, the hypoblast or primitive endoderm. The epiblast 
contains the pluripotent cells that will form the three germ layers and the 
hypoblast will give rise to the yolk sac (Carlson, 2014; Moore et al.; Schoenwolf 
et al.). The formation of the bilaminar embryonic disc marks the appearance of 
the first axis in the embryo, the primitive dorsal-ventral axis with the epiblast 
defining the dorsal side and the hypoblast defining the ventral side of the 
embryo (Carlson, 2014; Moore et al.; Schoenwolf et al.). 
At the start of the third week of human development, the cells of the embryonic 
epiblast begin to differentiate in a process known as gastrulation – formation of 
the three germ layers. This process, which marks the beginning of 
morphogenesis (creation of body shape), initiates between days fourteen and 
sixteen after fertilization and at this stage the embryo is known as gastrula 
(Schoenwolf et al.). The first morphological sign of gastrulation is the formation 
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of a longitudinal midline structure, the primitive streak (PS), on the surface of 
the epiblast, near the caudal end of the bilaminar embryonic disc (Moore et al.). 
This structure results from the proliferation and movement of the epiblast cells 
to the median plane of the embryonic disc. As the primitive streak elongates by 
the addition of cells to its caudal end, its cranial end proliferates to form the 
primitive node or Hensen’s node (Moore et al.). The primitive node contains a 
circular depression called the primitive pit, which is continuous caudally down 
the midline of the primitive streak with a trough like depression called the 
primitive groove (Carlson, 2014). This groove results from the invagination 
movement (inward movement) of cells from the epiblast through the primitive 
streak, a process called ingression (Schoenwolf et al.). 
Shortly after the primitive streak appears, cells from the epiblast move toward 
the primitive streak, ingress in this structure and then migrates, in a temporal 
and spatial well-defined sequence, into the interior of the embryonic disc, to 
form two new germ layers. During this process, the cells change their structure 
and organization, undergoing an epithelial-mesenchymal transition (EMT). 
While in the epiblast they present the typical properties of epithelial cells, i.e. 
closely connected, well-defined apical and basal surfaces, expression of E-
cadherin, when they become free of the epiblastic layer in the primitive groove, 
they assume the morphology and characteristics of mesenchymal cells (spindle-
shaped morphology, expression of N-cadherin instead of E-cadherin), which are 
able to migrate as individual cells if provided with the proper extracellular 
environment (Carlson, 2014). 
The first epiblast cells to ingress in the primitive streak invade the hypoblast, 
displacing its cells and replacing them with a layer of definitive endoderm. 
Others epiblast ingressing cells remain there and organize into the space 
between the epiblast and definitive endoderm to form a third germ layer – the 
intraembryonic mesoderm. As soon as the definitive endoderm and 
intraembryonic mesoderm are formed, epiblast cells no longer migrate toward 
the PS nor ingress through it. This remaining epiblast cells now constitutes the 
last germ layer, the ectoderm (Carlson, 2014; Moore et al.; Schoenwolf et al.). 
The embryonic ectoderm gives rise to peripheral and central nervous systems, 
the epidermis, hair, nails, sensory epithelia of eyes, ears and nose, many 
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Figure 1.1 – Summary of the first three week of human development.  
During the first two weeks of gestation, the initial zygote embraces a period of cell proliferation that 
culminates with the implantation in the uterine wall and appearance of a bilaminar embryonic disc 
consisting of the epiblast and hypoblast. During the third week, gastrulation occurs and the bilaminar 
embryonic disc was converted in a three-layered disc, composed of ectoderm, endoderm and 
mesoderm. 
connective tissues of the head, some glands and neural crest cells, which 
contribute to the formation of many organic systems (Moore et al.; Schoenwolf 
et al.). Embryonic endoderm is the source of the epithelial linings of the 
digestive and respiratory tracts, auditory tube, urinary bladder and most of the 
urethra. It also contributes to the parenchyma of the liver, pancreas thymus, 
thyroid and parathyroid glands (Carlson, 2014; Gilbert, 2010; Moore et al.; 
Schoenwolf et al.). Embryonic mesoderm gives rise to striated and smooth 
muscles, blood cells, blood vessels lineage, serosal linings of all body cavities, 
ducts and organs of the reproductive and excretory systems, and most of the 
cardiovascular system. It is the source of all connective tissues, including 
cartilage, bones, tendons, ligaments, dermis, and stroma (connective tissue) of 
internal organs, excluding the head and limbs (Carlson, 2014; Gilbert, 2010; 
Moore et al.; Schoenwolf et al.). By the end of the third week, the process of 
gastrulation is completed and the bilaminar embryonic disc was converted into a 
flat three-layered disc, composed of ectoderm, endoderm and mesoderm that 
will give rise to all the tissues and organs of the embryo. Furthermore, 
gastrulation is responsible for the definition of all major body axes through the 
formation of a temporary structure called the primitive streak. The primitive 
streak establishes a visible longitudinal axis of bilateral symmetry around which 
all embryonic structures will organize and align.  
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2. Patterning the embryo – Left-Right Axis Specification 
2.1. Anterior-posterior and dorsal-ventral axis 
As three-dimensional objects, all vertebrate and invertebrate organisms present 
three different body axes, the anterior-posterior (AP) axis, the dorso-ventral 
(DV) axis and the left-right (LR) axis. The formation of these axes however 
varies from species to species. Whereas in fish and frog the dorso-ventral and 
anterior-posterior axes are determined at fertilization by the distribution of the 
yolk and the entry position of the sperm (Gilbert, 2010), in mouse and human, 
when the embryo implants into the wall of the uterus it is still symmetric without 
any axe. In these embryos, as embryogenesis proceeds, the DV axis is 
specified as the proximal-distal axis from the implantation site. Subsequently, 
the AP axis is arbitrarily determined in the plane perpendicular to the DV axis 
(Alarcon & Marikawa, 2003; Beddington & Robertson, 1999). So, after 
implantation, the future AP axis is marked anteriorly by the polarization of the 
head primordium and posteriorly (tail) by the appearance of the primitive streak, 
while the prospective DV axis is defined by the formation of the three germ 
layers, the endoderm marking its ventral side and the ectoderm being dorsal 
(Hamada & Tam, 2014; Hirokawa et al., 2009).  
 
2.2. Left – right asymmetry 
Theoretically, in a three-dimensional structure, once the orientation of two 
orthogonal axes is acquired, the orientation of a third axis would be spatially 
delineated by default (Hamada & Tam, 2014). This axiom of geometry seems to 
fit to the formation of the three body axes.  
During development, once the AP and DV axes are established, it is argued that 
the LR axis is consistently oriented relative to the dorsal–ventral and anterior–
posterior axes (Hashimoto & Hamada, 2010). Although many insights had been 
made regarding the generation of the anterior-posterior and dorsal-ventral axes, 
much remains to be understood about how the LR axis is consistently oriented 
with respect to the other two and what are the molecular mechanisms 
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underlying the process of LR asymmetry generation (Vandenberg & Levin, 
2012). In the past 25 years, this process has been extensively studied and 
many genes and pathways were uncovered.  Nonetheless, the precise 
mechanisms have not been determined making difficult to conceptualize 
therapeutic or preventative approaches (Amack, 2014). 
In the next pages, I will provide a review about the current knowledge of how 
left-right symmetry is established in animal models. Resuming the agreements 
and disagreements in the field and the proposed models to explain how by 
breaking the bilateral symmetry and creating LR differences in the body plan, 
the initial symmetric embryo is transformed into a complex organism, externally 
bilateral symmetric and internal asymmetric.   
 
2.2.1. The three main steps 
The establishment of left-right (LR) asymmetry during early embryogenesis is 
critical for the organization of the embryo body plan and for the correct 
positioning and morphogenesis of the internal organs (Shiratori & Hamada, 
2014). There is a general agreement in the field that the process by which this 
LR asymmetry is generated requires and can be divided in three different main 
phases/steps (Figure 1.2): In the first step, there is a breaking of the initial 
bilateral symmetry, allowing that the LR axis is consistently oriented relative to 
the dorsal-ventral and anterior-posterior axes. The second step consists in the 
transference of an LR-biased signal (or signals) to the lateral plate mesoderm 
(LPM), which leads to differential gene expression of signaling molecules in cell 
fields on either side of the midline. In the third step, this asymmetric gene 
expression of signaling molecules drives changes in cell behavior, such as 
proliferation and migration rate, which lead to the LR asymmetric position and 
morphogenesis of the internal organs (Shiratori & Hamada, 2006, 2014; 
Vandenberg et al., 2013; Vandenberg & Levin, 2013). In the last years, this 
process has been extensively studied to decipher the molecular mechanisms 
underlying these three steps of left-right asymmetry establishment. These 
studies revealed a general agreement between researchers regarding the main 
molecular pathways involved in steps two and three, decoding that these 
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Figure 1.2 – General process of LR asymmetry generation. 
Generation of LR asymmetry comprises 3 steps. In the first one, LR axis is oriented relative to the DV 
and AP axes due to the action of an asymmetric signal. The second steps involve the transference of 
this signal to the LPM and differential genetic expression on either side of LPM. The last step relay on 
the LR asymmetric position and morphogenesis of the internal organs. 
(Adapted from: (Vandenberg, Lemire, & Levin, 2013)) 
Step 1 – Symmetry breaking 
 LR axis consistently oriented relative 
to the dorsal-ventral and anterior-
posterior axes. 
Step 2 – Amplification and transmission of 
a left–right-biased signal to LPM 
Differential genetic expression on either 
side of LPM. 
Step 3 – situs-specific 
morphogenesis 
LR asymmetric position and 
morphogenesis of the internal 
organs.  
Step 2  
Step 3  
cascades are highly conserved from sea urchin to mouse (Nakamura & 
Hamada, 2012). In contrast, the origin of the symmetry-breaking event (first 
step) is controversial because no unifying mechanism between model 
organisms has been identified to date and it seems that this process has 
diverged during evolution (Nakamura & Hamada, 2012; Sauer & Klar, 2012).  
 
 
 
 
 
 
 
 
 
 
2.2.1.1. Models for symmetry breaking (first step) 
The mechanism beyond the process of symmetry breaking was put in debate 
with the conceptual F-molecule model (Figure 1.3) proposed by Brown and 
Wolpert in the nineties (Brown & Wolpert, 1990). In their analysis, they 
postulated that a symmetric embryo must distinguish is left from its right side 
after the establishment of the anterior-posterior and dorsal-ventral axis, by 
consistent orientation of an intracellular component that is chiral by virtue of its 
biochemical structure (Vandenberg & Levin, 2013). This “F-molecule” would 
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have three arms and when two arms are aligned with the preexisting axis, the 
third arm would be automatically aligned along the future LR axis (Brown & 
Wolpert, 1990; Hashimoto & Hamada, 2010; Vandenberg & Levin, 2013). 
Therefore, in the field, there is an agreement about the need of an “F” molecule 
for the origin of asymmetry prior asymmetric transcriptional events. However, 
there is considerable debate on some major issues: what is the chiral element 
that first breaks symmetry? When during embryogenesis is asymmetry 
initiated? How conserved across diverse species are these mechanisms, and 
which model systems best represent the “general case”?(Vandenberg et al., 
2013; Vandenberg & Levin, 2013). In recent years, two models, which are 
cytoskeleton-dependent and whose mechanism of action fulfill the chiral “F” 
molecule hypothesis proposed by Brown and Wolpert, were identified and 
debated. One model predicts that unidirectional cilia-driven extracellular fluid 
flow (nodal flow), produced on the LR organizer, during gastrulation, is the 
origin of LR asymmetry, whereas the second model – intracellular model – 
postulates that LR asymmetry originates during very early developmental 
stages due to the chiral nature of the cytoskeleton (Levin, 2003, 2004; 
Vandenberg et al., 2013; Vandenberg & Levin, 2013). Although both 
mechanisms implicate the cytoskeleton, as the cilium is effectively a 
microtubular extension of the cytoskeleton, and lead to asymmetric Nodal 
activity (May-Simera & Kelley, 2012), they act at two very different 
developmental stages and seem to have less in common. Here, I will introduce 
only the first model. 
 
 
 
 
 
 
 
Figure 1.3 – “F” molecule model. 
(A) The chirality of a molecule (schematized by an F) tethered with respect to the other axes can 
orient the direction of the LR axis. (B, C) Three-dimension representation of how an “F” molecule 
allows each cell to know which direction is left and which is right. 
(Adapted from: (Levin, 2004)) 
 
 
R L 
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2.2.1.1.1. The leftward flow model 
In some mammals (mouse, rabbit and humans), fish and amphibians the LR 
symmetry seems to be broken by the action of rotating cilia in a pit like structure 
called the “embryonic node” in mouse, “Kupffer’s vesicle’’ in zebrafish, and 
‘‘gastrocoel roof plate’’ in frogs (Shiratori & Hamada, 2006; Yoshiba & Hamada, 
2014; S. Yuan, Zhao, Brueckner, & Sun, 2015).  The mouse node (Figure 1.4A), 
formed during gastrulation, is a transient small triangular structure with 50–100 
μm in width and 10–20 μm in depth, located between the anterior notochord 
and the primitive streak in the ventral midline of the embryo (Hamada & Tam, 
2014; Hirokawa et al., 2009).  There are two types of cells in this cavity, the 
node pit cells, which are columnar epithelial cells located in the central region of 
the ventral node and the crown cells, squamous epithelial cells located on the 
edge of the node (Yoshiba & Hamada, 2014). Although both cell types present 
monocilia that project into the extraembryonic space, the crown cells have in 
most of the cases (90%) immotile cilia that are believed to sense the nodal flow, 
whereas, most of pit cells possess motile rotating cilia which are responsible for 
the generation of the asymmetric left-directed flow of extracellular fluid (nodal 
flow) in the node cavity (Figure 1.4B) (Hirokawa, Tanaka, & Okada, 2012). 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 – Node structure and cilia microtubules organization. 
A) Scanning electron microscope of a mouse node at 7.5 days postcoitum. B) Direction of the leftward 
fluid flow across the ventral node. Motile cilia are located at the central region of the node, while 
immotile cilia are present at the periphery of the node cavity (marked by dashed lines). C) Normal cilia 
with nine pairs of 9+2 arrangement microtubules connected with dynein motors. D) The central pair of 
microtubules is missing in immotile primary cilia and nodal cilia. In nodal cilia, the dynein motors 
remain in a chiral arrangement and produce a rotation-like movement (arrows). (Adapted from: 
(Hamada & Tam, 2014; Hirokawa, Tanaka, & Okada, 2009)) 
 
A) B) 
C) D) 
Left Right 
A) B) 
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2.2.1.1.1.1. Cilia and the generation of the 
unidirectional leftward flow 
Normal motile ciliated cells present an axoneme composed of nine pairs of 
double microtubules arranged longitudinally along the axes and a pair of 
microtubules, referred as central pair, in the center of the cilia (9+2 
arrangement) (Figure 1.4C) (Hirokawa et al., 2009). This central pair of 
microtubules, which defines the direction of the beating plane, is absent in the 
axoneme of immotile cilia cells and nodal cells. Thus, based on the microtubule 
arrangement (9+0) (Figure 1.4D), the node monociliated cells were thought to 
lack motility (Hirokawa et al., 2009). However, in 1998, Nonoka and co-workers 
examined the behavior of these monocilia using video-light microscopy. They 
discovered, for the first time, that the monocilia presented in the mouse node 
are motile but instead of move back and forth, like most motile cilia or flagella, 
they rotate vigorously at approximately 600rpm (Nonaka et al., 1998). 
Furthermore, when they added fluorescent beads in the extraembryonic fluid at 
the node region of wild-type embryos, they verify that the cilia of these cells 
rotate in a clockwise direction, generating a leftward (right-to-left) flow of fluid in 
the node cavity, which they designated nodal flow (Takeda et al., 1999) (Figure 
1.5A). Okada also supported this hypothesis in 1999, by the analysis of node 
monocilia motility of inversus viscerum (iv) mutant mice, which harbors a 
mutation in the axonemal dynein protein Dnah11 (Lrd) gene. These results 
confirmed that the monocilia of heterozygous iv mutant embryos also rotates as 
fast as the wild-type embryo (~600rpm) and this movement can also generate a 
leftward flow of extraembryonic fluid in the node cavity. In contrast, in the iv 
mutant homozygous mice, the cilia are almost immotile and the flow absent 
(Okada et al., 1999), suggesting that in fact cilia are the responsible for the 
generation of the nodal flow.  
But how and why is the flow generated in a leftward direction by the rotational 
movement of the motile monocilia? The answers to these questions rely in the 
posterior position of the basal body of each cilium, which lead to a posterior 
tilting of the cilia in the node cells. High-speed video microscopy observation 
revealed that the node cilia do not project vertically from the node cells, but they 
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are tilted posteriorly at an average angle of 30°- 40º (Nonaka et al., 2005), 
which allows the cilia to orient along the anterior‐posterior and dorsal‐ventral 
axes, as the F-molecule model proposed by Brown and Wolpert. These 
observations also revealed that a rightward rotational movement of the cilium 
occurs close to the cell surface, whereas a leftward motion is away from the 
surface (Hirokawa et al., 2009). Based on this, hydrodynamic principles predict 
that the shear resistance of the cell surface slows the rightward swing, but 
leaves the leftward stroke unimpeded to generate a leftward fluid flow, leading 
to a more efficient sweep of the cilia towards the left as opposed to the right 
(Okada, Takeda, Tanaka, Izpisua Belmonte, & Hirokawa, 2005). However, 
these observations do not explain the posterior tilting of the cilia. This tilting 
could be explained by the convex curvature of the apical membrane of the node 
cells and the shifting in the position of the basal body (Figure 1.5B), which 
seems to be related with planar cell polarity (PCP). Indeed, some core PCP 
components, like Dishevelled (Dvl), Van Gogh like 1 (Vangl1) and Prickle2 have 
polarized subcellular localizations (Figure 1.5B) in the node cells and knockout 
mice for these components result in disrupted posterior position of nodal cilia, 
abnormal nodal flow and LR defects (Hirokawa et al., 2012; Yoshiba & Hamada, 
2014). Thus, the posterior positioning of the basal body, ensued from a 
mechanism of PCP, results in the posterior tilting of the cilia, which in turn is 
responsible for the generation of a unidirectional leftward flow that disrupts the 
initial LR symmetry in the mouse embryo.  
 
 
 
 
 
 
 
 
A) 
B) 
Node cells 
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2.2.1.1.1.2. Sensing the flow – morphogen/    
chemosensor model 
It is widely accepted that while central cilia of pit cells are mostly motile and 
generate the nodal flow, peripheral cilia of crown cells are mostly immotile and 
act as sensors of the fluid flow. However, how these cells at the edge of the 
node sense the flow is still debated. Two main model hypotheses have evolved 
to answer to this question. One hypothesis, termed “morphogen gradient” or 
chemosensor model, was firstly proposed by Nonaka and colleagues in 1988 
(Figure 1.6A) (Nonaka et al., 1998). This model assumes that signaling 
morphogens, with sizes between 20-40 kDa, like Sonic Hedgehog (Shh), 
Fibroblast growth factor (FGF), Retinoic Acid (Ra) or Nodal are secreted into 
the node cavity and transported, due to the action of the unidirectional nodal 
flow, towards the left side of the embryo, where they bind to cell surface 
receptors and initiate a signaling cascade (Hirokawa, Tanaka, Okada, & 
Takeda, 2006). This stationary asymmetric accumulation of a determinant 
morphogen triggers signaling events that cement the asymmetry in the 
developing embryo. Although simple and straightforward, this hypothesis is 
questionable whether nodal flow can generate a chemical gradient in a closed 
cavity of node, where the leftward flow is balanced by the rightward counterflow 
(Hirokawa et al., 2006). Furthermore, what is the identity of the morphogen 
itself? 
 In a more sophisticated version of the chemical model (Figure 1.6B), the 
authors observed flowing materials, named nodal vesicular parcels (NVPs) 
(Hirokawa et al., 2012) that are released from slowly growing filopodia-like 
processes in all regions of the ventral node into the extracellular fluid flow, 
fragmented by contacting rotational cilia and finally absorbed by left-sided node 
cells (Hirokawa et al., 2012). Furthermore, pharmacological studies suggest that 
FGF, Shh and RA regulate the release of NVPs and that NVPs seem to carry 
Figure 1.5 – Leftward nodal flow in the ventral node and posterior tilting of cilia. 
A) Unidirectional leftward flow (blue) is generated by the clockwise rotation of nodal cilia due to the 
posteriorly tilting of these cilia. B) Posterior tilting of cilia result from the posterior position of the basal 
body, which seems to be related with the subcellular localization of some core planar cell polarity 
molecules, Dishevelled, Van Gogh like 1 and Prickle2. Adapted from: (Yoshiba & Hamada, 2014). 
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Figure 1.6 – The two versions of the “morphogen gradient”/chemosensor model. 
A) First “morphogen gradient” model proposed by Okada and colleagues. In this model, a morphogen 
secreted into the node becomes asymmetrically accumulated on the left side due to the action of the 
nodal flow. Resulting thereby in symmetry breaking. B) Recent version of the “morphogen gradient” 
model propose that nodal vesicular parcels (NVPs) containing a morphogen are carried to the left side 
of the node by nodal the flow. These NVPs are then fragmented and absolved by left-sided node cells, 
resulting therefore in the breaking of symmetry. Adapted from: (Norris, 2012). 
the signal to elevate the calcium (Ca2+) concentration on the left side of the 
node, which in turn is thought to influence the asymmetric gene expression in 
adjacent cells (Hirokawa et al., 2006). Indeed, Shh and RA are unsheathed and 
transported in the NVPs but they are unlikely to be the molecular determinant of 
LR polarity because asymmetric expression of downstream Shh or retinoic acid 
response genes has not been detected in or near the mouse node.  
 
 
 
 
 
 
 
 
2.2.1.1.1.3. Sensing the flow – Two 
cilia/mechanosensor model 
An alternative to the chemosensor hypothesis is that the hydrodynamic force 
generated by the flow is mechanosensed in the responding cells, most likely the 
crown cells, in the peripheral region of the ventral node (McGrath, Somlo, 
Makova, Tian, & Brueckner, 2003). This model, named “two-cilia” model (Figure 
1.7), postulates that motile cilia at the center of the node produce an 
asymmetric left-directed flow of extracellular fluids detected by mechanical 
bending of a second non-motile group of cilia, which contain the Ca2+ 
permeable cation channel Polycystin-2 (Pkd2) exclusively on the left edge of the 
A) 
B) 
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node. This results in the elevation of intracellular Ca2+ and leads to subsequent 
asymmetric patterns of gene expression (Hamada & Tam, 2014; McGrath et al., 
2003; Yoshiba & Hamada, 2014).  
Some evidences are in agreement with this idea, the first comes from kidney 
cells in which immotile cilia respond to flow-induced bending mechanical stress 
by initiating an influx of extracellular Ca2+ through mechanosensory complex 
channels (Pkd1/Pkd2 (Praetorius & Spring, 2001). Surprisingly, nodal cilia cells 
(motile and immotile) do not express Pkd1 and in its absence LR asymmetry is 
not disrupted (Karcher et al., 2005), suggesting that in nodal cells, Pkd2, which 
is thought not to be a sensory protein per se, will form a sensory complex with 
another partner. In fact, in mouse and fish cilia, Pkd2 physically interact and 
form a complex with a paralogue of Pkd1, Pkd1l1. Moreover, PKd1l1 is 
expressed in a pattern that corresponds spatially and temporally to the 
establishment of LR asymmetry and both proteins localize in motile and 
immotile cilia of the ventral node (Field et al., 2011; Kamura et al., 2011). So, in 
nodal cells, the same process of sensing the flow may occur via the flow-
sensing complex Pkd1l1/Pkd2, being Pkd1l1 the sensor and Pkd2 the effector. 
Second, asymmetric elevation of intracellular Ca2+ became randomized in iv 
mice (flow absent) and absent when Pkd2 was deleted (Babu & Roy, 2013). 
Moreover, rescues assays of the Pkd2 gene in specific regions of the Pkd2 
deficient mice revealed that Pkd2 expression is not necessary in pit cells, 
composed mostly of motile cilia, for correct LR development. However, correct 
LR development requires Pkd2 expression specifically in crown cells, where 
most immotile cilia are located, suggesting that Pkd2 function is needed in the 
immotile cilia to sense and respond to the flow (Norris & Grimes, 2012). Lastly, 
an elegant work by Hamada’s lab in Japan has provided proof of the sensory 
function of cilia in Nodal cascade induction. First, the authors verified that only 
two rotating cilia were required to establish normal sidedness. Second, they 
verified that artificially applied fluid flow was able to rescue the Nodal cascade 
in a mouse model of Kartagener syndrome, i.e. in embryos without flow due to 
immotile cilia, in a mechanism dependent on the calcium channel Pkd2.  
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Furthermore, rescue of Kinesin family member 3A (Kif3a) expression only in the 
crown cells of these animals, results in the generation of a weak leftward flow 
and Nodal expression in the LPM. These observations suggest that a weak and 
transient local flow produced by the few motile cilia crown cells and sensed by 
the neighboring immotile cilia cells is sufficient to initiate LR asymmetric gene 
expression.  
Although all the evidences mentioned above support the two cilia hypothesis, 
the bending of sensory cilia has not been verified by in in vivo observations and 
all the cilia in Kupffer’s vesicle of Medaka fish were directed visualized as motile 
cilia, expressing Lrd, Pkd1l1 and Pkd2 (Babu & Roy, 2013). Furthermore, 
inhibition of FGF signaling, which is involved in the release of NVP in the 
morphogen hypothesis, suppresses Ca2+ asymmetric intracellular elevation 
without disturbing the flow, suggesting that FGF signaling and NVPs are 
needed for the asymmetric distribution and consequent normal LR patterning 
(Tanaka, Okada, & Hirokawa, 2005). Therefore, these two mechanisms may not 
be mutually exclusive, but rather may run in parallel or work synergistically with 
each other. 
 
Figure 1.7 – “Two cilia” model. 
Motile cilia at the center of the node generate a leftward nodal flow that is detected by mechanical 
bending of immotile cilia cells in the left edge of the node. These cells contain the Ca2+ permeable 
channel Pkd2 and Pkd1l1 exclusively on the left edge of the node resulting in the elevation of intra 
cellular Ca2+ and subsequent asymmetric patterns of gene expression. Adapted from: (Yoshiba & 
Hamada, 2014). 
Flow Flow 
 18 
  
General Introduction Chapter 1 
2.2.1.1.1.4. Readouts of the nodal flow – the role of    
   Cerl2/DAND5  
Although the precise mechanism, chemical or mechanical, of how crown cells at 
the edge of the node senses the flow remains controversial, two main readouts 
of the flow on the crown cells of the left margin of the node have been reported. 
These are the elevation of intracellular Ca2+, most likely via Pkd1l1/Pkd2 
complex channels, and the elevation of the Nodal activity (Hirokawa et al., 
2012).   
Nodal activity/signaling (Figure 1.8) is triggered when the transforming growth 
factor beta TGF-β family ligand Nodal binds to a target cell through interaction 
with type I (ALK4 and ALK7) and type II (ActRIIa and ActRIIb) serine-threonine 
kinase receptors in the presence of one EGF-CFC (epidermal growth factor-
Cripto-FRL1-Cryptic) family protein co-receptor, Cripto or Cryptic. This leads to 
the phosphorylation of regulatory Smads (Smad2 and Smad3), their association 
with Smad4 and translocation of this complex into the nucleus. In the nucleus 
this complex interact with the transcription factor FoxH1, which is the main 
responsible for transducing the Nodal signaling and activating downstream 
target genes like Nodal itself (auto regulation), Lefty2 and Pitx2 [15, 54]. Nodal 
signaling at the level of the node is inhibited by the Cerl2/Dand5 molecule, 
which asymmetric expression represents the most immediate molecular 
response to the flow in the crown cells of this embryonic left-right organizer 
(Hamada & Tam, 2014). DAND5, also known as Charon in fish, Coco in 
Xenopus and Cerl2 in mouse, belongs to the Cerberus/Dan family, encodes a 
20-kDa secreted growth factor with the ability to bind directly to Nodal and to 
inhibit its signaling pathway (Marques et al., 2004). The level of Cerl2 mRNA in 
crown cells is initially bilaterally equal (L=R) at early head-fold (EHF) stage 
(embryonic day 7.5), when the flow is very weak or not apparent.  However, as 
the velocity of nodal flow increases by late head-fold stage (LHF) (E7.75), the 
expression of Cerl2 in the left side began to decline in intensity 
(downregulated), giving rise to an L<R asymmetric expression pattern among 
the perinodal cells from 1-somite stage (E8.0) (Figure 1.9A) (Inacio et al., 2013; 
Kawasumi et al., 2011). 
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Figure 1.8 – Nodal Signaling. 
In the absence of Lefty and Cerl2, Nodal-GDF1 bind type I and type II receptor in conjunction with the 
co-receptor, EGF-CFC protein. This leads to cross-phosphorylation of receptor I and II and 
subsequently to phosphorylation of a receptor-regulated SMAD (Smad2/3), allowing this protein to 
associate with Smad4. This complex moves into nucleus, associates with a DNA-binding partner 
(FoxH1), binds to specific enhancers in targets genes, and activates their transcription. Adapted from: 
(Arnold & Robertson, 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
This L<R asymmetry of Cerl2 mRNA is regulated at post-transcriptional level by 
the degradation of Cerl2 mRNA via its 3’UTR (untranslated region) in response 
to the leftward flow (Nakamura et al., 2012). This initial L<R bias in Cerl2 
expression is subsequently amplified by the Wnt-Cerl2 feedback loop, in which 
Wnt3 up-regulates Wnt3 expression and promotes Cerl2 mRNA decay whereas 
Cerl2 promotes Wnt3 degradation (Nakamura et al., 2012).  
Furthermore, a recent study by Sun Brueckner and co-workers, in 2015, 
revealed another possible important mechanism involved in the left 
downregulation of Dand5/Cerl2. In this study, the authors recorded highly 
dynamic intraciliary calcium oscillations (ICOs), which coincide with the onset of 
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cilia motility, in response to leftward flow, predominantly on the left side of 
zebrafish Kupffer’s vesicle (S. Yuan et al., 2015). These oscillations were 
dependent on Pkd2 and cilia motility, and were followed by cytoplasmic calcium 
asymmetries in the same left-right organizer (LRO) and in neighboring cells, i.e. 
en route to the lateral plate mesoderm, the site of Nodal cascade induction. 
Most interestingly, when these ICOs were suppressed, Dand5 was not properly 
downregulated on the left side of the LRO in response to ciliary motility. 
Therefore, the authors proposed that flow and Pkd2-dependent intraciliary 
calcium oscillations control Dand5 asymmetry at the top of the left–right 
signaling cascade and the mechanism of Dand5 mRNA degradation might be 
regulated in a calcium-dependent manner (S. Yuan et al., 2015). 
While the Cerl2 expression in the perinodal region (crown cells) changes from 
symmetric to asymmetric (L<R) , the mRNA levels of Nodal and Gdf1, which is 
co-expressed and forms a heterodimer with Nodal, functioning as a stabilizer of 
the mature Nodal protein, remain distributed symmetrically in this region from 
EHF stage to 1-somite stage (Figure 1.9B) (Kawasumi et al., 2011; Shiratori & 
Hamada, 2014; Yoshiba & Hamada, 2014). Moreover, pSmad2, an indicator of 
Nodal signaling activity, was already detected asymmetrically (L>R) on the left 
side of the node at LHF stage (Figure 1.9C) (Kawasumi et al., 2011). 
 
 
 
 
 
 
 
 
Nodal Nodal Nodal 
Cerl2 Cerl2 Cerl2 
pSMAD2 pSMAD2 pSMAD2 
A) 
B) 
C) 
L R 
EHF LHF 1ps 
 21 
 
General Introduction Chapter 1 
Figure 1.9 – Cerl2, Nodal and pSMAD2 activity in perinodal cells of the mouse node. 
A) Cerl2 is initial equal expressed in both side of the perinodal cells by EHF stage. At LHF Cerl2 
mRNA starts to be detected asymmetrically (L<R) and by 1-somite stage Cerl2 is clearly more 
expressed in the 
 right side of the node. B)  At these stages, however, Nodal expression remain symmetrically 
distributed in the perinodal cells. C)  On the other and, pSmad2 activity, a readout of the Nodal 
signaling, was not detected at the EHF stage but was apparent on the left side of the node at the LHF 
stage and is clearly evident in the same cells by 1-somite stage. Adapted from: (Kawasumi et al., 
2011). 
 
Altogether, these results suggest that Cerl2 is the major target of the flow and is 
not the asymmetric Nodal expression, but the L<R expression of Cerl2 the 
responsible for the pSmad2/3 asymmetry in perinodal cells. So, it was proposed 
that L<R asymmetric expression of Cerl2 is responsible for L>R asymmetric 
Nodal activity in the perinodal cells and thus the role of Cerl2 is to restrict the 
Nodal activity to the left side of the node, preventing its signaling in the right 
side. 
Although the L<R expression of Cerl2 resembles the expression pattern of 
Cerl2 protein until 2-somite stage, the same does not happen from 3 to 6-somite 
stage (Figure 1.10), suggesting that Cerl2 protein could have another role in 
addition to the restriction of the Nodal activity to the left side of the node. In fact, 
at early stages (EHF to LHF stage), Cerl2 protein is expressed in both sides of 
crowns node cells, in a horseshoe shape, like its mRNA (Inacio et al., 2013). 
Later, when Cerl2 expression starts to become L<R, Cerl2 protein begin to 
accumulate on the right side of the node until 2-somite stage, preventing the 
activation of Nodal cascade on the right-LPM. By 2/3 somite stage, when Cerl2 
expression remain L<R, Cerl2 protein is translocated to the left side of the node 
in a nodal flow depend way, suggesting that Cerl2 protein, also due to its small 
20-kDa size (fitting the size of a determinant morphogen), may be transported 
by the flow (Inacio et al., 2013). At 5-somite stage, Cerl2 protein is accumulated 
on the left side of the node until 6-somite stage, when its signal starts to 
disappear (Figure 1.10).  This dynamic right-to-left translocation of Cerl2 
protein, after the asymmetric Nodal expression starts in left LPM, seems to 
shutdown Nodal activity in the left side of the node at the 6-somite stage, which 
coincides with the termination of the Nodal expression and activity in the left 
LPM.  
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Figure 1.10 – Cerl2 mRNA and protein localization. 
From EHF to 2-somite Cerl2 expression localizes with the distribution of Cerl2 protein in both sides of 
the mouse node.  However, from 3-somite stage to 6-somite stage, this pattern disappears and Cerl2 
mRNA do not localize with Cerl2 protein distribution. At 3-somite stage, when Cerl2 expression remain 
L<R, Cerl2 protein present equally in both sides of the node and by 4/5-somite stage Cerl2 is 
accumulated in the left side of the node, contrary to its expression. At 6-somite stage Cerl2 mRNA and 
protein start to disappear in opposites sites in the edge of the node. Adapted from: (Inacio et al., 
2013). 
 
 
 
 
 
 
 
 
 
 
Therefore, Cerl2/Dand5 is a key molecule in the establishment of the left-right 
asymmetry, being the only molecule that summons the two main hypothesis 
mechanisms of flow action (mechanosensor and chemosensor). 
 
2.2.1.2. Transmission of a left–right-biased signal to LPM 
(second step) 
2.2.1.2.1. The Signal 
Once the orientation of LR asymmetry has been determined relative to the AP 
and DV axes it is essential that this asymmetric signal (or signals), generated at 
the node, must be transferred to the LPM, where it induces the asymmetric 
expression of Nodal and consequent its signaling cascade in order to execute 
LR asymmetric organogenesis. If the signal is transferred from the node to the 
left LPM, it must be produced at the node and its expression will need to be 
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critical for any kind of patterning of LPM, correct or abnormal. Among the 
several molecules expressed at the node, recent evidence suggests that an 
active form of Nodal, probably the Nodal-Gdf1 heterodimer protein, in which 
GDF1 functions as a stabilizer of the Nodal protein (Kawasumi et al., 2011; 
Shiratori & Hamada, 2014; Yoshiba & Hamada, 2014), is the best candidate 
signal that is transmitted from the node to the left lateral plate mesoderm. 1 – 
Specific ablation of Nodal expression in the perinodal crown cells prevents 
Nodal expression in either side of LPM. Since Nodal is expressed bilaterally at 
the node (in perinodal crown cells) before the onset of its expression in the left 
LPM, this suggests that Nodal expression in the node are absolutely critical for 
Nodal expression in the lateral plate (Brennan, Norris, & Robertson, 2002). 2 – 
Asymmetric Nodal expression in the LPM is conferred by two Nodal-responsive 
enhancers (ASEs) and can be induced by Nodal signaling (Adachi et al., 1999; 
Norris & Robertson, 1999; Saijoh et al., 2005). 3 – Introduction of a Nodal 
expression vector in the right LPM can induce ectopic endogenous Nodal 
expression on the right side. 4 – Gdf1 is co-expressed with Nodal bilaterally in 
the perinodal crown cells, and Gdf1 mutant is maintained Nodal expression at 
the node but it is completely lost in the lateral plate mesoderm [15, 23]. 
 
2.2.1.2.2. The Route of the signal to LPM 
The transference of the left-right asymmetric signal (or signals) generated at the 
node to the LPM is still a controversial issue. It has been suggested that if 
Nodal-Gdf1 heterodimer protein is indeed transported to the left LPM, it can 
follow at least two transportation routes. First, Nodal-Gdf1 heterodimer protein 
may be secreted into the node cavity, transported toward the left side of the 
node by the leftward flow and incorporated, via crown cells, into endodermal 
cells located at the surface of the embryo. The Nodal signal may then be 
relayed, across the endodermal cell layer, to the left LPM, where it induces 
endogenous Nodal expression (extraembryonic route) (Figure 1.11B) (Hamada 
& Tam, 2014; Shiratori & Hamada, 2014; Yoshiba & Hamada, 2014). 
Alternatively, the Nodal-Gdf1 heterodimer protein may be secreted within the 
embryo and directly transported along extracellular matrix (ECM) to the left LPM 
(intra-embryonic route) (Figure 1.11B) (Hamada & Tam, 2014; Shiratori & 
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Hamada, 2014; Yoshiba & Hamada, 2014), where it induces the asymmetric 
expression of its own signaling cascade in order to form asymmetric organs. 
While the extraembryonic route is unlikely, mostly because exposure of 
endoderm to recombinant Nodal protein does not induce Nodal expression in 
any side of LPM or non-LPM tissues (Oki et al., 2007), some evidences support 
the intra-embryonic route.  
 
 
 
 
 
 
 
 
 
 
First, the injection of the Nodal protein into the right side of the embryo (near the 
paraxial mesoderm and LPM) induces Nodal expression in the right LPM (Oki et 
al., 2007). Second, transgenic rescue experiments showed that the Nodal co-
receptor Cripto/Cryptic is required only in the LPM, not at the node, for left 
asymmetric Nodal expression in the LPM, indicating that the Nodal signal is not 
relayed indirectly between the node and LPM (Oki et al., 2007). Third, Nodal 
binds to sulfated glycosaminoglycans (GAGs), which are specifically localized at 
the extracellular matrix, between the node and LPM, and inhibition of sulfated 
GAG biosynthesis prevents Nodal expression in the LPM, suggesting that Nodal 
produced at the node might travel directly to the LPM via interaction with 
sulfated GAGs (Oki et al., 2007). Fourth, ectopic expression of Nodal in mouse 
or Xenopus embryos is capable to diffuse over a long distance like from LPM to 
Figure 1.11 – Nodal expression and the route of the signal to LPM. 
A) Anterior and posterior view of a mouse embryo at ~E8.25 showing Nodal expression in the node 
and left LPM. B) Possible routes of how Nodal are transferred from node to LPM. Asymmetric signal(s) 
generated by the leftward flow in the node (black wavy lines) might be transferred to the left LPM, 
either through the endoderm (pink line) – extraembryonic route – or directly transported along 
extracellular matrix (ECM) through the PAM (red line) – intraembryonic route –. The location of pit 
cells, crown cells, paraxial mesoderm (PAM), LPM, endoderm and prospective floor plate are shown. 
Adapted from: (Saijoh, Viotti, & Hadjantonakis, 2014; Shiratori & Hamada, 2006) 
 
 
A) 
B) 
Anterior view Posterior view 
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the midline (Kawasumi et al., 2011). Lastly, autocrine-paracrine Nodal signaling 
in perinodal cells is dispensable for LR patterning of LPM, given that its 
inhibition by expression of dominant negative forms of Smad3 or ALK4 was still 
associated with normal (left-sided) Nodal expression in LPM (Kawasumi et al., 
2011). Although the transport of the heterodimer Nodal-Gdf1 has not been 
directly detected, secreted Nodal protein was observed undergoing transport in 
the frog embryo (Marjoram & Wright, 2011). These results collectively suggest 
that Nodal protein, produced at the node, is transported to the left LPM following 
an intra-embryonic route. Nevertheless, we cannot exclude the possibility other 
signaling pathways that act in a paracrine manner, in the mesoderm or 
endoderm, to transmit the Nodal signal to the LPM (Hamada & Tam, 2014). For 
instance, a study reported that gap junction proteins in the endoderm are 
essential to transfer the Nodal signal to the LPM and gap-junction-dependent 
Ca2+ signal can travel from the node to the left LPM (Saund et al., 2012; Viotti, 
Niu, Shi, & Hadjantonakis, 2012). However, the authors do not propose a 
mechanism by which Ca2+ signal activates Nodal expression in the LPM, like 
Oki et al. proposed in their intra-embryonic route model. Nevertheless, we can 
think in a combined model of Viotti and Oki hypothesis. This integrated 
hypothesis, called the Viotti-Oki model (Norris, 2012), proposes that Gap 
junction-mediated propagation Ca2+ signaling may influence the underlying 
ECM, facilitating ECM-mediated transport of Nodal protein from the node to the 
LPM (Norris, 2012; Saijoh et al., 2014; Yoshiba & Hamada, 2014). 
 
2.2.1.2.3. Patterning the LPM 
After symmetry breaking in the node, asymmetric gene expression arises in the 
lateral plate mesoderm on the left side. This process is perhaps the best 
understood step in the establishment of the LR asymmetry and, in mouse, 
Nodal and Lefty genes (Lefty1 and Lefty2) play a major role in this process 
(Shiratori & Hamada, 2006). Although these genes have a similar expression 
pattern on the left side of the embryo, they have opposite functions. Whereas 
Nodal acts as a left-side determinant, the Lefty genes are antagonists of Nodal, 
restricting Nodal activity to the left side of LPM and also the intensity of Nodal 
expression (Hamada et al., 2002).  
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The asymmetric expression of Nodal and Lefty2 genes in the left LPM is 
conserved in all vertebrate species (Nakamura & Hamada, 2012) and its 
mechanism of action is thought to spread rapidly to the appropriate tissues 
during its period of competence. To allow the proper engagement of effective 
programs, the intensity and duration of the signal must be restricted in time and 
space. This is achieved due to a tighter regulation mediated at two levels, one 
at the node, due to the action of the Cerl2/Dand5 molecule (explained in section 
2.2.1.1.1.4.) and other in the LPM, by the action of Lefty genes, which are direct 
targets of Nodal signaling and act as feedback inhibitors by competitive 
interaction with the Nodal receptors/co-receptors. Both Nodal and Lefty2 genes 
are expressed asymmetrically and transiently in the left side of the LPM, starting 
in a small region adjacent to node, at 2-somite stage, and then expanding along 
the AP axis, disappearing by the 6-7-somite stage, lasting only several hours 
(Figure 1.12). Nodal is also thought to travel to the midline or prospective floor 
plate (PFP), where it induces Lefty1 expression. Lefty1 expression is also 
temporary, beginning at the 2-somite stage, near the node, expanding anteriorly 
and disappearing by the 5-6-somite stage (Hamada et al., 2002). Such dynamic 
asymmetric expression is achieved by FoxH1-dependent asymmetric 
enhancers (ASEs) that are necessary and sufficient for the left side expression 
patterns of these genes in vivo (Saijoh et al., 2005), ensuring the presence of 
the Nodal signal at the correct time and place.  
 
 
 
 
 
 
 
 
When Nodal protein interact with a target cell in the LPM, triggers the Nodal 
signaling cascade that in turn leads to the activation of Nodal itself and Lefty2. 
Figure 1.12 – Expression pattern of Nodal and Leftys in wilt-type mice. 
At E8.2 Nodal is expressed in the node and in left LPM whereas expression of Lefty genes localizes in 
the left LPM (Lefty2) and midline (Lefty1). Later, at the time of situs specific morphogens of internal 
organs, expression of Nodal and Lefty was no longer found in the mouse embryo. Adapted 
from:(Hamada, Meno, Watanabe, & Saijoh, 2002) 
Nodal Nodal Leftys Leftys 
E9.5 E9.5 E8.2 E8.2 
R L 
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The Nodal protein produced will amplify the expression of Nodal (positive-
feedback loop) and Lefty2, whereas the Lefty2 produced will regulate the 
expression of Nodal in left LPM. This negative loop mediated by Lefty2 restricts 
the intensity and area of Nodal signaling in a highly precise manner, explaining 
therefore the fact that asymmetric expression of Nodal and Lefty is indeed 
transient (Hamada et al., 2002; Saijoh et al., 2005; Shiratori & Hamada, 2006). 
Lefty1 in turn may function as a midline barrier that prevents Nodal to cross the 
midline and to induce bilateral expression of left-specify genes like Lefty2 and 
Pitx2. In fact, Lefty1 mutant mice present bilateral expression of Nodal, Lefty2 
and Pitx2 and pulmonary left-isomerism (Meno et al., 1998). Moreover, Lefty1 
begins to be expressed on the floor plate just before Nodal expression starts on 
the LPM.  
This combination of positive and negative feedback loops between Nodal and 
Lefty genes might constitute a self-enhancement lateral inhibition (SELI) 
system, a type of reaction-diffusion system that is able to amplify a small 
difference between the left and right of the node into a robust difference in the 
LPM since the inhibitor diffuses more rapidly than the activator (Nakamura & 
Hamada, 2012; Shiratori & Hamada, 2006, 2014). Since the Cerl2/Dand5 
molecule is responsible for the termination of the Nodal activity at the node, it is 
thought that this shutdown will also terminate the expression of Nodal in the left 
LPM and consequently the action of the SELI system (Inacio et al., 2013; 
Nakamura et al., 2006). 
 
2.2.1.3. Asymmetric position and morphogenesis of the 
internal organs 
After the genetic cascade of asymmetric gene expression is accomplished in 
the left LPM, visceral organs can initiate LR asymmetric morphogenesis 
synchronized with tissue differentiation. For that, the LR specific orientation 
initiated around the node and subsequently propagated through the LPM must 
be interpreted by the different organ primordia and translated into asymmetric 
gene expression patterns in/or surrounding these primordia. As a result, the 
cells will undergo asymmetric morphogenesis, which is tightly regulated and 
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very specific for each organ. This asymmetric morphogenesis can result from at 
least three different mechanisms: 1 – Directional looping: occurs in organs that 
are formed from a tube, like heart and gut, and that undergo a series of looping, 
bending and rotations steps. 2 – Initially symmetric organs develop side specific 
differences in their size or branching pattern (i.e. lung). 3 – Agenesis of one 
part: one side of an initial bilateral symmetric structure, such as blood vessels, 
undergoes regression and disappears, leaving only the other side (Figure 
1.13A) (Hamada et al., 2002; Shiratori & Hamada, 2006). 
At molecular level, the main readout of Nodal signaling in LPM is the induction 
of Pitx2 expression (Shiratori & Hamada, 2014), suggesting that this molecule is 
the major player in the regulation of asymmetric organogenesis in response to 
the initial break of symmetry in the node. Pitx2 is a bicoid-type homeobox 
transcription factor, which, like Nodal and Lefty2, is asymmetrically expressed in 
the left LPM (Yoshioka et al., 1998). However, unlike Nodal and Lefty2 genes, 
the expression pattern of Pitx2 in the LPM persists until much later stages 
(Figure 1.13B) and is still apparent in the organ primordia of heart, gut, and 
blood vessels. This expression is controlled by an intronic enhancer (ASE) in 
Pitx2 gene that contains multiple Nodal-responsive, Foxh1-dependent binding 
sites and an Nkx2-binding site (Shiratori et al., 2001). Thus, the left-side 
expression of Pitx2 is initiated by Nodal and maintained by Nkx2, a transcription 
factor expressed in the developing heart, in the absence of the Nodal signal.  
 
 
 
 
 
 
 
 
B) 
Figure 1.13 – Mechanisms for the generation of morphological asymmetries and Pitx2 
expression pattern. A) Asymmetric morphogenesis of organs can result from directional looping (i.e. 
heart), differential branching (i.e. lungs) and agenesis of one part (i.e. blood vessels). B) Pitx2 seems 
to be the major player in the regulation of asymmetric organogenesis. Pitx2 is expressed in the left 
LPM and heart-forming region at E8.2 and its asymmetric expression persists during situs-specific 
organogenesis. Red and green represent L/R asymmetric signals. Adapted from:(Hamada et al., 
2002) 
A) 
Pitx2 
R L 
Pitx2 
E9.5 E8.2 
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Pitx2 gene encodes three isoforms, Pitx2a, Pitx2b and Pitx2c, in most 
mammalian and a Pitx2d isoform in humans, however, only the Pitx2c isoforms 
seems to be cardiac-specific and asymmetrically expressed (Kitamura et al., 
1999). Absence of Pitx2c in mice results in laterality defects in most visceral 
organs, like right atrial isomerism and right pulmonary isomerism, and Pitx2-null 
mutant mice also display severe defects in valve formation, sinoatrial 
morphogenesis and atrioventricular connections, including double outlet right 
ventricle and transposition of the great arteries (Kitamura et al., 1999; Liu et al., 
2002). Pitx2c is expressed in the in the left, not right, side of the developing 
heart tube prior to looping morphogenesis, suggesting a role for this 
transcription factor in this process. Although ectopic right-sided expression of 
Pitx2c results in a high frequency of reversed heart orientation (situs inversus), 
cardiac isomerism and reversed heart looping, the null Pitx2 and Pitx2c 
knockout mice show normal cardiac looping and a broad spectrum of cardiac 
defects (Ramsdell, 2005), suggesting that Pitx2c is dispensable for this aspect 
of the looping process. However, another study in Xenopus shows that loss-of-
function of Pitx2c causes abnormal shifting of the outflow tract (OFT), 
confirming that Pitx2c can mediate later aspects of looping (Ramsdell, 2005). 
Furthermore, Pitx2c was also expressed in the left atrium, atrioventricular canal, 
left OFT, interventricular myocardium and second heart field (Furtado, Biben, 
Shiratori, Hamada, & Harvey, 2011). Together, these evidences suggest that 
Pitx2 could be involved in the regulation of cardiac looping and morphogenesis 
of complex cardiac structures. Moreover, errors in the leftward shifting and/or 
rotation of the OFT are associated with double outlet right ventricle (DORV), 
transposition of great arteries (TGA), and ventricular septal defects (VSDs), 
suggesting that the abnormal Pitx2c function could account for these types of 
Congenital Heart Disease. 
Therefore, although the evidence that cardiac looping takes place normally in 
the absence of Pitx2 suggesting that this molecule do not control the initial 
direction of looping, its function seems to be necessary and essential for the 
normal development of the cardiac structures that result from the looping 
process. 
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3. How to make a functional heart 
During embryonic development, the heart is one of the first organs to form and 
become fully functional. During this period of heart development, which occurs 
between days 15-19 and days 56-60 after conception (Sylva, van den Hoff, & 
Moorman, 2014), many coordinated biological processes take place within the 
fetus to ultimately result in a four-chambered organ with two parallel 
circulations. In all higher vertebrates, heart development follows similar basic 
patterns until the formation of a functional heart. Cardiac development starts 
with the formation of two bilateral pools of mesodermal precursor cells, the 
cardiac crescent or so called first heart field, that fuses and folds, giving rise to 
a simple linear heart tube at the ventral midline (Meilhac, Lescroart, Blanpain, & 
Buckingham, 2014). After that, the linear heart tube elongates, bends and 
loops, due to the addition of cardiac progenitor cells by the secondary heart field 
region (Meilhac et al., 2014; Sylva et al., 2014). Subsequently, growth, 
differentiation, specialization and septation of the four chambers, valves and 
great vessels takes place to provide all the necessary components for the 
physical separation of the systemic and pulmonary circulation of blood. 
Furthermore, the development of the cardiac conduction system provides the 
components necessary for the generation of the electrical stimulus as well the 
means to propagate this impulse to the myocardial cells of the chambers, which 
results in the heartbeat and the proper sequential contraction of the chambers 
(Anderson, Spicer, Brown, & Mohun, 2014). Lastly, epicardial and neural crest 
cells migrate and integrate into the heart. The combination of these changes, 
along with the generalized maturation of the cardiomyocytes, culminates in the 
development of the functional four-chambered heart (Meilhac et al., 2014; Sylva 
et al., 2014). 
 
3.1. Embryonic origins of the heart 
Heart formation is a complex process that starts during gastrulation, at day 15 
of human development (E6.5 in mouse), when cells that will form the mesoderm 
ingress through the primitive streak (Schleich, Abdulla, Summers, & Houyel, 
2013). 
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A) B) C) 
Figure 1.14 – Embryonic origins of the heart. 
A) Localization of cardiac progenitor cells after their invagination into the primitive streak. B) Migration 
of the progenitor cardiac cells cranially and laterally results in the formation of two heart-forming 
regions in each side of the embryo. C) Inductive and inhibitory signal released from surrounding 
tissues results in the specification of the cardiac mesoderm. Adapted from: (Schoenwolf, Bleyl, 
Brauer, & Francis-West) 
Fate mapping studies have shown that cardiac progenitors that ingress early, at 
the midstreak stage, become located in the anterior region of the primitive 
streak (PS) (Figure 1.14A), which comprises newly forming mesoderm (Meilhac 
et al., 2014). These naıve cardiogenic mesodermal cells migrate away from the 
primitive streak, anteriorly and laterally on either side of the embryonic midline, 
to take up a position under the head folds in each side of the splanchnic layer of 
lateral plate mesoderm, forming two bilateral heart-forming regions (Figure 
1.14B), at about day 17-19 in humans and E7.5 in the mouse embryo (Meilhac 
et al., 2014; Schleich, Abdulla, Summers, & Houyel, 2013). Once they have 
taken up their position under the head folds, the paired heart-forming regions 
migrate to the anterior ventral midline and join, giving rise to a crescent-shaped 
group of cells, where the first and second heart fields can be distinguished. The 
transition from mesodermal to cardiac progenitor cells requires the induction 
and specification of the splanchnic mesoderm into cardiac mesoderm, which is 
mediated by intrinsic signals from the primitive streak and from the surrounding 
tissues.  
 
 
 
During gastrulation, mesodermal cells that ingress through the PS change from 
expressing Brachyury T, a T-box transcription factor, to express mesoderm 
posterior 1 (Mesp1), when they enter in the precardiac mesoderm stage of 
development (Wu, Chien, & Mummery, 2008). Mesp1, which represents the 
earliest marker of cardiac progenitors, seems to play a role in the migration of 
these cells towards the cranial regions of the embryo to form the cardiac 
crescent (Harvey, 2002). Moreover, Mesp1 induce cardiogenic mesoderm 
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through the inhibition of genes that promote early mesoderm and endoderm 
specification and through up-regulation of the core cardiac transcriptional 
machinery, such as Gata4, Nkx2.5, Mef2c, Hand2 and Smarcd3 (BAF60c) 
(Bondue et al., 2008). In addition, inducing signals from the adjacent endoderm 
(BMP, FGF and Shh) together with inhibitory signals from the notochord (noggin 
and chordin) and the developing neural plate ectoderm (Wnt11/Wnt3a) refines 
the site in which the cardiogenic transcriptional program is firstly activated 
(Figure 1.14C). 
 
3.2. Heart fields and cardiac looping  
Around 3 weeks after human development has begun (E8 in mouse), the first 
cells that migrate to the heart-forming regions, the so-called first heart field 
(FHF) (Figure 1.15), move ventrally and fuse or coalesce to form a linear heart 
tube, consisting of an inner layer of endocardial cells and an outer layer of 
myocardial cells, separated by extracellular matrix or cardiac jelly secreted by 
the myocardium (Srivastava, 2006). At this stage, the heart is characterized with 
an anteriorly positioned outflow, or arterial pole, and a posterior inflow, or 
venous pole, blood starts to courses through the heart tube and heartbeat is 
initiated (Dunwoodie, 2007). The FHF cardiac progenitor cells, originates from 
the anterior splanchnic mesoderm, are exposed to cytokines of the BMP and 
FGF families as well to inhibitors of the Wnt pathway, resulting in the onset of 
cardiac differentiation, marked by the expression of key regulators of the 
lineage, namely, Nkx2.5, Gata4 and Tbx5 (Meilhac et al., 2014). FHF derived 
cells, ultimately, give rise to the majority of the left ventricle (LV), atrioventricular 
canal, and parts of the atria (Dunwoodie, 2007). As development proceeds, 
from day 23 to 28 of human development (E8.5-10.5 in mouse), the heart tube 
undergoes a dramatic increase in length. This elongation is essentially driven 
not by proliferation of cells within the linear heart tube, which has been shown to 
have extremely low cell-cycle times, but by the addition of cardiac progenitor 
cells from outside the early heart tube to the arterial and venous poles (Miquerol 
& Kelly, 2013). These cells originated in the pharyngeal mesoderm contiguous 
and medially to the cardiac crescent have been termed the second heart field 
(SHF) (Figure 1.15) (Waardenberg, Ramialison, Bouveret, & Harvey, 2014). 
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Figure 1.15 – Heart fields regionalization of the heart. 
First and second heart field can be distinguished at the time of the cardiac crescent. First heart field 
derived cells will form mostly the left ventricle and contribute for the formation of the atria. SHF 
derivatives will form the main parts of the atria, the right ventricle, and the outflow tract myocardium. 
Adapted from: (Xin, Olson, & Bassel-Duby, 2013). 
 
SHF cells are characterized by continued proliferation and differentiation delay 
relative to the cells that gave rise to the linear heart tube and by the expression, 
along with Nkx2.5, of Isl1. This expression, which demarks the SHF from FHF 
derivatives, is dependent on canonical Wnt signaling, and Isl1 function is 
required for survival, proliferation, migration and commitment of the SHF 
progenitors into the primitive heart tube.  Ultimately, SHF derivatives will form 
the main parts of the atria, the right ventricle (RV) and the outflow tract 
myocardium (Meilhac et al., 2014; Waardenberg et al., 2014). Concomitant with 
the increase in length, the heart tube undergoes rightward looping, in the first 
morphological manifestation of embryonic laterality (Figure 1.15) (Srivastava & 
Olson, 2000) 
 
During cardiac looping, the anterior portion of the heart tube (primitive 
ventricular region) bends towards its ventral side and simultaneously rotates to 
the right, forming a C-shaped tube. Next, the C-shaped tube is converted into 
an S-shaped loop. In this process, the ventricular bend, which was originally 
cranial to the inflow attachment and atrium, is now caudal (Kirby, 2007). Later 
looping steps involve the shift of the ventricular position from its originally 
anterior to its definitive position, posterior to the atria, the shift of OFT from its 
right lateral position with respect to the atria towards its definitive position 
ventral to the right atrium and the atrioventricular canal alignment with both 
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ventricles (Dunwoodie, 2007). Cardiac looping brings the four presumptive 
chambers of the future heart into their correct spatial relationship to each other 
and with the vasculature. It is also during the early stages of looping that 
primitive segments become evident in the heart tube. These include the outflow 
tract (conotruncus), future right ventricle, future left ventricle, atrioventricular 
canal, and future atria (Kirby, 2007; Rana, Christoffels, & Moorman, 2013). 
Rightward cardiac looping is the first morphological indication of asymmetry in 
the vertebrate embryo and the mechanisms that drive this process are 
intrinsically related with the correct establishment of the LR axis during 
gastrulation. In turn, this correct left or right identity depends of a complex 
network of signals and molecules that are straight regulated and maintained on 
the lateral plate mesoderm in the form of Pitx2 expression, like it was described 
in the section 2.2.1.3. 
3.3. Chamber morphogenesis and maturation of the 
heart 
The primitive heart tube is composed of slowly proliferating myocardium, low 
sarcomeric and sarcoplasmic reticular transcripts, low velocity conduction and 
poor automaticity and contractility (Rana et al., 2013). As the tubular heart 
continues to develop, its outer curvature initiates a distinct genetic program by 
which localized differentiation and proliferation cause expansion of the atrial and 
ventricular chambers, in a process of ballooning morphogenesis, at ~28-32 of 
human development (E10.5 of mouse) (Miquerol & Kelly, 2013). While low rates 
of proliferation are maintained at the inner curvature of the heart tube, including 
the outflow tract and atrioventricular canal region, the differentiating myocardial 
cells of the future atrial and ventricular chambers acquire fast conduction 
velocity, high contractility, high automaticity and well developed sarcomeric 
structures, which will ensure rapid contractions and efficient blood pumping 
(Miquerol & Kelly, 2013; Rana et al., 2013). Chamber specification is straightly 
regulated by the T-box transcription factors. TBX20 and TBX5 promote 
chamber myocardial development while TBX2 and TBX3 repress the chamber 
genetic program and promote cushion development in the atrioventricular canal 
and outflow tract (Miquerol & Kelly, 2013). 
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Once the chambers are specified and start to grow, its remodeling and 
maturation processes are initiated. This leads to the formation of the trabeculae, 
a sponge-like layer of myocytes at the luminal side of the fetal ventricles, that 
increase the surface area for oxygen uptake in the absence of a coronary 
circulation (Dunwoodie, 2007). Chamber remodeling and maturation also result 
in the formation of the ventricular septum at the interface between left and right 
ventricles, a process that is dependent on a single structure, the interventricular 
septum (IVS), which has both muscular and mesenchymal components and 
derives from both right and left ventricular cardiomyocytes (Rosenthal & Harvey, 
2010).  
It is also during this period that the cardiac conduction system develops from 
the slow-conducting non-chamber myogenic tissue (Miquerol & Kelly, 2013), 
consisting of the His-Purkinje system, the sinoatrial node and atrioventricular 
node. The sinoatrial node (the cardiac pacemaker), located in the right atrium 
generates a pacemaker impulse, whereas the atrioventricular node delays an 
electrical impulse for separating the contraction of the atrial and ventricular 
chambers of the heart (Xin et al., 2013). The His-bundle propagates the signal 
to the Purkinje fibers, which are embedded in the ventricles, enabling fast and 
coordinated conduction of impulses throughout the ventricular muscle (Miquerol 
& Kelly, 2013). The outer layers of the ventricles become highly proliferative, 
resulting in a thickening of the chamber walls to form the compact layer of the 
myocardium (Dunwoodie, 2007). 
Concomitant with cardiac septation, endocardial cushions in the atrioventricular 
canal and outflow tract become remodeled to form the cardiac valves, which 
separate and control the blood flow (Miquerol & Kelly, 2013). In this process, at 
the level of the OFT and AVC, a cardiac jelly, secreted by the myocardium, 
between the endocardium and the myocardium, are populated by endocardial 
cells, which migrate and proliferate to form opposing tissue masses, called 
endocardial cushions (Miquerol & Kelly, 2013). In the AVC, endocardial 
cushions are the precursors of the tricuspid and mitral valves, while in the OFT, 
they will form the aortic and pulmonary valves and a scaffold for the 
aorticopulmonary septum, which divides the OFT into the aorta and pulmonary 
artery (Schleich et al., 2013). 
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3.4. Other sources of cells in heart development 
In addition to the myocardial and endocardial populations of cells, epicardial 
and cardiac neural crest cells are also essential for proper cardiogenesis. 
Proepicardial cells, localized caudally from the heart, migrate over its outer 
surface, surround the entire heart, and into the subjacent myocardium, giving 
rise to the epicardium and contributing to the cardiac-cushion mesenchyme, the 
cardiac fibroblasts, and to the endothelial and smooth muscle cells of the 
coronary arteries (Chong, Forte, & Harvey, 2014; Miquerol & Kelly, 2013). 
Moreover, cardiac neural crest cells (CNC) migrate from the dorsal neural tube 
to the heart, playing essential roles in septation, contributing to the division of 
the outflow tract into the base of the ascending aorta, outlet of the left ventricle, 
pulmonary trunk and outlet of the right ventricle, atrioventricular septum and 
cardiac valves (Chong et al., 2014). Around week 8 of human development 
(E16.5-17.5 in mouse), the heart morphogenesis is complete and the fourth 
chambered heart is now prepared to support the circulatory system where RV – 
pulmonary ventricle – pumps venous blood to the lungs (pulmonary circulation) 
at the same time that the LV – systemic ventricle – pumps arterial blood to the 
rest of the body (systemic circulation) (Figure 1.16). 
This overview of the major steps in heart development points to the complicated 
processes that are highly susceptible to disturbances and can, ultimately, result 
in congenital heart defects. 
 
 
 
 
 
 
 
 
Human heart 
Figure 1.16 – Mature 4-chambered human heart. 
Final morphology of the mature four-chambered heart, showing its different compartments and the 
direction of the blood flow (white arrows). 
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4. Congenital Heart Diseases 
The earliest mention of any Congenital Heart Disease (CHD) dates from 
Babylonian clay tablets back to 4000 BC. In one of these tablets, ectopia cordis, 
a type of congenital heart defect, come along with the description “When a 
woman gives birth to an infant that has the heart open and has no skin, the 
country will suffer from calamities” (Savona & Grech, 1999). From that period to 
now, many important breakthroughs were achieved in the identification, 
characterization and etiology of some forms of Congenital Heart Disease. 
However, despite all the notable efforts in critical care for affected patients, 
CHD remains the first cause of both infant morbidity and mortality in the first 
year of life. Furthermore, the etiology of most CHDs remains unknown, and they 
are so-called “multifactorial” diseases. 
 
4.1. Epidemiology of Congenital Heart Diseases 
With an incidence of approximately 8 per 1000 live births (~1%), Congenital 
heart defects (CHDs) are the most common type of birth defects, and the 
leading non-infectious cause of infant mortality (Mozaffarian et al., 2015). 
Additionally, approximately 3 of every 1000 newborn require some expert 
cardiologic intervention during the first year of life, which can be debilitating and 
compromise the quality of life of patients. Therefore, CHDs are also one of the 
largest cause of infant morbidity and a significant source of economic burden 
(Cowan & Ware, 2015). Taking into account the high rates of stillbirths with 
CHDs (10%) (Fahed, Gelb, Seidman, & Seidman, 2013), the presumed cases 
of spontaneous abortuses, the subclinical abnormalities and the mild lesions 
that are quiescent for decades, the true overall incidence of CHDs is 
undoubtedly much greater. Moreover, because prenatal diagnosis, medical and 
surgical treatments of CHDs become extremely advanced, today, over 75% of 
children with CHDs that survive in the first critical year of life will live to 
adulthood (Fahed et al., 2013), making this disease no longer just a childhood 
disease, but also an important adulthood problem with a high healthcare 
resource utilization and a significant source of global economic burden.  
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4.2. Etiology of Congenital Heart Diseases 
The etiology of CHD is complex and heterogeneous (Table 1), associated with 
either genetic and non-genetic causes or a combination of both. Non-genetic 
causes of CHD include teratogens (dioxins, polychlorinated biphenyls, 
pesticides), maternal exposures to alcohol, tobacco and drugs, infectious 
agents (rubella) and known risk factors, like obesity, diabetes mellitus and 
hypercholesterolemia (Fahed et al., 2013). The genetic landscape of CHD is 
very heterogeneous and CHD origins are diverse, such as abnormal 
chromosome structure, coding and non-coding gene alterations, single 
nucleotide polymorphisms (SNPs), modifier genes, microRNA dysfunction, 
epigenetic alterations and copy number variants (CNVs). This genetic 
abnormality can occur as part of a well-defined syndrome, in conjunction with 
additional extracardiac anomalies, not formally recognized as a syndrome, or, 
as in the majority of the cases, occurring sporadically in non-syndromic patients 
(Azhar & Ware, 2016). Syndromic cases of CHD, which accounts for 20-30% of 
the cases (Azhar & Ware, 2016), includes chromosomal alterations, such as 
trisomy 21 (Down syndrome), trisomy 13 (Patau syndrome), trisomy 18 
(Edwards syndrome), and Turner syndrome aneuploidies, and microdeletions 
associated with DiGeorge syndrome and Williams syndrome (Azhar & Ware, 
2016; Fahed et al., 2013; Fahed & Nemer, 2012). Furthermore, the majority of 
CHDs with a monogenic mode of inheritance result from well-known syndromes 
like, Holt-Oram syndrome, Alagille syndrome, and Noonan syndrome 
(Cecchetto et al., 2010). In contrast, most non-syndromic CHDs occur 
sporadically, and families with clear monogenic inheritance are infrequent 
(Wessels & Willems, 2010). This makes the identification of human disease 
genes involved in non-syndromic difficult and approaches for identify the causes 
of CHD in non-syndromic patients came mostly from sequencing candidate 
gene screenings or genome wide association studies (gwas). 
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Table 1.1. Causes of Congenital Heart Disease. 
Cause CHD attributed (%) Reference 
Environmental  2 [81] 
Genetic   
Single gene 3-10 [78] 
Chromosomal/aneuploidy 8-10 [78] 
Copy number Variation 3–25 (syndromic), 3–10 (isolated [78] 
Multifactorial Unknown, estimated 80–85 [78] 
 
With the advance in the understanding of the molecular basis of heart 
development, mostly using animal models, and the recognition that 
perturbations during embryonic heart development are at the origin of CHD. 
Studies on large cohorts of isolated CHD identified three characteristics of the 
disease: genetic heterogeneity, reduced penetrance and variable expressivity 
(Cecchetto et al., 2010). Therefore, it became evident that not all CHD 
manifests true Mendelian inheritance and it is possible that multiple common 
low penetrance genetic variants will have a weak to moderate effect in raising 
an individual’s risk of having a heart malformations when considered together 
(Lalani & Belmont, 2014). At this time, a model involving both rare and common 
variants, possibly with gene-gene and gene-environmental interactions, is the 
most likely explanation for the high frequency of CHDs. 
 
4.3. Laterality defects and Congenital Heart Disease 
Laterality defects describe a group of congenital disorders that involve abnormal 
arrangement and morphology of the abdominal and/or thoracic organs (Cohen 
et al., 2007). In addition to these anomalies, it is usual to find complex 
malformations within the heart, often requiring cardiac surgery in the neonatal 
period. Laterally defects result from abnormalities in the left-right axis 
establishment during the early stages of development and the spectrum of the 
disease includes different arrangements of the normal situs of the body, called 
situs solitus (Figure 1.17) (Peeters & Devriendt, 2006).  This spectrum includes, 
situs inversus and heterotaxy (Figure 1.17). Situs inversus (SI) is a defect in the 
global situs orientation and results in a complete mirror image of the normal 
arrangement of the body and organs (situs solitus). This condition, which is 
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Figure 1.17 – Human laterality defects. 
Illustration of normal arrangement (situs solitus) of internal organs according left–right asymmetry and 
the spectrum of laterality defects that affect the lungs, heart, liver, stomach and spleen. Left or right 
isomerism reflects a duplication of the left or the right side respectively. Adapted from: (Capdevila, 
Vogan, Tabin, & Izpisua Belmonte, 2000). 
characterized by the maintenance of the normal position of all organs with 
respect to each other, occurs in 1 per 6000-8000 newborns and presents an 
incidence of congenital heart defects around 3% (Peeters & Devriendt, 2006). 
Heterotaxy (HTX), also called situs ambiguus or heterotaxy syndrome, refers to 
any disruption in the normal left-right asymmetry of the thoracoabdominal 
organs that cannot be strictly classified as situs solitus or situs inversus (S. J. 
Kim, 2011). The incidence of heterotaxy is estimated as 1 in 10000 births and 
its etiology is genetically highly heterogeneous with reduced penetrance, 
presumably because of monogenic, polygenic or multifactorial causes (H. Deng, 
Xia, & Deng, 2015; Peeters & Devriendt, 2006). Furthermore, SI and HTX occur 
among families or in sporadic cases, associated with other syndromes or in 
isolated cases (Peeters & Devriendt, 2006). In the latter, alterations in genes 
involved in the Nodal signaling pathway seem to be the most probable cause of 
the disease. In addition, SI is usually characterized by autosomal recessive 
inheritance, while HTX displays X-linked inheritance, autosomal dominant 
inheritance with reduced penetrance, or autosomal recessive inheritance (H. 
Deng et al., 2015).  
Contrarily to SI, which presents an incidence of congenital heart defects around 
3%, almost all the patients (90%) with heterotaxy also have complex congenital 
heart defects like pulmonary atresia/stenosis, transposition of the great arteries 
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(TGA), double outlet right ventricle (DORV), ventricular septal defects (VSDs), 
atrial septal defects (ASDs), atrioventricular septal defects (AVSD), hypoplastic 
left heart, anomalous venous return and coarctation of the aorta (Mohapatra et 
al., 2009). Furthermore, heterotaxy also includes isomerisms (Figure 1.17), a 
condition in which asymmetric organs fail to show asymmetry. In left isomerism, 
the heart has two long narrow atrial appendages and both lungs are bilobed 
whereas in right isomerism, both atrial appendages are pyramidal in shape and 
the lungs are trilobed (Peeters & Devriendt, 2006). Both of these conditions 
present characteristic heart and extra-cardiac alterations, which are not 
mutually exclusive to one or other phenotype and may overlap. The prognosis 
of patients with complex cardiac lesions and heterotaxy is poor, with the 
mortality in the first year of life being >85% for patients with right isomerism and 
>50% for patients with left isomerism (S. J. Kim, 2011). 
Taking into account the vast number of studies, from animal models, in heart 
morphogenesis and determination of left-right axis during embryogenesis, the 
evidence that the mortality of laterality disease are almost always attributed to 
complex congenital heart defects and the fact that the developing heart is 
extremely susceptible to disturbances in embryonic left-right patterning 
(Ramsdell, 2005), is fair enough suggest that congenital heart diseases could 
be due to problems of laterality. Therefore, the genes that control left-right 
specification could be implicated in the etiology of isolated cases of CHDs. In 
the same line of thinking, alterations in these genes might also contribute for 
some phenotypes of CHD patients. 
 
4.3.1. Cardiac left-right asymmetry 
The first sign of cardiac molecular asymmetry comes from the cells that form 
the primitive heart fields. These cells, which migrate from the primitive streak to 
the left and right embryonic midline, are exposed to different left-right patterning 
and will contribute to the formation of different regions of the heart. As an 
example, the cells that contribute to the posterior region of the heart tube are 
the same subset of cells that previously expressed Nodal and Lefty2 prior to 
their incorporation into the primary heart tube (Ramsdell, 2005). This suggests 
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that although these genes are no longer expressed once cardiac cells become 
incorporated into the heart tube, this subset of posterior cardiac cells possesses 
a background of molecular asymmetries that distinguishes it from other cells in 
the heart. Furthermore, the second heart field, which arises from an area that 
includes the mesoderm surrounding the aortic sac and all of the pharyngeal 
arches, also presents left-right differences since Pitx2c expression is detected 
in the left, but not right, aortic sac mesoderm and left pharyngeal arch 
mesenchyme (Rosenthal & Harvey, 2010). The SHF cells, which present an 
asymmetric Pitx2c expression, will contribute to the conotruncus or outflow tract 
of the heart. This means that as cardiac mesoderm becomes established and 
as it contributes to the heart tube, these cells are already specified, at least to 
some extent, for left–right identities. 
As cardiac development progresses, the linear heart tube undergoes rightward 
looping, under influence of  Pitx2-dependent or Pitx2-independent Nodal 
signaling, with inner curvature remodeling and outer curvature proliferation, the 
endocardial cushions of the inflow and outflow tracts are brought together at the 
inner curvature and become adjacent to each other (Ramsdell, 2005). If either 
ends of the heart tube are delayed or impaired in the looping, the chance to 
occur septal defects increase. In addition, abnormal leftward looping results in 
reversal ventricular topology such that the morphological right ventricle 
(pulmonary circulation) is situated to the left of the heart and the morphological 
left ventricle (systemic circulation) on the right, a phenotype that can be found in 
Zic3 and Cited2 knockout mice, which are molecules also involved in left-right 
asymmetry establishment (Dykes, 2014).  
Subsequently, in the inflow tract, the common atrioventricular canal becomes 
divided into left and right components by an atrioventricular septum that shifts to 
the right. This results in alignment of the atrioventricular canal (AVC) with the 
ventricles. If the inflow tract fails in shift to the right both atria communicate with 
the left ventricle in a condition known as double-inlet left ventricle (DILV) 
(Kathiriya & Srivastava, 2000; Ramsdell, 2005). Meanwhile, at the outflow 
region, the conotruncus shifts to the left, becoming positioned above the AVC, 
and simultaneously twists 180º to position the aorta properly over the left 
ventricle and the pulmonary artery correctly positioned over the right ventricle. 
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Failure in shift to the left, results in double-outlet right ventricle (DORV), a 
condition in which the right ventricle communicates with both the aorta and the 
pulmonary artery and the left ventricle has no outlet, whereas defects in the 
rotation results in transposition of the great arteries (TGA), a condition in which 
the right ventricle communicates with the aorta and the left ventricle with the 
pulmonary artery (Kathiriya & Srivastava, 2000; Ramsdell, 2005). 
Left and right atria results from common atrium, which division may be related 
to differences in atrial cells that derive from left vs right primary heart field. 
Failure in this process is the base of atrial isomerisms (Ramsdell, 2005). 
Because the right atrium contains the sino-atrial node and other specialized 
structures of the conduction system, right atrial isomerism is associated with 
cardiac arrhythmias as a result of node duplication while left atrial isomerism is 
associated with hypoplastic or absent sino-atrial node. Pitx2c expression is 
required in the left atrium during the late phase of asymmetric differentiation 
where it appears to actively suppress the development of the conduction 
system (Dykes, 2014). Moreover, during cardiac cushion formation from the 
AVC, myocardium in the AVC exhibits left, but not right, side expression of 
Pitx2c. Laterality disturbances of AVC affect the formation of the valves and 
increases the risk of valvuloseptal defects (Ramsdell, 2005). Ultimately, the left 
atrium and right atrium are aligned with the left ventricle and right ventricle, 
respectively. 
Therefore, the correct morphogenesis of the various compartments of the heart 
depends on the correct establishment of left-right axis. If this complex process 
fails, it might result in many congenital heart defects with or without associated 
extracardiac laterality defects, depending on the levels and distribution of the 
left determinants in lateral plate mesoderm and heart.  
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5. Disease modeling using patient-derived iPSCs 
Despite all the advances in medical therapy, heart disease remains a leading 
cause of mortality and a major worldwide healthcare burden (Ebert, Diecke, 
Chen, & Wu, 2015). Animal models have provided indispensable insights into 
the pathogenesis of genetic cardiac diseases, however not all findings from 
research in animal models cardiomyocytes can be translated into human 
cardiomyocytes. For example, mouse models are not always able to fully 
recapitulate the disease phenotype seen in patients, due to species differences 
at both physiological and genetic levels (Avior, Sagi, & Benvenisty, 2016). 
Moreover, the limited regeneration capacity of heart myocardial cells (Dell'Era et 
al., 2015) in conjunction with the fact that heart transplantation is a very limited 
option due to organ supply paucity, immunosuppression and organ rejection, 
makes it difficult to study cardiac disorders and emphasize the need for novel 
human cellular and physiological models of heart diseases (Ebert et al., 2015).  
To overcome these limitations several efforts were made in the last 15 years 
and one of the most exciting was the ground breaking work reported by 
Yamanaka a decade ago. In 2006-2007, Yamanaka reprogramed for the first 
time murine and human somatic cells to a pluripotent state, transducing 
retrovirus-carrying four specific transcription factors (Oct3/4, Sox2, c-Myc, and 
Klf4 also known as the Yamanaka factors) (Takahashi et al., 2007; Takahashi & 
Yamanaka, 2006) in those cells. The resulting induced pluripotent stem cells 
(iPSCs) present an intrinsic capability for indefinite self-renewal and have the 
potential to differentiate into virtually any cell type, resemble embryonic stem 
cells (ESCs), the “gold standard” for pluripotency (Bellin, Marchetto, Gage, & 
Mummery, 2012).  
iPSCs technology has captured scientists with the promise and hope that these 
cells hold a potential that can be used in disease modeling, drug development 
and regenerative medicine without the ethical and political concerns associated 
with the use of human embryos for the generation of human embryonic stem 
cells (C. Kim, 2014). 
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Figure 1.18 – Applications of iPSCs technology 
Patient iPSCs are mostly generated using the four Yamanaka factors and can be used in disease 
modeling, drug development and regenerative medicine. 
 
 
 
 
Since the initial publication, human iPSCs have developed into impetuous, 
spectacular, and groundbreaking research field and in our days iPSCs can be 
generated in any period of patient’s life from almost any type of differentiated 
cells (C. Kim, 2014). It is now possible obtain iPSCs-derived cardiomyocytes 
from healthy people and also from patients suffering of a genetic disease very 
similar to native cardiomyocytes in morphology, gene expression pattern, 
electrophysiological rates, and sensitivity to chemical substances (Bayzigitov et 
al., 2016). The resulting human iPSCs-derived cardiomyocytes will keep the 
entire genetic information of the patient, allowing the study of the effect of the 
variant in different backgrounds and the functional effect of the variant 
compared to the healthy people cardiomyocyte. 
Therefore, the use of hiPSC disease model is an alternative platform for 
studying mechanisms of CVD and evaluating novel therapeutic avenues. In 
addition, human iPSCs present the unprecedented opportunity to study 
disease-specific differences in a patient-specific manner. 
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6. Objectives 
Despite all the notable efforts over the last 15 years, recurring to a vast array of 
both approaches and techniques/technologies, in the attempt to unveil the 
causes of all forms of CHDs, the etiology and the genetic basis of the majority 
of congenital defects remains unknown. There is a distinct lack of data 
concerning the molecular mechanisms that are required for normal human 
cardiac development and is difficult to make the connection between normal 
cardiac development and CHDs, mostly because there are no direct methods 
for determining which developmental step(s) were disturbed in any single 
affected individual. Furthermore, many CHDs have an ambiguous embryologic 
origin and they may be interpreted as arising from multiple alternative early 
events or later and more specific processes. 
Therefore, in the sequence of several studies in heart morphogenesis and 
determination of the left-right axis during embryogenesis, concerning to the 
Nodal pathway and the role of its involved genes, it becomes clear the need of 
beginning the translational research, applying the new data resulting from the 
animal models research to the human cardiac disease, in particular to the 
disorders of laterality and/or isolated cases of CHDs. 
The purpose of this project, in a close collaboration between research and 
clinical practice is the molecular and functional study of human genes involved 
in the Nodal pathway, focusing mostly in DAND5 (human homolog of mouse 
Cerl2), but also trying to find alterations in the other intervening genes of the 
pathway, namely CFC1 (human homolog of mouse Cripto), NODAL and 
PITX2C.  
The objectives of this thesis were: 1- to define the cellular and molecular 
mechanisms that underlie cardiac asymmetry on the congenital heart disease 
(CHD) and the laterality defects. 2- to identify the correlation between the 
observed/described phenotypes in affected children and their genotype. 3- to 
understand the hereditary mode of transmission in case of pathologic alteration 
identification and assess the frequency and role of these genetic variations in 
children with congenital heart defects resulting from left-right abnormalities. 
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1. Ethics 
This study was conducted in accordance with the ethical principles of the 
revised Declaration of Helsinki. The research protocol was approved by the 
local institutional ethics committee of Hospital de Santa Cruz, Centro Hospitalar 
de Lisboa Ocidental, E.P.E., Hospital de Faro, Centro Hospitalar do Algarve, 
E.P.E., Hospital Sta. Marta, Centro Hospitalar de Lisboa Central, E.P.E. 
(Supplementary Material 1 as example) was obtained from all guardians 
participants prior to DNA collection. The biological samples collected were 
anonymized to ensure the confidentiality and privacy of patients and data.  
  
2. Study population 
The study sample included 38 Caucasian unrelated pediatric patients with 
congenital heart defects arising from possible left-right defects recruited from 
Hospital de Santa Cruz, Centro Hospitalar de Lisboa Ocidental, E.P.E. (11), 
Hospital de Faro, Centro Hospitalar do Algarve, E.P.E. (24), Hospital Sta. 
Marta, Centro Hospitalar de Lisboa Central, E.P.E (3). The sample was 
obtained according to the convenience and availability of physicians in each 
hospital. 
 
3. Clinical evaluation and inclusion criteria  
Patients were evaluated by individual and familial history, review of the medical 
records and individual anatomic descriptions of the patients’ defects were 
obtained by the review of echocardiogram, echocardiography, magnetic 
resonance imaging, angiography or direct view during cardiac surgery.  
Since DAND5 (Cerl2 in mice) gene was recently associated to congenital heart 
defects arising during embryo development, we decided to base our inclusion 
criteria firstly in the phenotype features observed on Cerl2 KO mice. In this 
animal model it was observed that 35% of the homozygous mutants died within 
the first 48 h after birth, presenting several cardiovascular malformations, 
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including incomplete atrial and ventricular septation, conotruncal defects, 
ventricular hypertrophy, and/or to laterality defects like left isomerism and 
thoracic heterotaxy or situs inversus. In addition, it was performed an 
exhaustive bibliographic search of the most commons symptoms and features 
presented by the animal models used in the study of CHD and laterality 
disorders, namely the generated KO mice for other genes involved in the Nodal 
signaling pathway, and the clinical symptoms presented by affected children or 
adults with CHD associated mainly with laterality defects. Nevertheless, 
throughout the contact with clinicians, in particular with the paediatric 
cardiologist, it was defined a list of the main diagnosed CHD phenotypes in 
each of the involved institutions. Conjugating all of these factors, the inclusion 
criteria required the presence of congenital heart malformations and/or laterality 
defects, namely: a) left or right isomerism; b) heterotaxy; c) situs inversus; d) 
transposition of great arteries (TGA); e) double inlet left ventricle (DILV); f) 
double outlet right ventricle (DORV); g) tetralogy of Fallot or Fallot like 
phenotype; h) atrioventricular septal defects (AVSD); i) atrial septal defects 
(ASD); j) ventricular septal defects (VSD) and j) ventricular hypertrophy 
(Supplementary Material 2 as example). The patients with known chromosomal 
abnormalities or syndromic cardiovascular defects, such as Down syndrome, 
Turner syndrome, Marfan syndrome, Di George syndrome, and Holt–Oram 
syndrome, were excluded from the study.  
 
4. Patient’s phenotypes 
The phenotypes of the patients included in the study are described in the table 
2.1:  
 
Table 2.1. Patient´s Phenotypes 
HStM001 Left Isomerism; pulmonary atresia; VSD; right-sided aortic arch; inferior vena 
cava interruption; visceral situs inversus 
HStM004 Left Isomerism; AVSD 
HStM006 Situs inversus totalis; AVSD; TGA; Univentricular Heart; right-sided aortic arch 
HsTC001 VSD; coarctation of the aorta; aortic stenosis; mitral valve stenosis 
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HStC002 Hypoplastic right ventricle with pulmonary atresia and tricuspid atresia  
HsTC003 Hypoplastic right ventricle; pulmonary atresia with intact ventricular septum 
HsTC004 VSD; pulmonary atresia; MAPCAs; PLSVC 
HsTC005 TGA; pulmonary atresia; tricuspid atresia 
HsTC006 AVSD 
HsTC007 Left Isomerism; VSD with overriding aorta; pulmonary atresia 
HsTC008 TGA 
HsTC009 VSD; pulmonary atresia; MAPCAs 
HsTC010 Situs inversus; levocardia; pulmonary atresia; single ventricle; single 
atrioventricular valve 
HsTC011 TGA; VSD 
HCF001 ASD; pulmonary atresia 
HCF002 Tetralogy of Fallot 
HCF003 Tetralogy of Fallot 
HCF004 Right isomerism with asplenia; dextrocardia; TGA; AVSD; pulmonary stenosis; 
TAPVC; right-sided aortic arch 
HCF005 Dextrocardia; VSD 
HCF006 Tetralogy of Fallot, TAPVC 
HCF007 AVSD 
HCF008 VSD; pulmonary atresia 
HCF009 TGA 
HCF010 Hypoplastic left heart, TAPVC 
HCF011 AVSD 
HCF012 VSD; pulmonary atresia; TGA 
HCF013 Left Isomerism 
HCF014 TGA 
HCF015 TGA; DILV 
HCF017 Pulmonary atresia; VSD 
HCF019 DILV 
HCF021 Tetralogy of Fallot  
HCF023 Tetralogy of Fallot; Dextrocardia  
HCF025 Tetralogy of Fallot; Pulmonary valve agenesis 
HCF027 Tetralogy of Fallot; Double outlet right ventricle 
HCF029 AVSD 
HCF030 AVSD 
HCF032 Hypoplastic Aortic Arch; VSD; ASD 
TGA - Transposition of the great arteries; AVSD - Atrioventricular septal defects; DILV - Double inlet left 
ventricle VSD - Ventricular Septal defects; TAPVC - Total anomalous pulmonary venous connection; 
DORV - Double outlet right ventricle; MAPCAs - Major Aorto-Pulmonary Collateral Arteries; PLSVC - 
Persistent left superior vena cava 
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5. Genetic Screening of Nodal signaling pathway genes 
5.1. Sample collection 
To have a rapid, reproducible and non-invasive/painless way for biological 
sample collection in children, which could be easy to transport and to conserve, 
we collected buccal epithelial cells using buccal swabs. The samples collection 
was performed during the clinical follow up consultation in the health institution 
where the affected children are being followed. It was recommended that the 
patients avoid eating thirty minutes before the samples collections and washed 
the mouth only with water. The sample protocol was simplified and briefly, we 
identified the swabs with the patient data and collect the sample scraping the 
inside of the cheek approximately 6-10 times. Then we let the swaps with the 
samples dry at room temperature for about 15 minutes and finally the collected 
samples were sent to our laboratory (directly in the same day of collection, by 
mail, or other).  
 
5.2. DNA extraction and quantification of DNA 
concentration 
The DNA from the buccal epithelial cells was extracted using the Isolate 
Genomic DNA mini kit (BIOLINE) according to the manufacturer’s instructions 
for DNA isolation from buccal swabs (Supplementary Material 3). 
After extraction, the concentration of DNA sample suspensions was determined 
by spectrometry using an NanoDrop 2000 UV-Vis Spectrophotometer 
(ThermoScientific). 
 
5.3. Genes analyzed   
The clinical complexity and genetically heterogeneity of congenital heart 
diseases suggests that some of these defects could arise due to alterations in 
more than one gene that orchestrate the cardiac program, or in gene pathways 
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that control essential embryonic processes before the cardiac program starts. 
Therefore, in order to have a better picture of the genetic cause of a particular 
CHD phenotype, some of the NODAL signaling pathway genes were 
sequenced, namely DAND5, NODAL, CFC1 and PITX2C. 
The nucleotide and protein sequences of these genes or gene products were 
obtained through the genomic databases for human gene sequences and 
diseases, namely the OMIM, Ensembl, Uniprot and some NCBI sub-databases 
(the reference of each gene from each of the chosen databases are showed in 
table 2.2). From the gene nucleotide sequences, it was analyzed the exonic and 
intronic regions, the coding and non-coding regions, and the main domains 
already identified for each gene in order to find the more relevant sequences for 
gene variant screening. Consequently, it was decided to search for variants in 
the exons and exon-intron boundaries of all the genes mentioned above. 
 
Table 2.2. Reference of the genes analyzed in this study in the different databases. 
Gene 
Gene ID 
(NCBI) 
Ref Seq 
accession 
number 
OMIM 
identifier 
Ensemble Uniprot 
DAND5 199699 NM_152654.2 609068 ENSG00000179284 Q8N907 
NODAL 4838 NM_018055.4 601265 ENSG00000156574 Q96S42 
CFC1 55997 NM_032545.3 605194 ENSG00000136698 P0CG37 
PITX2C 5308 NM_000325 601542 ENST00000306732 Q99697 
  
5.4. Oligonucleotide primers design 
To perform the DNA amplification by polymerase chain reaction (PCR), 
considering the genes DAND5, NODAL, CFC1 and PITX2C, several sets of 
primers were designed targeting the coding exons and flanking exon-intron 
boundaries using the online program PRIMER-BLAST. The designed primers 
were checked with the PRIMER-BLAST software (internet free access), in order 
to amplify only the target gene region, without homology for other 
genes/genomic regions that could interfere in the genetic analysis and on 
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Figure 2.1 – Genomic localization of DAND5; NODAL; CFC1 and PITX2C primers. 
Primers are notated with “P” letter; the corresponding nucleotide sequences are shown in table 2.3. 
Vector NTI to access the dimerization capability and significant hairpin 
formation. 
The genomic localization, the nucleotide sequence and the amplicon length of 
the designed primers are shown in Figure 2.1 and table 2.3, respectively: 
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Table 2.3. Primers used for amplification of specific genomic regions 
Gene and 
exon 
Forward (5’ – 3’) Reverse (5’ – 3’) 
Amplicon 
size (bp) 
DAND5 Ex1 P1 - GTCGACTGCTAGTGACCTTGAG P2 - TCAGGTGGAGGATACAGGACTT 499 
DAND5 Ex2 P3 - GGAAGTGGACAGGTGATTATCC P4 - CACGTCTTTCTTGGTCCATCTC 399 
NODAL Ex1 P1 - GCTGAGGCCCAGGATATAAG P2 - CCAACCCACAGCACTTCC 341 
NODAL Ex2a P3 - CCTCACTCACCCTCCTTCC P4 - CTCCAGCTACCCTGGACATC 383 
NODAL Ex2b P5 - CCTCTCTCCAAGTGGCTGAAG P6 - GCAAAGCTAGAGCCCTGTCC 489 
NODAL Ex3 P7 - CTATTCTGACCTGCCCATC P8 - CTGGATTAGATGGTTATCATGTC 292 
CFC1 Ex1 P1 - CATCCACATCTTCTGTACTC P2 - GCACTACGATTTATTCTGAG 234 
CFC1 Ex2-3 P3 - GCCTCAGAATAAATCGTAGTGC P4 - CTCAGGTCCTAAACTCTGAGTCC 646 
CFC1 Ex4 P5 - GGCTGGAGGCTGATTTTACTG P6 - GACCCGCAGGTCCCTCAC 289 
CFC1 Ex5 P7 - CAGGTCCCCGTCTTCTCAG P8 - CACTGGAAGATGCACTGTGG 229 
CFC1 Ex6 P9 - GCAGGCGTTTCTATTGCAC P10 - CCAGTGCTTCAGCTTACGG 334 
PITX2C Ex1b P1 - CAGTAGCCAAGGACTAGTAG P2 - CAGAATTGCTCGCGCCCTTAG 472 
PITX2C Ex4 P3 - AGTGAATGTGCCGCTGCAGT P4 - TCGGAGAGGGAACTGTAATC 646 
PITX2C Ex5 P5 - GTTGGCCTCCGATGGAAGTT P6 - GCCCACGACCTTCTAGCATAA 728 
Note: The primers listed above were used for the DNA amplification of the buccal swab 
samples. 
 
 
 
5.5. DNA amplification 
For each patient genomic DNA sample, PCR reactions for each of the genes 
analyzed (DAND5, NODAL, CFC1 and PITX2C) were performed using the 
primers listed in table 2.3. PCR reactions were carried out using 10 - 30 ng of 
genomic DNA in a 25 µL reaction containing 1X Phusion HF Buffer 
(ThermoScientific), 0.5 µM of each primer (Sigma- Aldrich), 0.2 mM dNTPs and 
0.02 U/µL of Phusion High-Fidelity DNA polymerase (ThermoScientific). PCR 
cycling (Figure 2.2) was performed on C1000 Thermal Cycler (Bio-Rad) using a 
denaturation cycle at 98ºC for 1 min followed by 35 cycles of denaturation at 
98ºC for 15 s, annealing of primers at a specific temperature, depending on the 
gene/exon, for 30 s and extension at 72ºC for 30 s and a final extension step at 
72ºC for 5 min.  
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After amplification and to determine the quality and yield of the PCR reaction, 5 
µL of PCR product of the genomic DNA of interest and its correspondent 
amplicons length was analyzed by 1-2% (w/v) agarose gel electrophoresis. 
 
 
 
 
 
 
 
 
 
 
5.6. Purification of PCR products 
Purification of the specific PCR products were performed using three different 
technics. Ethanol and sodium acetate precipitation (Supplementary Material 4) 
procedure was the first choice during the first two years of PhD but since we 
experience some problems in the sequencing of some amplicons, we decided 
to perform the purification of the DNA using an available commercial kit. In 
some amplicons it was systematically detected the presence of unspecific 
bands in the agarose gel electrophoresis, and it was decided to extracted the 
specific band from the gel and perform the purification of the DNA using an 
available commercial kit. 
  
Kit purification 
The PCR product containing only the specific DNA fragment of interest was 
purified using the commercial kit NZYGelpure kit (NZYTech) and according the 
manufacturer’s protocol. The DNA was ultimately eluted in 30 µL nuclease-free 
water and kept at -20ºC till further analysis.  
 
Extraction of DNA from Agarose Gels 
Following agarose gel electrophoresis, agarose gels were viewed under UV 
illumination and regions containing relevant DNA fragments were cut from the 
98 º C 1 min 
98 ºC 15s 
Specific ºC 30s 
72 ºC 30s 
72 ºC 5 min 
12ºC 00 
 
35X 
Figure 2.2 – Standard PCR protocol used for the amplification of DAND5, NODAL, CFC1 and PITX2C. 
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gel using a sterile scalpel. DNA products were then recovered using the 
NZYGelpure kit (NZYTech). The manufacturer’s protocol was then followed with 
DNA eluted in 30 µL nuclease-free water and kept at -20ºC till further analysis. 
 
5.7. Sequencing and sequencing analysis 
Direct bidirectional sequencing of each PCR product were performed with an 
ABI Prism 3130 automated genetic analyzer (Applied Biosystems) and ABI 
3730xl DNA Analyzer (Applied Biosystems) according to the protocols from the 
Sequencing Service of CCMAR (http://www.ccmar.ualg.pt/) and STAB VIDA 
(http://www.stabvida.com/), respectively. The primers used for the sequencing 
were the same used to obtain the amplicons of each PCR product. 
The chromatogram of each DNA sequence were analyzed using the BioEdit 
Sequence Alignment Editor Software 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) and the sequences were aligned 
and compared with consensus sequences obtained from the human genome 
databases in the online program BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi), 
from NCBI.  
The variants found were confirmed by sequencing three independent PCR-
generated amplicons from the same patient. Additionally, the identified 
sequence variation was queried in the single nucleotide polymorphism (SNP) 
database at NCBI (http:// www.ncbi.nlm.nih.gov/), the human gene mutation 
(HGM) database (http://www.hgmd.org/), the 1000 Genome Project (1000 GP) 
database (http://www.1000genomes.org/) and the ExAC browser 
(http://exac.broadinstitute.org/) to confirm its novelty. 
 
5.8. Sequence alignment of the variant proteins 
among vertebrate species 
Conservation of the amino acid altered by each missense allelic variant was 
estimated by aligning the human protein of the corresponding gene variant to 
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the homologous proteins in chimpanzee, rat, mouse, xenopus and zebrafish 
using Clustal Omega program from Uniprot (http://www.uniprot.org/). 
 
5.9. Characterization of the Causative Potential of the 
Variants  
The potential effect of the p.R152H DAND5 variation and CFC1 variant were 
characterized by the software programs Polyphen-2 
(http://genetics.bwh.harvard.edu/pph2/) Mutation Taster 
(www.mutationtaster.org), PROVEAN (http://provean.jcvi.org/), and I- Mutant 
3.0 (http://gpcr.biocomp.unibo.it/) . Polyphen-2 utilizes a combination of 
sequence, function, evolutionary conservation and structure based attributes 
and uses naive Bayesian classifier to determine the effect of an amino acid 
alteration. The output levels of damaging in the protein were classified as 
deleterious (≤ 0.5) and the benign level being classified as tolerated (≥ 0.51). 
Mutation Taster software’s analysis are based on protein structure/function and 
evolutionary conservation and employs a Bayes classifier to eventually predict 
the disease potential of an alteration. The outcome of all tests can be either a 
disease mutation or a harmless polymorphism.   
PROVEAN based analysis takes into account the alignment and measurement 
of similarity between variant sequence and protein sequence homolog and the 
output classifies the alteration as deleterious (≤ -2.5) or neutral (≥ 2.51). I-
Mutant 3.0 is a support vector machine-based tool that predicts the stability 
change of a mutated protein. The output prediction classifies the alteration in 3 
classes: neutral alteration (− 0.5 ≤ DDG ≤ 0.5 kcal/mol), large decrease of 
stability (≤−  0.5 kcal/mol) and large increase of stability (> 0.5 kcal/mol).  
 
6. Functional analyses of the p.R152H DAND5 protein 
variant in the Nodal signaling  
In order to study the effect of the p.R152H variant in the Nodal signaling 
pathway we used a Nodal-dependent luciferase assay system as described in 
the methods, section 6.2. To perform that assay, the human version of the main 
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intervenient genes in this pathway, namely, NODAL, CRIPTO, DAND5, DAND5 
R152H variant and FOXH1, was cloned in expression vectors.  To ensure the 
same backbone plasmid for each gene the plasmids were subcloned into the 
expression vector pCS2+.  
 
6.1. Plasmids 
hNODAL 
The plasmid containing the hNODAL gene cloned in the pcDNA3 expression 
vector was obtained as a gift from Dr. Michael R. Kuehn from the Center for 
Cancer Research National Cancer Institute. To subclone the hNODAL 
sequence into the expression vector pCS2+, the hNODAL sequence was cut 
using the restriction enzymes XhoI and EcoRI (ThermoFisherScientific). Then, 
the digested fragments were separated by electrophoresis in a 1% agarose gel, 
the specific band containing the hNODAL sequence extracted from the gel with 
a scalpel and purified using the commercial available kit NZYGelpure 
(NZYTech). Next, we performed the ligation of this DNA fragment to the pCS2+, 
which had been previously linearized and purified in the same way as hNODAL, 
using the T4 DNA Ligase (TihermoFisherScientfic) according to the 
manufacturer’s instructions. The ligation product was then transformed into 
competent Top 10 bacteria. Three clones were picked, grown in suspension 
overnight and the plasmids purified using the NZYMiniprep kit (NZYTech). 
Ultimately, the purified plasmid was sequenced to confirm that the hNODAL 
was successfully integrated into pCS2+ expression vector.  
 
hCRIPTO 
The plasmid containing the hCRIPTO gene cloned in the pEF6/V5-His TOPO 
cloning vector was obtained as a gift from Dr. Michael R. Kuehn from the Center 
for Cancer Research National Cancer Institute. To subclone the hCRIPTO 
sequence into the expression vector pCS2+ we used the same strategy as for 
the hNODAL gene. The only difference was the enzymes that were used for cut 
the hCRIPTO gene from the initial vector, in which we used the BamH1 and 
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XbaI. Ultimately, the purified plasmid was sequenced to confirm that the 
hCRIPTO was successfully cloned into pCS2+ expression vector.  
 
hDAND5 
The encoding full-length human DAND5 (IRCMp5012B019D) was purchased 
from Source BioScience LifeSciences, Nottingham, United Kingdom, cloned in 
the pCR4-TOPO vector, which isn’t an expression vector.  To subclone the 
hDAND5 sequence into the expression vector pCS2+ we used the same 
strategy as for the hNODAL gene and hCRIPTO butwecut the pCR4-TOPO 
vector and pCS2+ with EcoRI (ThermoFisherScientific). To prevent self-ligation 
dephosphorylation of the pCS2+ plasmid with alkaline phosphatase was used. 
Ultimately, the purified plasmid was sequenced to confirm that the hDAND5 was 
successfully integrated into pCS2+ expression vector.  
 
hDAND5 c.455G>A 
The c.455G>A variant of DAND5 was generated from the hDAND5 pCS2+ 
plasmid by site-directed mutagenesis using the QuikChange kit (Stratagene, La 
Jolla, CA, USA) with the following pair of primer: Forward: 5´ 
GTATGCCTGCTCACAAGCGTTGGG 3´; Reverse: 
5´CCCAACGCTTGTGAGCAGGC  3´ according to the manufacturer’s 
instruction. Ultimately, the purified plasmid was sequenced to confirm that the 
hDAND5 c.455G>A alteration was successfully introduced into the pCS2+ 
expression vector.  
 
6.2. Nodal-dependent luciferase assay 
Human embryonic kidney 293T cells were cultured in Dulbecco's modified 
Eagle's medium supplemented with 10% fetal calf serum and seeded overnight 
at 50–60% confluence in 96-well plates. Next day, the cells were transiently co-
transfected with Lipofectamine 2000 (Lifetechnologies) and the following 
plasmids: pAR3-lux, that contain three copies of the activin response element 
(ARE) in the front of a luciferase reporter, which is specifically activated by 
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nodal signaling; hDAND5; hDAND5 R152H; hNODAL; hCRIPTO, a Nodal co-
receptor necessary for the proper activation of the Nodal signaling; hFoxH1, the 
major transcriptional transducer of nodal signaling; CMV-β-Gal plasmid as 
control, and various amounts of pCS2+ vector to maintain a constant amount of 
total DNA. Transfections were performed in triplicate and in three independent 
experiments with a total amount of 100ng DNA per well with the following 
conditions: (1) Cells transfect with 6ng of pAR3-lux; (2) Cells transfected with 
6ng of AR3-Lux and 1,5ng of FoxH1 plasmid; (3) Cells transfected with 6ng of 
AR3-Lux, 1,5ng of FoxH1 plasmid and 17ng of hCRIPTO plasmid; (4)  Cells 
transfected with 6ng of AR3-Lux, 1,5ng of FoxH1 plasmid, 17ng of hCRIPTO 
plasmid and 17ng of hNODAL plasmid; (5) Cells transfected with 6ng of AR3-
Lux, 1,5ng of FoxH1 plasmid, 17ng of hCRIPTO plasmid, 17ng of hNODAL 
plasmid and 17ng of hDAND5 plasmid; (6) Cells transfected with 6ng of AR3-
Lux, 1,5ng of FoxH1 plasmid, 17ng of hCRIPTO plasmid, 17ng of hNODAL 
plasmid and 17ng of mutant hDAND5 plasmid. Twenty-four hours after 
transfection, cell lysates were prepared, luciferase activity measured and the 
results were normalized to b-galactosidase control. 
  
7. In silico analysis of the intronic variants found in 
NODAL and PITX2C genes. 
To study if the intronic alterations found in NODAL and PITX2C genes could 
alter the normal process of splicing, we decide to use the online software 
Human Splicing Finder. This software is a tool that predict the effects of 
mutations on splicing signals or identify splicing motifs in any human sequence. 
It contains all available matrices for auxiliary sequence prediction as well as 
new ones for binding sites of the 9G8 and Tra2-β Serine-Arginine proteins and 
the hnRNP A1 ribonucleoprotein and includes new algorithms derived from the 
Universal Mutation Database (UMD) to allow the evaluation of the strength of 
5′ss, 3′ss and branch points. In addition, in order to identify cis-acting elements 
it includes already published algorithms, such as the RESCUE-ESE and ESE-
Finder as well as new algorithms designed to use available or newly created 
matrices. To allow the study of virtually any human sequence, HSF includes all 
 62 
 
Chapter 2 Methods 
genes and alternative transcripts as well as intronic sequences that were 
extracted from the Ensemble human genome database. 
 
8. Generation and characterization of human iPSC line 
8.1. Ethics statement and informed consent 
All the experimental protocols included in the present study were approved by 
the Institutional Ethical Committee of the NOVA Medical School according to 
European Union legislation and written informed consent was obtained from 
guardian patient prior to the collection of the urine sample (Supplementary 
Material 5 as example). The biological samples collected were anonymized to 
ensure the confidentiality and privacy of patients and data.  
 
8.2. Isolation of cells from urine 
Isolation of cells from urine was performed as described by (Zhou et al., 2012). 
Briefly, to obtain urinary cells, approximately 50 to 120 ml of urine were 
collected and centrifuged 400g for 10 min at room temperature. The 
supernatant was discarded, leaving only ~1ml, and the cell pellet was washed 
with 10 ml of washing buffer (PBS containing 100 U/ml of penicillin, 100 μg/ml 
streptomycin (Lonza) and 500 ng/ml of amphotericin B. Following another 
centrifugation at 200g for more 10 min, the pellet was resuspended in 2 ml of 
primary medium (Dulbecco's Modified Eagle Medium (DMEM): nutrient Mixture 
F-12 (DMEM/F-12) (1:1), supplemented with 10% (vol/vol) Fetal Bovine Serum 
(FBS) (Sigma), 100 U/ml penicillin, 100 μg/ml streptomycin (Lonza), the REGM 
SingleQuot kit supplements (Lonza) and 2.5 μg ml − 1 amphotericin B (Lonza)) 
and seeded in one well of a 12-well plate (Corning) coated with 0,1% (w/t) 
gelatin (Sigma). In the following three days 1 ml of primary medium was added 
and at day four after plating, most of the medium was removed and replaced by 
proliferation medium (Renal Cell Basal Medium (REBM) supplemented with 
REGM BulletKit (Lonza)). Subsequently, half of the culture medium was 
changed every day and after 4–6 days small 2–4 cell colonies started to appear. 
Cells were rounded or elongated which represent type I or type II of renal 
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epithelial (RE) cells, respectively. Once cells reached 90% density, they were 
passaged and expanded, using TrypLE Select (Life Technologies), to a 6-well 
plate (Corning).  
8.3. Non-integrative reprogramming and 
establishment of iPSC lines 
Reprogramming was performed using Sendai virus vectors (CytoTune-iPS 2.0 
Reprogramming Kit, Life Technologies). Briefly, 7,5 × 105 cells, seeded in one 
well of a 6-well plate coated with gelatin and cultured in RE proliferation 
medium, were transduced using a 1,5 MOI (multiplicity of infection) of each of 
the 3 CytoTune® 2.0 vectors, KOS (Klf4–Oct3/4–Sox2), hc-Myc, and hKlf4. 
After 24h, the medium was replaced by fresh RE proliferation medium and cells 
were cultured for seven days with medium changes every other day. On day 8 
after transduction, cells were passaged using TrypLE Select and seeded with a 
density of 6 × 105 cells/dish in RE proliferation medium onto a 100 mm culture 
dish (Corning) coated with Geltrex (Gibco, Thermo Fisher Scientific). On the 
next day medium was changed to Essential 8 (E8) flex medium (Gibco, Thermo 
Fisher Scientific) supplemented with100 U/ml penicillin, 100 μg/ml streptomycin 
and replaced every day until hiPSC colonies appeared. 17 days after infection, 
individual colonies were picked using a pipette tip and expanded to 24-well 
plates coated with Geltrex in E8 flex medium supplemented with100 U/ml 
penicillin, 100 μg/ml streptomycin and revitacell (Gibco, Thermo Fisher 
Scientific). In the next day, the medium of all the colonies picked was replace by 
flesh E8 flex medium without revitacell.  
 
8.4. Culture of iPSC 
The hiPSC were cultured in Geltrex (Gibco, Thermo Fisher Scientific) 6-well 
coated plates with Essential E8 flex medium (Gibco, Thermo Fisher Scientific). 
Cells were routinely passaged using 0,5 ml of TrypLE Select (Life 
Technologies) every two days at a ratio of ~1:10. 
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8.5. Sequencing analysis 
Total DNA from the patient’s hiPSCs was extracted using the Isolate Genomic 
DNA mini kit (BIOLINE) according to the manufacturer’s instructions for DNA 
isolation from eukaryotic cells. Subsequently, amplification by PCR of the exon 
2 of DAND5 gene, containing the c.455G>A alteration, was carried out using 
the following primers (Table 2.4): DAND5 Ex2F: 5′-
GGAAGTGGACAGGTGATTATCC-3′ and DAND5 Ex2R: 5′- 
CACGTCTTTCTTGGTCCATCTC-3′). Following PCR amplification, quality of 
amplification products was analyzed using a 1% agarose gel and direct 
sequencing of amplicon was performed on both strands using a ABI 3730xl 
DNA Analyzer in STAB VIDA (http://www.stabvida.com/).  
 
8.6. Quantitative polymerase chain reaction (qPCR) 
analyses   
Total RNA was extracted and purified from patient and control iPSC lines, H9 
human embryonic stem cell line as a positive control and exfoliated renal 
epithelial cells using TRizol Reagent (Invitrogen) plus Direct-zol™ RNA 
MiniPrep kit (Zymo Research) according to the manufacturer's instructions. 1 μg 
of total RNA was used to synthesize cDNA with the RevertAid RT Reverse 
Transcription Kit (Thermo Scientific). cDNA was then diluted 1:10, with 
nuclease-free water, and 2 μl were used to quantify by qRT-PCR the expression 
of the endogenous pluripotency associated genes (NANOG, SOX2, KLF4, 
OCT4 and NODAL). qRT-PCR was performed on a Applied Biosystems® 7500 
Real-Time PCR machine and reactions were run with SYBR® Select Master 
Mix (Applied Biosystems) plus the primers listed in table 2.4. CT-values were 
normalized to the geometric mean of the two housekeeping genes GAPDH and 
β-actin and with H9 human embryonic stem cell (ESC) line as reference (set to 
1). 
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Table 2.4. Primers used to characterize the patient and control derived iPSC lines. 
Target  Primer Sequence (5´to 3´) 
Product 
size 
(bp) 
Sequencing 
analysis 
   
DAND5 exon 2 
Forward GGAAGTGGACAGGTGATTATCC 
399 
Reverse CACGTCTTTCTTGGTCCATCTC 
Pluripotency 
analysis 
   
NANOG 
Forward CATGAGTGTGGATCCAGCTTG 
191 
Reverse CCTGAATAAGCAGATCCATGG 
OCT4 
Forward AGTGAGAGGCAACCTGGAGA 
110 
Reverse ACACTCGGACCACATCCTTC 
SOX2 
Forward GGGAAATGGGAGGGGTGCAAAAGAGG 
151 
Reverse TTGCGTGAGTGTGGATGGGATTGGTG 
Klf4 
Forward ACCAGGCACTACCGTAAACACA 
79 
Reverse GGTCCGACCTGGAAAATGCT 
NODAL 
Forward GGGCAAGAGGCACCGTCGACATCA 
234 
Reverse GGGACTCGGTGGGGCTGGTAACGTTTC 
GAPDH 
Forward CTGGTAAAGTGGATATTGTTGCCAT 
81 
Reverse TGGAATCATATTGGAACATGTAAACC 
β-actin 
Forward GCAAAGACCTGTACGCCAAC 
144 
Reverse AGTACTTGCGCTCAGGAGGA 
 
8.7. Fluorescent immunocytochemistry 
Undifferentiated patient and control derived iPSCs were grown on Geltrex 
coated cover slips, fixed at room temperature with 1% PFA (Sigma-Aldrich) in 
PBS for 15 min and then permeabilized with 0.1% Triton X-100 (Sigma-Aldrich) 
in PBS for 30 min. Non-specific binding was blocked with 1% BSA for 30 min. 
The cells were then incubated with primary antibodies overnight at 4 °C. To 
assess the expression of pluripotent markers, immunofluorescence staining was 
performed with primary antibodies against OCT4 (1:400), NANOG (1:200) and 
SSEA4 (1:200) as shown in table 2.5. After three washes with 0.1% Triton X-
100 in PBS for 5 min each, the cells were incubated with fluorescence-
conjugated secondary antibodies (AlexaFluor 488: Donkey anti-mouse 1:400, 
Invitrogen and AlexaFluor 488: Donkey anti-rabbit 1:400, Invitrogen) for 60 min, 
and mounted on glass slides with mounting medium containing DAPI (Life 
technologies). Images were acquired with Zeiss Axio Imager.Z2 microscope 
(Carl Zeiss). 
 
 66 
 
Chapter 2 Methods 
Table 2.5. Primary antibodies used for immunofluorescence  
 
Antibody and host 
species 
Dilution 
Company and 
catalog number 
 
   
 Rabbit anti-NANOG 1:200 Abcam, ab21624 
Pluripotency 
analysis 
Rabbit anti-OCT4 1:400 Abcam,ab19857 
 Mouse anti-SSEA4 1:200 Abcam,ab16287 
 
 
8.8. Karyotyping  
Karyotyping was performed according to the protocols from Laboratório de 
Citogenética e Genómica, Faculdade de Medicina da Universidade de Coimbra. 
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1. Abstract 
Background: Perturbations on the Left-Right axis establishment lead to 
laterality defects, with frequently associated Congenital Heart Diseases (CHDs). 
Indeed, in the last decade, it has been reported that the etiology of isolated 
cases of CHDs or cases of laterality defects with associated CHDs is linked with 
variants of genes involved in the Nodal signaling pathway. Methods: With this 
in mind, we analyzed a cohort of 38 unrelated patients with Congenital Heart 
Defects that can arise from initial perturbations in the formation of the Left-Right 
axis. Genomic DNA was extracted from buccal epithelial cells, and variants 
screening was performed by PCR and direct sequencing. A Nodal-dependent 
luciferase assay was conducted in order to determine the functional effect of the 
variant found. Results: In this work, we report two patients with a DAND5 
heterozygous non-synonymous variant (c.455G>A) in the functional domain of 
the DAND5 protein (p.R152H), a master regulator of Nodal signaling. Patient 1 
presents left isomerism, ventricular septal defect with overriding aorta and 
pulmonary atresia, while patient 2 presents ventricular septal defect with 
overriding aorta, right ventricular hypertrophy and pulmonary atresia (a case of 
extreme tetralogy of Fallot phenotype). The functional analysis assay showed a 
significant decrease in the activity of this variant protein when compared to its 
wild-type counterpart. Conclusion: Altogether, our results provide a new insight 
into the molecular mechanism of the laterality defects and related CHDs, 
priming DAND5 as a candidate determinant for CHDs in humans. 
Keywords: DAND5, Congenital Heart Diseases, laterality defects, Nodal 
signaling, allelic variation. 
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2. Background 
Heart morphogenesis is a complex process involving multiple cell types (cardiac 
and non-cardiac) thus requiring a precise control of all molecular and cellular 
mechanisms (Srivastava, 2001). Subtle deviations in heart development lead to 
Congenital Heart Diseases (CHDs), which are the most prevalent form of birth 
defect (postnatal incidence of 0.8 % of all newborns) and the leading non-
infectious cause of death in the first year of life (Andersen, Troelsen Kde, & 
Larsen, 2014; Koefoed, Veland, Pedersen, Larsen, & Christensen, 2014). The 
etiology of CHD is incompletely understood, thought to be multifactorial, 
involving multiple genetic and environmental factors and the likely interactions 
between those factors (Pediatric Cardiac Genomics et al., 2013). Nevertheless, 
in the last years, CHDs are seen as disorders resulting from alterations in genes 
that control basic embryonic processes between the third and eight week of 
gestation, when the majority of the cardiovascular structures develop and when 
the integrity of the left-right (LR) axis is established (Cecchetto et al., 2010; 
Icardo, Garcia Rincon, & Ros, 2002).  In fact, in the majority of cases presenting 
laterality disorders, a complex heart malformation is also observed, suggesting 
that CHDs could be due to a laterality defect in the formation of the heart (Levin, 
2004). In others words, even in children that born with CHDs and that do not 
present others extracardiac laterality abnormalities, the etiology of these CHDs 
could arise from subtle faults in the formation of the left-right axis.  
The molecular control of LR axis development is mainly achieved by the Nodal 
signaling pathway (Shiratori & Hamada, 2006). Studies in mice revealed that 
during gastrulation, Nodal, a growth factor from the TGF-ß family, is 
asymmetrically expressed in the node, and this expression is expanded and 
amplified in the left-lateral plate mesoderm (L-LPM), but inhibited in the right-
lateral plate mesoderm (R-LPM) (Shiratori & Hamada, 2014). Nodal itself 
induces its intracellular signaling by binding to type I (ALK4 and ALK7) and type 
II (ActRIIa and ActRIIb) serine-threonine kinase receptors in the presence of 
one EGF-CFC (epidermal growth factor-Cripto-FRL1-Cryptic) family co-
receptor, Cripto or Cryptic. This leads to the phosphorylation of regulatory 
Smads (Smad2 and Smad3), their association with Smad4, translocation into 
the nucleus, and to the interaction with the transcription factor FoxH1, which at 
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the end activates the expression of Nodal target genes, in particular Pitx2 
(Shiratori & Hamada, 2014). Pitx2 is a transcription factor that regulates the fate 
of cells that will form the visceral organs, including the heart (Nakamura & 
Hamada, 2012; Shiratori & Hamada, 2006). The impairment of the Nodal 
signaling in the lateral plate mesoderm, by variants in the genes involved in the 
pathway such as ActRIIB (MIM #602730) (R. Kosaki et al., 1999; Ma, Selamet 
Tierney, Lee, Lanzano, & Chung, 2012), LEFTY 1 (MIM #603037) (X. Deng et 
al., 2014; K. Kosaki et al., 1999), LEFTY 2 (MIM #601877) (X. Deng et al., 
2014; K. Kosaki et al., 1999), CRYPTIC/CFC1 (MIM #605194) (Goldmuntz et 
al., 2002; B. Wang, Wang, et al., 2011), CRIPTO/TDGF1 (MIM #187395) 
(Roessler et al., 2008; B. Wang, Yan, et al., 2011), FOXH1 (MIM #603621) (De 
Luca et al., 2010; B. Wang et al., 2010), NODAL (MIM #601265) (Mohapatra et 
al., 2009; Roessler et al., 2009) and PITX2C (MIM # 601542) (J. Wang et al., 
2013; F. Yuan et al., 2013) had already been associated to laterality disorders 
and/or CHDs in humans. For example, the heterozygous variant p.G260R in 
NODAL was associated with transposition of the great arteries (TGA), atrial and 
ventricular septal defects, double outlet right ventricle (DORV) and/or 
heterotaxy (Mohapatra et al., 2009). On the other hand, the NODAL p.S60I 
variant has been associated with the tetralogy of Fallot (TOF) phenotype 
(Roessler et al., 2009).  Additionally, several variations in Nodal co-receptor 
CFC1 were linked to TOF, TGA, DORV and/or laterality defects (Bamford et al., 
2000; Goldmuntz et al., 2002; Roessler et al., 2008).  
Recently, we reported that a DAN family member, the Nodal-antagonist 
Cerberus-like 2 (Cerl2) – DAND5 in humans (MIM #609068; refseq - 
NM_152654.2) – controls Nodal signaling at the mouse node (Belo et al., 2009; 
Oki et al., 2009) and the transmission of LR asymmetry information to the left-
lateral plate mesoderm in a precise time window (Inacio et al., 2013; Kawasumi 
et al., 2011).  Furthermore, the absence of Cerl2 in Cerl2 KO embryos leads to 
a range of laterality defects and/or cardiovascular malformations such as 
incomplete atrial and ventricular septation, TGA, DORV, randomized positioning 
of the cardiac apex, ventricular hypertrophy and/or heterotaxy of the abdominal 
organs, and a significant mortality rate within a few hours after birth is observed 
(Araujo, Marques, & Belo, 2014; Marques et al., 2004). 
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Here, in order to advance the understanding of DAND5 in the genetic etiology of 
laterality disorders and associated CHDs, we conducted a genetic screening to 
identify DAND5 allelic variants in children affected with CHDs and/or LR 
asymmetry defects. We identified a DAND5 allelic variant in two patients, which 
reduces the inhibitory activity of DAND5. We propose that this variant might 
contribute to the risk of congenital heart disease and/or laterality defects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
   75 
 
Results – Part I Chapter 3 
3. Results and discussion 
We studied thirty-eight well-defined probands meeting the inclusion criteria for 
congenital heart defects with a possible left-right abnormality cause (Table 3.1). 
These defects include atrial septal defects, ventricular septal defects, 
atrioventricular septal defects, conotruncal defects – pulmonary 
atresia/stenosis, tetralogy of Fallot, transposition of the great arteries, double 
inlet left ventricle, double outlet right ventricle, aortic coarctation, overriding 
aorta – left isomerism, right isomerism, dextrocardia and other cardiac 
malformations (right sided aortic arch, inferior vena cava interruption, 
univentricular heart, aortic stenosis, mitral valve stenosis, tricuspid atresia, 
hypoplastic right ventricle, hypoplastic left heart, major aortopulmonary 
collateral artery, persistent left superior vena cava, single ventricle and total 
anomalous pulmonary venous connection). Pulmonary atresia is the more 
frequent cardiac phenotype, being present in 37% of the cases. Nevertheless, 
this malformation was rarely found as an isolated case and, in almost all the 
cases, the patients present another cardiac malformation. Indeed, typically, 
each subject had complex defects with more than one abnormality, which is in 
agreement with the complexity, heterogeneity and diversity of this trait and 
represents, in many cases, severe forms of CHDs. Moreover, seven of the 
patients presented obvious defects resulting from abnormal left-right patterning, 
including four patients with left isomerism, one patient with right isomerism, one 
with situs inversus totalis and another with partial visceral situs inversus.   
 
 
Table 3.1. Clinical characteristics of the patients genotyped  
 
Prevalence of different types of CHD Nº of Patients (n=38) 
Atrial Septal Defect 2 (~5%) 
Ventricular Septal Defect 11 (~29%) 
Atrioventricular septal defects 8 (~21%) 
Conotruncal defects   
   Pulmonary atresia/stenosis  14 (~37%) 
   Tetralogy of Fallot 7 (~18%) 
   Transposition of the great arteries 8 (~21%) 
   Double inlet left ventricle 2 (~5%) 
   Double outlet right ventricle 1 (~3%) 
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   Aortic coarctation 1 (~3%) 
   Overriding aorta 1 (~3%) 
Left isomerism 4 (~11%) 
Right isomerism 1 (~3%) 
Dextrocardia 3 (~8%) 
Other cardiac malformations 20 (~53%) 
Extracardiac abnormalities  
   Situs inversus totalis 1 (~3%) 
   Visceral situs inversus 1 (~3%) 
   Asplenia 1 (~3%) 
 
Other cardiac malformations included right sided aortic arch, inferior vena cava interruption, univentricular 
heart, aortic stenosis, mitral valve stenosis, tricuspid atresia, hypoplastic right ventricle, hypoplastic left 
heart, major aortopulmonary collateral artery, persistent left superior vena cava, single ventricle, total 
anomalous pulmonary venous connection. Note: Almost all the patients have more than one type of CHD. 
 
The DNA sequencing analysis of this unrelated children cohort revealed two 
patients, patient 1 and patient 2, displaying the same variant in DAND5 gene.  
For validation, all exons were sequenced using forward and reverse internal 
primers flanking the missense variant. Clinically, patient 1 presented ventricular 
septal defect with overriding aorta, pulmonary atresia and left isomerism, while 
patient 2 presented overriding aorta, ventricular septal defect, right ventricular 
hypertrophy and pulmonary atresia (a case of extreme tetralogy of Fallot 
phenotype; Table 3.2).  
 
Table 3.2. Clinical and molecular findings of patient 1 and 2. 
 Genotype 
Protein 
alteration 
Phenotype 
Proband 1 DAND5 c.455GA DAND5 p.R152H 
Left isomerism; VSD with 
overriding aorta; Pulmonary 
atresia 
Proband 2 DAND5 c.455GA DAND5 p.R152H 
Tetralogy of Fallot; Pulmonary 
atresia 
                                               VSD – ventricular septal defect 
                          Wild type DAND5 refseq.  -  NM_152654.2 
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A) 
The variant was identified in both patients as heterozygous non-synonymous 
c.455G>A (Figure 3.1A). The phenotypically normal mother of patient 2 also 
presented heterozygosity the DAND5 c.455G>A variant, suggesting incomplete 
penetrance. Unfortunately, the father of patient 2 and the parents of patient 1 
were not available for sequencing. 
The c.455G>A variant in exon 2 of DAND5 results in a substitution of an 
Arginine (R) residue for an Histidine (H) (p.R152H) located in a highly 
conserved region of the cysteine-rich DAN domain (Figure 3.1B).  
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Figure 3.1 – Genomic localization of DAND5 455 allelic variant. 
 A) Forward and reverse DNA sequence chromatograms of patient 1 and 2 showing the c.455G>A 
allelic variant (highlighted by arrows). B) Schematic diagram of DAND5 structure with approximated 
localization of the variant identified in this study and cross-species sequence alignment of DAND5 
showing the conservation of amino acid R152 (highlighted by red box). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The available protein function prediction algorithms estimated differing 
functional effect of this variant in DAND5 (Table 3.3). In 2013, Polyphen-2 
algorithm (http://genetics.bwh.harvard.edu/pph2/index.shtml) indicated that this 
variant was possibly damaging for the DAND5 protein but, using an up-to-date 
version Polyphen-2 we now observed that the DAND5 p.R152H variant had no 
effect on the DAND5 protein (classified as benign). Moreover, Mutation Taster 
algorithm (www.mutationtaster.org) predicted that this variant is a polymorphism 
that might affect DAND5 protein features, namely alterations in the cysteine-rich 
domain. PROVEAN software (http://provean.jcvi.org/) predicted a deleterious 
effect (score -2.84) on the normal function of the DAND5 protein, and I-Mutant 
3.0 predicted that the a.a. alteration will reduce largely the stability of the protein 
(a score of −1.28 a reliability index of 9; disease reliability index of 3). 
B) 
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Nevertheless, these algorithms have only an accuracy of 65-80% in the 
prediction of known disease missense variants, being even less accurate when 
examining missense variants with milder effect (Richards et al., 2015).  
Table 3.3.  In silico protein prediction effect of DAND5 p.Arg152His alteration 
 Score Prediction effect 
Polyphen-2  0,49 (2013) / 0,120 (2016) Possible damaging / Benign 
Mutation Taster Polymorphism Might affect protein features 
PROVEAN -2,84 (cutoff= -2,5) Deleterious 
I-Mutant 3.0 -1,28 Kcal/mol 
Reduced stability of the protein and 
related to disease 
 
 
Taking this in attention, and to clarify the function of this protein variant, we 
reproduced the p.R152H variant in an expression vector containing the human 
DAND5 cDNA, and we evaluated the in vitro effect of p.R152H in the regulation 
of Nodal activity by using a well-established Nodal-dependent luciferase assay 
as readout.  This assay consists in a luciferase reporter gene under the control 
of three activin-responsive elements promoter, pAR3-lux, which is 
transcriptionally activated by Nodal signaling (Mohapatra et al., 2009) In 
addition, we used the human version of the main intervenient genes, NODAL, 
CRYPTIC/CRIPTO, FOXH1, all necessary for a reliable transduction of the 
levels of Nodal signaling in this type of assay. The results, from triplicates of 
three independent experiments, showed that the p.R152H DAND5 variant 
causes a significant reduction in the normal NODAL-inhibitory activity of DAND5 
(Figure 3.2). Since p.R152H is located in the functional domain of the DAND5 
protein and because DAND5 inhibits NODAL by direct binding (Marques et al., 
2004), we hypothesize that the protein alteration caused p.R152H variation 
might interfere with the interaction DAND5-NODAL. Therefore, we further 
extrapolate that, most probably, during the embryonic development of patients 
with p.R152H DAND5, which has a DAND5 molecule with reduced activity, the 
overall activity of NODAL on the node is above the proper levels. This abnormal 
NODAL activity on the node might be reflected then in an excess of NODAL 
activity on the left-lateral plate mesoderm and/or an ectopic expression of 
NODAL and PITX2 on the right-lateral plate mesoderm of the embryo. 
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Figure 3.2 – Functional analysis of DAND5 variant. 
The identified p.R152H variant was evaluated through a luciferase assay as readout of Nodal 
signaling. In this assay a luciferase reporter gene under the control of three activin-responsive 
elements promoter, pAR3-lux, which is transcriptionally activated by Nodal signaling, was used. The 
results, from triplicates of three independent experiments, showed that the p.R152H DAND5 variant 
leads to an increase of NODAL signaling when compared to WT DAND5 protein 
Interestingly, the phenotypes observed in these two patients, are consistent with 
an ectopic expression of NODAL and PITX2 on the right side of the embryo. 
 
 
 
 
 
 
 
 
 
Tetralogy of Fallot is a malformation of the cardiac outflow tract (OFT) that 
comprises ventricular septal defect, over-riding of the aortic valve, right 
ventricular outflow tract obstruction (pulmonary stenosis or in its most severe 
form, pulmonary atresia), and right ventricular hypertrophy (Goodship et al., 
2012).  The OFT forms during heart looping as a result of a coordinated process 
uncompressing proliferation, differentiation, and migration of the pre-cardiac 
cells of the secondary heart field (SHF). These cells are known to be sensitive 
to the asymmetrically left expression of the NODAL and PITX2 in the SHF 
(Nowotschin et al., 2006). Any imbalance in the LR patterning that might lead to 
an ectopic right-sided expression and loss-of-function of PITX2 results in 
reversed heart looping and abnormal shifting of the OFT (Martin, Amendt, & 
Brown, 2010; Ramsdell, 2005). Suggesting that anomalous LR body patterning 
has the tendency to develop severe congenital heart defects. Moreover, cases 
of fully bilateral expression of NODAL and PITX2 in the cells of both left and 
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right lateral plate mesoderm lead to left isomerism phenotypes, in which both 
atria present a left morphology, normally associated to atrioventricular septal 
defects (Shiraishi & Ichikawa, 2012). In agreement, it has been observed that 
the absence of Cerl2 (DAND5 mouse homolog) in Cerl2 KO mice leads to 
several cardiovascular malformations, including incomplete atrial and ventricular 
septation, conotruncal defects, ventricular hypertrophy, and/or to laterality 
defects like left isomerism and thoracic heterotaxy or situs inversus (Araujo et 
al., 2014; Marques et al., 2004).  
Interestingly, the DAND5 p.R152H variant had been already annotated in the 
NCBI (http://www.ncbi.nlm.nih.gov) and Ensemble (http://www.ensembl.org) 
databases as Single Nucleotide Variation (SNV - rs45513495), with a minor 
allele frequency (MAF) of ~ 1% (low-frequency variant; Supplementary. Material 
6) and described in ExAC database with an allele frequency of 0.01043 in all 
populations but never associated with disease, and even present in apparently 
16 normal homozygous. Indeed, the mother of patient 2 is phenotypically 
normal but displays the DAND5 p.R152H variant. Nevertheless, we cannot 
exclude the presence of a mild or undiagnosed heart defect on the mother of 
patient 2, or on the subjects of the genome projects, since detailed examination 
of these subjects is rarely available. In addition, the ExAC database and the 
American College of Medical Genetics and Genomics warns to the fact that in 
these population databases the presence of individuals with subclinical 
diseases among the supposed healthy individuals leading to minor 
discrepancies in some variant frequencies cannot excluded (Richards et al., 
2015). For example, some phenotypes of CHD such as small atrial septal 
defects and ventricular defects may be asymptomatic and undetected 
throughout life (Huang et al., 2010), or cases of apparent normal individuals 
whose laterality defects were only detected during adulthood (Channabasappa, 
Mohan, & Sarma, 2013). Besides that, the degree of the functional Nodal 
pathway impairment might be explained by factors like differential allelic 
expressivity, an incomplete penetrance, the presence of genetic modifiers, 
and/or environmental factors. Interestingly, ~40% of the Cerl2 KO mice become 
normal adults, without any CHD and/or laterality defect (Marques et al., 
2004).This suggests that the distribution and strength of the Cerl2 inhibitory 
 82 
 
Results – Part I Chapter 3 
signal and ultimately the imbalance of the dose-sensitive Nodal signaling might 
be sensitized by additional perturbations during LR patterning.  
Curiously, the sensitization of an imbalanced of Nodal signaling and its 
correlation to differences in phenotypes was also observed in the other genes of 
Nodal signaling cascade (Goldmuntz et al., 2002; Mohapatra et al., 2009; 
Roessler et al., 2008). For example, cryptic (CFC1 mouse homolog) full-mutant 
mice presents randomization of abdominal situs and complex cardiac 
malformations such as atrial and septal defects, dextrocardia, DORV and TGA, 
but normal configuration of the OFT was seen in one mutant (Gaio et al., 1999). 
In humans, it was identified and classified as disease variant due to its loss-of-
function effect, an heterozygous single-base-pair deletion (G174 del1) in CFC1 
in two patients both with dextrocardia and TGA but one of the patients 
presented right isomerism, whereas the other patient presented left isomerism. 
This CFC1 variant was also reported in one subject with sporadic DORV, 
ventricular septal defect, aortic arch hypoplasia (Goldmuntz et al., 2002) and in 
a patient with tetralogy of Fallot (Roessler et al., 2008). Interestingly, likewise 
we observed in p.R152H DAND5 variant, the mothers of these CFC1 variant 
patients were found to carry the G174del1 alteration but none presented any 
clinical phenotype, suggesting incomplete penetrance. Accordingly, similar 
cases of reduced penetrance have been reported in CHD by others (Bamford et 
al., 2000; Megarbane et al., 2000).  
Although the DAND5 p.R152H did not attest a specific genotype-phenotype link, 
our functional results support a model in which the proper levels of Nodal 
signaling, on both left and right lateral plate mesoderm, are particularly sensitive 
to gene dosage effects for all genes involved in the pathway. The imbalance in 
dosage-sensitive Nodal signaling is a final common way for laterality defects 
and associated CHDs.  
In conclusion, our findings firstly prime DAND5 as one of multiple candidate 
determinants involved in the complex trait mechanism that cause CHDs, 
associating the human vulnerability for CHDs with the reduced activity of 
heterozygous DAND5 p.R152H variant. 
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1. Abstract 
Perturbations in the establishment of the Left-Right axis lead to laterality 
defects, which in most of the times have associated complex CHDs 
comorbidities. Therefore, genes of the Nodal signaling pathway have been 
reported to be implicated in the etiology of CHDs and/or laterality defects. 
Considering the high conservation of genetic pathways regulating cardiac 
development in mouse and human, the study of the human genes involved in 
this pathway will bring us new data of the cellular and molecular mechanisms 
that underlie cardiac asymmetry on the CHD and the laterality defects. In the 
first chapter of results/discussion we identified and characterize a DAND5 
variant that seems to function as a risk allele for CHDs and/or laterality defects. 
Nevertheless, we cannot make a clearly genotype-phenotype correlation and 
the genetic data points to an incomplete penetrance, suggesting the presence 
of modifier variants or other alterations in genes which DAND5 normally 
interacts or in genes of the Nodal signaling pathway. Therefore, in addition to 
the DAND5 gene, we analyzed the NODAL, CFC1 and PITX2C genes in the 
same cohort of 38 patients presenting CHD and/or laterality defects. We have 
found two coding change alterations, one in NODAL and one in CFC1 and three 
intronic variants in the genomic sequence of PITX2C and NODAL. In silico 
analysis of the intronic variants using the splicing prediction software Human 
Splicing Finder indicates that these variants could somehow affect the splicing 
process of NODAL and PITX2C mRNA. Regarding the coding sequence 
alterations, the NODAL exonic variant was already described by other authors 
and classified as a potential modifier variant that can increase the risk of 
disease, depending on other genetic alteration in other genes. The CFC1 
variant, analyzed using prediction softwares to verify the potential effect of a 
mutation in the final protein, was predicted to have no functional effect in the 
CFC1 protein. Altogether, our data indicates that abnormal Nodal signaling 
caused by the presence of gene variants in various components of the pathway 
may be an important factor influencing or increasing the risk of developing 
CHDs during development. 
Keywords: Nodal Signaling, CHD, laterality defects, allelic variants. 
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2. Background 
Most congenital heart defects arise during embryonic development as 
consequence of failures in critical developmental processes that lead to the 
formation of the heart. This results in most cases from the disruption of a certain 
signaling pathway caused by genomic alterations in a gene or in various genes 
involved in that specific pathway. In this study, and as reported in the previous 
chapter, we found a DAND5 alteration that can function as a risk allele for the 
development of CHDs/ and or Laterality defects. Nevertheless, and since that 
the genotype-phenotype seems to represent a case of incomplete penetrance, 
we cannot exclude the hypothesis that the effect of this DAND5 p.R152H 
variant could be affected/modified by the presence of other alterations in genes 
involved in the Nodal signaling pathway. Moreover, alterations in these genes 
might also contribute for abnormal levels of the pathway and thus for the 
phenotypes of the patients. Therefore, even though our main focus was on the 
role of DAND5 in the NODAL signaling pathway, we extended the genetic 
screening to other genes from this cascade in order to understand how genomic 
alterations in NODAL signaling genes could impact the DAND5 alteration and 
congenital heart defects. In addition to the two exons of the DAND5 gene 
(Chapter 3, Part I), we also screened for alterations all the exons and exon-
boundaries of NODAL, CFC1 and PITX2C genes in the children cohort 
described anteriorly. NODAL gene, which is located at chromosome 10q22.1, 
contains three exons and encodes a secreted protein belonging to transforming 
growth factor (TGF-β) superfamily that is critical for establishing the left-right 
asymmetry during early development [120]. CFC1 is a six exons gene at 
chromosome 2q21.1 that belongs to the epidermal growth factor-CFC1 family. 
This gene encodes an extracellular protein that functions as a membrane-
associated Nodal co-receptor and plays a key role in intercellular left-right 
signaling pathway [98]. The paired-like homeodomain transcription factor 2 
(PITX2) gene is located at chromosome 4q25 and its isoform c results from 
splicing mechanisms that uses an alternative promoter located upstream of 
exon 4 [121]. Pitx2c isoform plays a critical role as a late effector in left–right 
asymmetry, being the major downstream effector of the Nodal pathway during 
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heart morphogenesis, presenting differential expression in various cardiac 
precursor cells and components the heart. 
 
3. Results and discussion 
From the sequences analyzed using sanger sequencing of the thirty-eight 
patients, we identified two non-synonymous sequence alterations and three 
intronic variants in the genes NODAL, CFC1 and PITX2C. The missense 
alterations were found in the exons of the NODAL (H165R) and CFC1 (A175T) 
genes whereas the non-coding sequence variants were found in the first intron 
of both NODAL (c.193+12 C>T) and PITX2C genes (c.205+88G>C; 
c.205+71A>G) (Table 3.4). 
 
Table 3.4. Localization and frequencies of variants found. 
Gene Nucleotide/ Protein Affected 
NODAL 494 A>G/H165R 33/38 
NODAL c.193+12 C>T (intron) 20/38 
CFC1 523G>A/A175T 1/38 
PITX2C c.205+71A>G (intron) 8/38 
PITX2C c.205+88G>C (intron) 17/38 
 
To understand if these sequence variants were newly identified variants, we 
searched on NCBI (http://www.ncbi.nlm.nih.gov/), Ensemble 
(http://www.ensembl.org), ExAC (http://exac.broadinstitute.org) and Human 
Gene Mutation Database (www.hgmd.cf.ac.uk) databases if those alterations 
had already been described by others or found in genome sequencing projects. 
According to our analysis, the NODAL and PITX2C variants were found in 
different sequencing projects and annotated in the NCBI, Ensemble and ExAC 
browser as Single Nucleotide Polymorphisms (SNPs). Regarding the CFC1 
genetic variation, we could not find any data related to that particular alteration, 
neither in the literature, nor in the available polymorphism/mutations databases, 
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Figure 3.3 – Sequencing and genomic localization of the NODAL 494 A>G allelic variant. 
and schematic diagram of NODAL structure with approximated localization of the variant identified in 
this study and cross-species sequence alignment of DAND5 showing the conservation of amino acid 
R152 (highlighted by red box). 
suggesting that it is likely a new variant that had not been studied so far. The 
results from this search are detailed below. 
3.1. NODAL H165R variant 
One of the alterations found in this study was a substitution of the ancestral 
nucleotide adenine to a guanine (Figure 3.3) in the 494th coding nucleotide 
(c.494A>G) in the exon 2 of the NODAL gene. At protein level, this alteration 
results in the missense replacement of a histidine for an arginine in the 165th 
position of the pro-domain of the NODAL protein (Figure 3.3).   
 
 
 
 
 
 
 
 
 
 
  
 
This genomic alteration was identified in thirty-three of our thirty-eight patients 
(Table 3.4), being homozygous in seven probands and heterozygous in twenty-
six. This alteration had already been described by others and/or in any 
polymorphism/mutations databases as an extremely common sequence variant, 
corresponding to the SNP rs1904589, with a heterozygosity of almost 50% and 
A     A    G     C   A/G   C     C     C       
5´                                                   3’ 
A     G      G     G    T/C    G     C      T      
3´                                                    5’ 
p.H165R 
Mature domain  
1 27 237 
347 
Signal peptide 
Pro-domain 
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a minor allele frequency (MAF) (allele A/T) of 46% in the European population 
of the 1000 genomes project (Figure 3.4). Moreover, it was also identified in two 
other studies, in 2008 and in 2009, conducted by Maximilian Muenke and co-
workers [103, 107]. 
 
 
 
 
 
 
In these studies, Maximilian Muenke and co-workers examined the genomes of 
individuals with CHD, laterality defects, and Holoprosencephaly (HPE) defects 
and found that the NODAL p.H165R alteration was present in the CHDs cohort 
patients [103, 107]. They also functionally characterized this variant using a 
Nodal-dependent luciferase assay showning that this common variant had less 
than 50% activity when compared to the wild-type NODAL protein (Figure 3.5) 
[107].  
 
 
 
 
 
 
 
 
 
Figure 3.5 –  Relative activity of human NODAL p.H165R variant. 
The p.H165H variant was evaluated through a luciferase assay as readout of Nodal signaling. The 
result showed that this NODAL variant leads to a decrease of about 50% of NODAL signaling (black 
arrowhead) when compared to wild-type NODAL protein (adapted from Roessler et al. 2009).  
Figure 3.4 –  NODAL 494 G(C)>A(T) allele frequency according to 1000 genome project. 
The NODAL 494 A>G variant present a minor allele frequency (MAF) of allele A = 0.46 in the 
European Population. AFR - African population; AMR - American population; ASN - Asian population; 
EUR - European population. 
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Furthermore, and since the variant allele (A/T) is the more frequent in the 
population, as shown in Figure 3.4, the author evaluated if the NODAL p.H165R 
variant had been observed in other vertebrates. As shown in Figure 3.6, the 
p.R165 variant only exists in chimpanzees and humans, not in other higher 
mammals, indicating that the p.H165 is the ancestral version and correctly used 
as the normal version of the gene/protein [107]. Therefore and due to its 
functional effect, the common p.R165 variant may serve as a common modifier 
associated with an increased risk of disease in the CHD patients.  
 
 
 
 
 
 
 
 
 
 
3.2. NODAL intronic mutation 
The other NODAL gene alteration identified in this study is localized in the first 
intron and consists of a substitution of a cytosine for a thymine (Figure 3.7), 
twelve nucleotides after the end of the exon 1 (c.193+12 C>T). This variant was 
observed in twenty patients of our cohort (Table 3.4), being heterozygous in 
seventeen and homozygous in three. This c.193+12 C>T allelic variant is also 
annotated in the public databases as a SNP – rs10999338 – (Ensemble, NCBI 
and ExAC). In fact, this SNP has been described as an extremely common 
sequence variant with a heterozygosity of 45% and a minor allele frequency (T) 
Figure 3.6 –  Conservation of the NODAL p.H165R variant between species. 
Cross-species sequence alignment of p.H165R NODAL protein variant showing the conservation of 
amino acid R165 (highlighted by red inverted triangle) only in the homo sapiens and pan troglodyte 
(adapted from Roessler et al. 2009). 
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of 44% in the European population sequenced in the 1000 genomes project 
(Figure 3.7). 
  
 
 
 
 
 
 
 
 
3.2.1. In silico analysis 
Although alterations in the coding regions of the genome are suggested to be 
the main and more logical cause of disease in humans, today, it is estimated 
that ~15% of all point mutations causing human disorders disrupt splice-site 
consensus sequences, particularly at intronic positions [122]. Therefore, due to 
the close localization of the c.193+12 C>T allelic variant to the 5’ splice site and 
in order to understand its relevance, we used the online software Human 
Splicing Finder to predict in silico if this intronic variation could be interfering 
with the normal splicing process. As shown in Figure 3.8, the prediction results 
indicate that this C>T substitution may lead to the generation of 3 new enhancer 
locals, including one for the ligation of the SF2/ASF splicing factor and other 
that allows the biding of the SRp55 protein to its motif with more affinity and 
may disrupt the “AGTGCC” enhancer motif (Figure 3.8B). The SRp55 and 
SF2/ASF proteins are involved in pre-mRNA splicing and in the specificity of 
Figure 3.7 –  Sequencing and allele frequency of the c.193+12C>T variant. 
Forward and reverse DNA sequence chromatograms of one patient showing the c.193+12 C>T allelic 
variant (highlighted by arrows) and representation of allele frequency of C and T alleles in the 
populations sequenced in the 1000 genomes project. AFR - African population; AMR - American 
population; ASN - Asian population; EUR - European population 
5´                                             3’ 3´                                              5’ 
T        G      C      C/T     G      C       G       C       G      C      A/G     G      C       A       
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alternative splice site selection. Furthermore, the presence of T nucleotide 
instead of the normal C in the c.193+12 position seems also to create new 
silencer motifs (Figure 3.8C). Altogether, these in silico results indicate that the 
c.193+12C>T can be creating new or interfering with existing splice sites, 
interfering with the normal splicing of the NODAL gene.  
 
 
A) 
B) 
C) 
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C     C     C     A   A/G   G     G      A       T      C     C     T/C      T    G       G      
5´                                             3’ 3´                                              5’ 
 
 
 
3.3. PITX2C variants 
The genetic screening in our patient cohort also revealed two variants in the 
intron of the PITX2 isoform C gene. These alterations localize close to each 
other in intron 1B, more specifically in the genomic positions c.205+71 and 
c.205+88, and lead to a substitution of an A>G and a G>C, respectively. The 
c.205+71A>G allelic alteration was identified in eight of the thirty-eight patients 
cohort, being heterozygous in six and homozygous in two whereas the 
c.205+88 G>C was present in seventeen patient, of which four are homozygous 
and thirteen heterozygous.  
 
 
 
 
 
 
 
 
 
In the same line of thought as for the alterations described above, we also 
checked in the public databases, NCBI, Ensemble, ExAC and HGMD for any 
Figure 3.9 –  Sequencing and allele frequency of the PITX2C c.205+71A>G substitution. 
Forward and reverse DNA sequence chromatograms of one patient showing the c.205+71 A>G allelic 
variant (highlighted by arrows) and representation of the allele frequency of T(A) and G(C) alleles in 
the populations sequenced in the 1000 genomes project. AFR - African population; AMR - American 
population; ASN - Asian population; EUR - European population 
Figure 3.8 – In silico analysis of NODAL intronic variant using the Human Splicing Finder 
online software A) Wild-type and variant genomic sequences analyzed by the HSF software. B) 
Predicted enhancer motifs created or broken due to the c.193+12C>T variant. C) Potential new 
silencer motifs. 
 94 
 
Chapter 3 Results – Part II 
reference to these two PITX2C intronic variants. We verified that the intronic 
c.205+71A>G substitution (Figure 3.9) in the PITX2C gene was reported in the 
public databases of NCBI and Ensemble as the rs28510307 SNP, but not in 
ExAC. Moreover, in these two databases, we also found some information 
about the frequency of the normal and variant nucleotide. As shown in Figure 
3.9, this common variant has a Minor Allele Frequency (allele G/C) of 16% in 
the European population and was detected as heterozygous in 27% of the 
same cohort of persons that participated in the 1000 genome project. Regarding 
the c.205+88 G>C variant (Figure 3.10), which we found to correspond to the 
SNP rs762401950, even though it was also described in the NCBI and 
Ensemble databases, it was not detected in the 1000 genome project or other 
big sequencing projects. Therefore, we could not have any relevant information 
about its frequency in the population our about the study context in which the 
variant was detected. 
 
 
 
 
 
 
 
 
3.3.1. PITX2C c.205+71A>G in silico analysis 
In order to understand the possible impact of the c.205+71 A>G allelic variant in 
the splicing process of the PITX2C gene isoform, we performed an in silico 
analysis of this variant using the previously mentioned Human Splicing Finder 
(HSF) online software. As presented in the Figure 3.11, the HSF predicted that 
the A>G nucleotide alteration could lead to the creation or disruption of splice 
site acceptors and creation of a new splice site donor (Figure 3.11B) in the 
C      C      G     G/C    G      G       G       C      C      C     C/G   C       G       G       
5´                                             3’ 3´                                              5’ 
Figure – 3.10 –  DNA Sequencing of PITX2C gene. 
Forward and reverse DNA sequence chromatograms of one patient showing the c.205+88 G>C allelic 
variant (highlighted by arrows). 
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B) 
genomic sequence of PITX2C gene. Moreover, this alteration could also disrupt 
a branch point site (Figure 3.11C), which could be involved in the selection of 
the next exon to incorporate into the mature RNA. But the impact of this variant 
in the splicing event of the PITX2C gene could not be just in the main 
interviewing sequences (donor and acceptor sites and branch point site) 
responsible for this process. As shown in Figure 3.11D and E, this nucleotide 
change seems also to alter several possible splicing enhancer and silencers 
motifs, being the more important ones the disruption of the splicing enhancers 
motifs responsible for the ligation of the SF2/ASF and 9G8 splicing factor 
proteins and the disruption of the splicing silencer motif “AAGGAA” responsible 
for the biding of the hnRNP A1 protein. 
 
   
A) 
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C) 
D) 
E) 
  
   97 
 
Results – Part II Chapter 3 
 
 
 
These results, from an in silico analysis performed using the online software 
HSF, indicate that the c.205+71A>G intronic variant could result in abnormal 
splicing of the isoform C of the PITX2 gene, mainly due to the 
disruption/creation of essential donor, acceptor or branch point sites and due to 
the broken of splicing enhancer/inhibitor motifs responsible for the biding of the 
spliceosome proteins. 
3.3.2.  PITX2C c.205+88 G>C in silico analysis 
As for the NODAL and the other PITX2C intronic variants described above, we 
also performed the in silico analysis of the PITX2C c.205+88 G>C nucleotide 
change using the HSF prediction software. This variant was predicted to create 
a new splice donor site, new enhancer motifs for the biding of the splicing factor 
SF2/ASF and disrupt some splice inhibitor motifs (Figure 3.12).  
  
 
 
 
 
 
 
 
 
 
Figure 3.11 – In silico analysis of the PITX2C c.205+71 A>G variant. 
A) Wild-type and variant genomic sequences analyzed by the HSF software. B) Potential donor or 
acceptor splice sites created or broken by the c.205+71 A>G alteration. C) Potential branch point 
disruption caused by the allelic variant. D-E) Predicted created or broken splicing enhancer and 
silencers motifs.  
A) 
B) 
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C) 
D) 
E) 
Figure 3.12 – In silico analysis of the PITX2C c.205+81 A>G variant. 
A) Wild-type and variant genomic sequences analyzed by the HSF software. B) Potential donor or 
acceptor splice sites created or broken by the c.205+81 A>G alteration. C) Potential branch point 
disruption caused by the allelic variant. D-E) Predicted created or broken splicing enhancer and 
silencers motifs.  
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G         C       G/ A       C       G       C/T         G         
C    
5´                                             3’ 3´                                              5’ 
Therefore, the predicted results illustrated in the Figure 3.12 indicated that this 
variant seems to have a milder effect on splicing compared with the other 
PITX2C variant, mostly because of the lack of effect in the motifs responsible 
for the biding of the 9G8, Tra2 and hnRNP A1 splicing factors. 
 
3.4. CFC1 missense alteration 
The sequencing analyses of our patient cohort revealed one proband displaying 
one alteration in the CFC1 gene. Clinically, the patient presented ventricular 
septal defect, coarctation of the aorta, aortic and mitral valve stenosis. The 
variant was identified as heterozygous non-synonymous and results in a 
substitution of guanine for an adenine in the 523th nucleotide of the coding 
sequence of the CFC1 gene. At protein level, this alteration results in the 
missense replacement of an alanine, a non-polar side chain amino acid, for a 
threonine, a polar side chain amino acid, in the 175th position of the hydrophobic 
C terminus - membrane-anchoring signal of the CFC1 protein (Figure 3.13).   
 
 
 
 
 
 
 
 
 
 
 
CFC1 523G>A  
Alanine (A)175 Threonine (T) 
123 
Hydrophobic C terminus - membrane-
anchoring signal 
  
1 25 90 169 
223 
119 
Signal peptide 
CFC domain 
EGF-like domain 
EGF CFC 
158 
A175T 
Figure 3.13– CFC1 allelic variant. 
 A) Forward and reverse DNA sequence chromatograms showing the c.523 G>A variant (highlighted 
by arrows). B) The alteration result in a substitution of an a non-polar by a polar side chain amino acid 
C) Schematic diagram of CFC1 structure with approximated localization of the p.A175T variant 
identified. 
 
A) 
B) C) 
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After searching in the public databases if this alteration was already described, 
we could not find any match related to that particular alteration, neither in the 
literature. This suggested that this alteration is likely a new variant. In order to 
understand the potential functional effect of this alteration in the structure and 
function of the CFC1 protein, we used the Polyphen-2, Mutation Taster, 
PROVEAN and I-Mutant 3.0 prediction softwares. As shown in table 3.5, all 
softwares predicted that the p.A175T amino acid alteration had no functional 
effect in the CFC1 protein. 
 
Table 3.5.  In silico protein prediction effect of CFC1 p.A175T alteration 
 Score Prediction effect 
Polyphen-2  0,010 Benign 
Mutation Taster Polymorphism No protein features affected 
PROVEAN -0,23 (cutoff= -2,5) Neutral 
I-Mutant 3.0 -0,36 Kcal/mol Decreased stability of the protein 
 
3.5. Conclusions 
Altogether, the results of the sequencing of the genes NODAL, CFC1 and 
PITX2C involved in the Nodal signaling pathway, which is essential for the 
correct establishment of the left-right axis and posterior heart morphogenesis, 
allowed us to identify 4 reported SNPs and a likely new CFC1 variant in our 
thirty-eight patient cohort. These variants have impact at the level of the 
functional protein, as in the case of the NODAL p.H165R variant, or in the 
splicing process of the RNA transcript as showed by the in silico analysis 
performed with the HSF software. Even though all the SNPs that we identified 
are relatively frequent in the apparently normal population, we cannot exclude 
the possibility that they can confer risk for disease especially if more than one 
SNPs are found in the same individual. Therefore, functional studies are 
needed in order to understand the real impact of these variants in Nodal 
signaling, ideally the combined impact of the different variants. Nonetheless, our 
data indicates that abnormal Nodal signaling caused by the presence of gene 
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variants in various components of the pathway may be an important factor 
influencing or increasing the risk of developing CHDs during development. 
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1. Abstract  
A 15-year old female child was clinically diagnosed with left isomerism, 
ventricular septal defect with overriding aorta and pulmonary atresia, defects 
that can be associated with early left-right establishment impairment. Genetical 
analysis indicate that this patient carries a heterozygous non-synonymous 
variant in exon 2 of DAND5 gene (c.455G>A), causing an amino acid change of 
p.R152H in the functional domain of the DAND5 protein, a master regular of 
Nodal signalling. In the work presented here, we generated a DAND5 455G>A, 
and a control iPSC lines using the CytoTune®-iPS 2.0 Reprogramming kit (Life 
Technologies, Invitrogen), which includes the reprogramming factors SOX2, 
OCT3/4, c-MYC and KLF4. For this purpose, exfoliated renal epithelial cells 
isolated from a urine sample were obtained from the patient and healthy control 
to serve as template cell for reprogramming. 
After reprogramming, iPSC colonies from each line were picked, expanded and 
ultimately characterized. Both cell lines displayed a typical small, round shape, 
and tightly packed ESC-like morphology with a high nucleus/cytoplasm ratio 
with prominent nucleoli. DNA Sanger sequencing confirmed the presence of a 
c.455G>A substitution in one of the alleles of exon 2 in the patient DAND5 gene 
corresponding to a R152H protein alteration and no such alteration in the same 
genomic region of the control cell line. Gene expression and 
immunofluorescence analysis confirmed the expression of pluripotency markers 
at mRNA (OCT3/4, NANOG, SOX2, KLF4 and NODAL) and protein (NANOG, 
OCT4 and SSEA4) levels, characteristic of pluripotent ES cells and illustrating 
the purity of the both iPSC lines. Karyotyping shows a normal 46, xx alignment 
of the chromosomes in the patient-derived iPSC line.   
 
 
 
Keywords: DAND5 allelic variant, Congenital Heart Diseases, laterality defects, 
iPSCs, Disease modelling. 
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2. Background 
Numerous animal models carrying defined mutations in their genome have 
been generated and used for the analysis of gene function and also to mimic 
human variants in vivo, either by gene knockin approaches or study of null 
mutations [122]. This approach give rise to a tremendous amount of data 
helping to increase our knowledge about the molecular mechanisms that lead to 
human congenital heart diseases. However, in most of the cases it fails in the 
effective recapitulation of the human phenotype mostly due to the considerable 
differences that exist between the human and mouse genomes (not all gene 
sequences or variants are known or sufficiently conserved between species), 
with many genetic modulators being human specific [122, 123]. In addition, 
wherein heterozygous alteration of human disease genes is often well tolerated 
in mice, homozygous alteration could cause in mice severe and even lethal 
phenotypes not observed in humans [122]. Also, interspecies differences in cell 
and organ physiology or cellular and molecular composition may preclude the 
phenotype from being revealed [123]. Therefore, the creation of in vitro models 
for human congenital heart abnormalities that accurately reflect the patients 
disease phenotypes are important not only for understanding the genetic 
mechanisms leading to the disease itself, but also for drug screening efforts 
aimed to the identification of potential treatment therapies. 
In 2006, the remarkable report of Yamanaka and colleagues showed that 
human adult somatic cells could be reprogrammed into a pluripotency state 
using a combination of four-transcription factors (Oct3/Oct4, Sox2, Klf4 and c-
Myc) (Takahashi & Yamanaka, 2006). This groundbreaking observation has 
revolutionized the stem cell and disease modelling fields, and, in our days, the 
generation of patient-specific induced pluripotent stem cells (iPSCs) is a well-
established technique and the gold standard for cellular models of diseases 
without the ethical and political concerns associated with the use of human 
embryos for scientific purposes (C. Kim, 2014).  
iPSCs can be generated from different sources of tissues, being the skin 
fibroblast or blood cells the more commonly used. Nevertheless, skin biopsy 
has many drawbacks since it is an invasive procedure, accompanied by 
  
    107 
 
Results – Part III Chapter 3 
Figure 3.14 – Genotype of patient and control samples used to generated iPSC lines.  
DNA sequence chromatograms of a specific region of DAND5 exon 2 showing the c.455G>A allelic 
variant (highlighted by arrows) in the proband with Congenital heart defects associated with laterality 
defects) and a normal nucleotide sequence in the healthy control. 
discomfort and risk of bleeding, infection, permanent scars on donors, the 
resulting cells expand slowly in culture, and the reprogramming efficacy is 
usually low (Jouni et al., 2015). Recently, it was demonstrated that the cells 
present in a simple urine sample could be an easy and non-invasive source for 
generating human iPSCs, overcoming the issues from the skin biopsies 
samples (Zhou et al., 2012). 
Here, to have a clear and robust insight into the mechanism of disease 
displayed by patients carrying the DAND5 455G>A allelic variant (chapter 3, 
part 1), we took advantage of the iPSCs technology to generate a patient-
specific cell line of pluripotent stem cells (Figure 3.14). In addition, we 
generated a iPSC line derived from a healthy adult donor without any alteration 
in the DAND5 gene to serve as control cell line (Figure 3.14).  
  
 
 
 
 
 
 
 
 
 
 
 
C      T    C   G    C   A    A       
5´                                                         3’ 
Healthy control 
5´                                                        3’ 
Proband 
C    T    C  G/A  C   A    A       
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3. Results and discussion 
3.1. Isolation and generation of Patient-Specific 
human iPSC lines from a Urine Sample. 
To evaluate the potential effect of the identified DAND5 455G>A allelic variant 
and to model the disease presented by the patient with this alteration, we 
isolated exfoliated renal epithelial cells isolated from a 15-year old female child 
patient and from an healthy control urine samples, as described in material and 
methods, section 8.2. The patient was clinically diagnosed with left isomerism, 
ventricular septal defect with overriding aorta and pulmonary atresia, defects 
that can be associated with early impairment of left-right axis establishment. 
Genetically, the patient carries a heterozygous non-synonymous variant in exon 
2 of DAND5 gene (c.455G>A), causing an amino acid change of p.R152H  in 
the functional cysteine-rich DAN domain of the DAND5 protein (Table3.6 ). 
  
Table 3.6. Clinical and molecular findings of patient and healthy control. 
 Genotype 
Protein 
alteration 
Phenotype 
Proband  
DAND5 
c.455GA 
DAND5 
p.R152H 
Left isomerism; VSD 
with overriding aorta; 
Pulmonary atresia 
Healthy control 
DAND5 
c.455GG 
DAND5 
p.R152R 
Without CHDs 
 
After isolation, the cells in culture were mostly squamous cells, some blood cells 
and barely detectable exfoliated renal epithelial cells (Figure 3.15A). With the 
daily replacement of the medium, the squamous cells completely disappear 
around day 4 and the first colonies of exfoliated renal epithelial cells become 
more evident. At this time, the cell culture is composed of two types of 
exfoliated renal epithelial cell colonies with distinct morphology. As shown in 
Figure 3.15B-C, type I colonies have a more regular appearance with smooth-
edged contours and cobblestone-like cell morphologies, whereas type II 
colonies are more elongated and randomly arranged, grow more quickly and 
are more abundant than type I cells. After 7 days in culture, the exfoliated renal 
epithelial cells reached 70-80% confluency (Figure 3.15D) and were passaged 
to a six-well plate well for further expansion and reprogramming. 
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Figure 3.15 – Morphology of the proband urinary cells at different time points after collection.  
A) Fresh urine samples mainly consist of squamous cells and a few blood cells (arrowheads). B,C) 
Type II  and type I urinary cell colonies (arrowheads) at days 4. D) Urinary cell colonies at days 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The reprogramming of the cells was performed by using the CytoTune®-iPS 2.0 
Reprogramming kit (Life Technologies, Invitrogen), which includes the 
reprogramming factors SOX2, OCT3/4, c-MYC and KLF4 (Takahashi & 
Yamanaka, 2006) and is based on a modified non-integrative, and non-
transmissible form of Sendai virus (SeV). After transduction with the viruses, the 
cells passed through a period of morphological changes, going from elongated 
type II urine cells at the time of infection into a cobblestone-like pattern of cells 
120 hours after infection, having higher nucleus to cytoplasmic ratio (Figure 
3.16). At 7 days post-transduction, clusters of reprogrammed urinary cells with 
stem cell-like morphology intercalated with elongated cells that were not 
reprogrammed could be observed (Figure 3.16G). 
A) B) 
C) D) 
Day 0 Day 4 
Day 4 Day 7 
Squamous cells 
Blood cells 
Type II cells 
Type I cells 
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0 hours 
24 hours 48 hours 72 hours 
Day 7 120 hours 96 hours 
A) 
B) C) D) 
E) F) G) 
Figure 3.16 – Morphology of the proband-derived cells at different time points during 
transduction with Sendai virus carrying the Yamanaka reprogramming factors. A) Elongated 
type II urinary cells at the day of infection.  B – G) Morphological transition of urinary cells after 
transduction, resulting in a cobblestone-like pattern of cells at 120 hours post-infection. 
 
 
 
 
In order to isolate the iPSCs and to allow the complete reprogramming of the 
stem cell-like colonies without the influence of the non-reprogrammed elongated 
cells, the cultured cells were expanded to a larger 100mm culture dish and 
cultured in the presence of stem cell E8 medium. As shown in Figure 3.17A, 
one day after passaging to a 100mm dish, the large clusters of iPSC-like cells 
were split and the culture composed mainly by individual cells. At this time there 
was also some cell death of the cells that did not attach to the plate, which were 
likely mostly the non-reprogrammed cells. With the replacement of the stem cell 
medium every day, the dead cells in suspension were removed from the culture 
and the adherent cells started to proliferate and form colonies (Figure 3.17B-D). 
At day 16, the reprogrammed cells assumed a typical stem cell colony 
morphology, with defined borders, containing dozens of small round cells each 
colony, with spaces between them, and large nuclei with notable nucleoli 
(Figure 3.17E). 
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To obtain homogenous and clonal iPSC lines, several single cell-derived iPSC 
colonies (Figure 3.17E) were manually picked and transferred to new plates at 
day 17 post-transduction. This clonal isolation and expansion allows the 
generation of iPSCs with a higher stemness and enriches the purity of the iPSC 
line.    
Although the age and gender of the donors were different, the same procedure 
was performed to generate control iPSC lines and equivalent results and 
timings were obtained for the isolation and generation of these control cells. 
 
3.2. Characterization of DAND5 allelic variant and 
healthy control human IPSCs lines.  
3.2.1. Morphology 
After clonal expansion (~15 clones of each cell line), both the healthy control 
and DAND5 allelic variant iPSC lines, continued to display a typical small, round 
shape, and tightly packed ESC-like morphology with a high nucleus/cytoplasm 
ratio with prominent nucleoli as presented in Figure 3.18. Suggesting that the 
generated iPSC lines were successfully reprogrammed.  
A) B) 
C) D) 
E) 
Day 8 Day 10 
Day 12 Day 14 Day 16 
Figure 3.17 – Morphology of proband iPSC-like cells at different time points after expansion.  
A) One day after passaging (8 days post-infection) most of the cells attach to the plate whereas some 
die. B – E) Recovery of the iPSC morphology, proliferation and clumping of the cells that survive and 
attach to the plate. 
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Figure 3.18 – Morphology of two picked clones of each iPS derived cell line.  
Both cells lines displayed a typical small, round shape, and tightly packed Embryonic Stem Cell-like 
morphology with a high nucleus/cytoplasm ratio. 
Figure 3.19 – Confirmation of DAND5 allelic variant and healthy control cell line genotype. 
DNA sequence chromatograms of DAND5 exon 2 showing the c.455G>A allelic variant (highlighted by 
arrows) in the DAND5 allelic variant derived iPS cell line and a normal nucleotide sequence in the iPS 
cells from the healthy control. 
DAND5 allelic variant cell line Healthy control cell line 
C      T     C    G     C    A 
5´                                             3’ 
G     C      T    C  G/A  C    A      
5´                                             3’ 
 
 
 
 
 
 
 
 
 
 
3.2.2. Genotyping 
DNA Sanger sequencing confirmed the monoallelic presence of the c.455G>A 
substitution in the exon 2 of DAND5 gene, corresponding to a R152H amino 
acid protein alteration, in one clone of the iPSC line derived from the disease 
proband (Figure 3.19). As expected, this alteration was absent in the healthy 
control at the same nucleotide genomic localization (Figure 3.19). 
 
 
 
 
 
Clone #15 Clone #18 
Clone #9 Clone #7 
DAND5 allelic 
variant cell line 
Healthy control 
cell line 
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3.2.3. Pluripotency analysis 
To confirm the expression of pluripotency markers at mRNA level, gene 
expression analysis through quantitative RT-PCR was performed in two clones 
of each control and patient derived iPSC lines (we just show the values for one 
clone of each cell line because they are equivalent). According to our analysis, 
the expression of the endogenous pluripotency genes OCT3/4, NANOG, SOX2, 
KLF4 and NODAL was present at comparable or higher level in both proband-
derived and control iPSC lines (Figure 3.20) when compared to the expression 
of those genes in a common human embryonic stem cells line (H9). 
Furthermore, these pluripotency genes were absent in exfoliated renal epithelial 
cells (Figure 3.20). 
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Figure 3.20 – Pluripotency analysis at mRNA level.  
Expression of endogenous pluripotency-associated markers NANOG, OCT3/4, SOX2, KLF4, and 
NODAL in both control and patient-derived iPSC lines were confirmed by qPCR. H9 and exfoliated 
renal epithelial cells were used as positive and negative controls, respectively.  CT-values were 
normalized to the geometric mean of the two housekeeping genes GAPDH and β-actin and with H9 
human embryonic stem cell line as reference (set to 1). 
  
At the protein level, immunofluorescence analysis, of the same clones tested for 
pluripotency gene expression, confirmed the presence of the self-renewal 
transcription markers NANOG, OCT4, and the surface marker SSEA4 
characteristic of pluripotent embryonic stem cells in all cells from the colonies, 
illustrating also the homogeneity and purity of the newly-generated iPSC lines.  
These markers were equally expressed in both control and patient-derived 
iPSCs without obvious differences between both cell lines (Figure 3.21).  
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Figure 3.21 – Pluripotency analysis at protein level. 
Immunofluorescence showing positive detection of the pluripotency-associated markers NANOG, 
OCT4 and SSEA4 at protein level in both patient and control derived IPSC lines. 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.4. Karyotype 
To confirm that the iPSCs obtained through the transduction of the CytoTune® 
vectors, KOS (Klf4–Oct3/4–Sox2), hc-Myc, and hKlf4 into the renal epithelial 
cells maintain a proper genomic content, we performed the karyotype of the 
patient-derived iPSCs at passage 12. As presented in the figure 3.22 the 
karyotype of the patient-derived iPSCs seems to be normal, presenting 22 pairs 
of autosomal chromosomes and 1 pair of sex chromosomes. Nevertheless, a 
more detailed analysis of the chromosomes banding is currently ongoing to 
exclude possible subtle deletions, inversions, insertions, translocations, fragile 
sites and other more complex rearrangements. 
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Figure 3.22 – Karyotype of patient-derived iPSCs. 
Karyotype showing the normal 46, XX chromosomal arrangement of the patient-derived iPSCs. 
 
 
 
 
 
 
 
 
 
The differentiation potential towards the all three germ layers from both control 
and patient iPSC lines is also important for the complete characterization of the 
iPSC lines. However, we were unable perform this analysis so far due to time 
constrains. We believe we should be able to complete this analysis in the near 
future. Despite that, the data obtained so far for the characterization of the iPSC 
lines indicate that we were able to successfully generate iPSC lines starting 
from urinary samples from control and the patient containing the DAND5 
genomic variant identified during this work. Moreover, this battery of 
characterization assays allows us to select the clones that will be used to 
functionally determine the effect of the DAND5 alteration in a cardiomyocyte 
specific context. This strategy eliminates the issues regarding the invasive 
fibroblast collection procedures, with the advantage of facilitating the study of 
controls and patients’ samples, broadening the potential for iPSC–guided 
personalized medicine. 
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The formation of the heart involves an incredible and precisely orchestrated 
series of molecular and morphogenetic events that goes from commitment of 
unique lineages that will form distinct regions of the heart to decisions of cell 
migration, proliferation and death that ultimately result in the formation of a 
mature four-chambered heart. The complexity of the molecular cascades 
involved in these events may explain the sensitivity of the heart to perturbations 
in these processes, which have catastrophic consequences in the form of 
congenital heart defects. Congenital heart diseases impose a massive burden 
on societies around the world due to its incidence and prevalence, together with 
the fact that almost all the children that survive need continuous treatment 
during all his life (Fahed et al., 2013). In addition, the limited capacity of the 
heart to regenerate and the difficulty to uncover the etiology of most of CHD 
represents the major challenges for current medical research, practice and 
geneticists. Therefore, it is urgent to better understand the mechanisms and 
genetic causes underlying heart development and congenital heart defects in 
order to generate genetic testing, effective therapies and to adopt genetic 
counseling (Cowan & Ware, 2015).  
Although the major cardiovascular structures develop between the third and 
eighth week of gestation (Cecchetto et al., 2010), we cannot exclude that CHDs 
may be originated earlier, when the cardiac progenitor cells undergo their 
commitment and migration to the cardiac fields. During this migration, the 
cardiac progenitor cells are submitted to different signals in the right or left 
lateral plate mesoderm. Thus, the mechanism and molecules that regulate 
normal left-right establishment, including this asymmetric signaling in the lateral 
plate mesoderm, must also be considerate as potential causes or contributors 
to the CHDs presented by some patients. In fact, several phenotypes observed 
in children with complex heart disease are similar to those found in mice models 
for laterality disorders (Peeters & Devriendt, 2006), which led us to hypothesize 
that mutations in these genes could be responsible for some cases of human 
situs abnormalities and/or CHD. 
Left-right axis establishment is a highly conserved feature in which the Nodal 
pathway seems to be one of the major players (Shiratori & Hamada, 2014). 
Genetic alterations, in one or more genes, that alter the normal threshold of the 
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Nodal pathway and ultimately disrupt the normal left-right axis establishment, 
can cause a range of outcomes in the normal situs of the body. This includes 
situs inversus, a complete inversion of the axis, heterotaxy, an arrangement of 
internal organs somewhere between situs solitus and situs inversus, and also 
isomerism, meaning a bilateral sidedness of the organs (Ramsdell, 2005). 
These situations get worse when a wide spectrum of complex heart defects is 
associated, what normally happens (S. J. Kim, 2011). 
The work presented in this dissertation aimed to contribute for the 
understanding of the mechanisms and genetic causes underlying congenital 
heart defects arising from left-right disturbances in the initial developmental 
stages of life, before the beginning of heart morphogenesis. Our first focus was 
to translate the knowledge and observations obtained with the generation and 
analysis of the Cerl2/Dand5 KO mice (Araujo et al., 2014; Marques et al., 2004), 
which represents a model of laterality defects associated with a vast array of 
CHD, into new discoveries that allow to answer to the etiology of some CHDs in 
humans. To do that, we performed a genetic screening in the DAND5 genomic 
region of a 38 pediatric children cohort. DAND5 is a secreted growth factor that 
binds directly to NODAL and inhibits its signalling pathway during the formation 
of the embryonic left-right axis, being therefore an essential molecule in the 
establishment of this process (Marques et al., 2004). Cerl2/Dand5 KO mice 
embryos show a variety of laterality anomalies, including situs inversus, 
heterotaxy and right and left isomerism. Additionally, the mice presented a vast 
array of heart malformations, including randomized positioning of the cardiac 
apex, incomplete atrial and/or ventricular septation, inversion of the loop 
(leftward loop) and failure of the outflow tract rotation leading to TGA and DORV 
and severe hyperplasia of the ventricular myocardium. Moreover, a significant 
mortality rate within a few hours after birth is observed (Araujo et al., 2014; 
Marques et al., 2004). 
In addition to the DAND5 gene, we also extend the genetic screening to other 
three genes involved in the Nodal signaling pathway, NODAL, CFC1 and 
PITX2C in the same patients cohort. The cohort was composed with Caucasian 
non-familiar and isolated cases of CHD and/or laterality defects. Only seven 
patients presented clear laterality defects (left or right isomerism and situs 
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inversus) associated with cardiac malformations. Moreover, almost all the 
subjects manifest more than one cardiac defect, which is in agreement with the 
complexity, heterogeneity and diversity of CHD trait (Gelb & Chung, 2014). 
The sequencing analysis of the 38 patients cohort revealed three exonic 
variants, one of them in the NODAL antagonist – DAND5/Cerl2, one in the 
member of the TGF beta superfamily – NODAL and another in the NODAL co-
receptor – CFC1 and three intronic sequence variants one in the NODAL gene 
and two in the Nodal signaling effector transcription factor –  PITX2 isoform C.  
 
DAND5 allelic variant 
The DAND5 455G>A allelic variant was identified in two of our 38 patients 
cohort. One of the patients presented ventricular septal defect with overriding 
aorta, pulmonary atresia and left isomerism, while the other presented 
overriding aorta, ventricular septal defect, right ventricular hypertrophy and 
pulmonary atresia (a case of extreme tetralogy of Fallot). The functional effect 
of the variant, which leads to a substitution of an arginine for an histidine in the 
position 152 of the highly conserved cysteine-rich DAN domain, was further 
evaluated using a Nodal-dependent luciferase assay. The results showed a 
substantial decreased in the function of the DAND5 variant protein when 
compared to the wild-type DAND5 protein [see Chapter 3, Part I]. Although the 
phenotypes of both patients have a great degree of similarity, we cannot make 
a clearly phenotype-genotype correlation mostly because this variant was also 
annotated in public databases as single nucleotide variation and the apparently 
phenotypically normal mother of one of the patients presented the variant in its 
genome. Nevertheless, we cannot exclude the presence of a mild or 
undiagnosed heart defect on the mother of patient 2, or on the supposed 
healthy individuals of the genome projects, since detailed examination of these 
subjects is rarely available (Richards et al., 2015).  
Attending that these complex disease phenotypes rarely were completely 
predicted by the genotype, mostly due to its genetic heterogeneity, incomplete 
penetrance, variable expressivity and dose-sensitive genes (Cooper, Krawczak, 
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Polychronakos, Tyler-Smith, & Kehrer-Sawatzki, 2013), we cannot exclude that 
a functionally deficient common low penetrance genetic variant may act as 
modifier, influencing the phenotypic expression of a CHD alteration gene, 
depending on the individual genetic background (Cooper et al., 2013). Modifiers 
are genes capable of modifying the manifestation of a mutant gene without 
having an obvious effect on the normal condition (Grüneberg, 1963). So, the 
presence of a functionally deficient common modifier in human population 
would provide the opportunity for an individually rare deleterious sporadic 
mutation to manifest itself (Roessler et al., 2009). In other words, the offspring 
of a clinically normal mutation carrier and a common context-dependent 
modifier gene carrier might has an enhanced risk for malformations. In this 
view, neither parents are directly affected by being carriers of a deleterious 
gene; it is only the combination of alleles in the offspring that results in a 
recognizable clinical outcome. 
 
NODAL H165R variant 
The NODAL 494 A>G exonic variant, found in almost 90% of our patients, is 
localized in the pro-domain of the NODAL protein and leads to a amino acid 
substitution of an Histidine for one Arginine in the residue 165 (H165R). Taking 
into account that the probands with this alteration have a broad and different 
range of congenital heart defects and because the variant is referred in the 
public databases (NCBI, Ensemble and ExAC) as an extremely common SNP 
(rs1904589) we cannot make a genotype-phenotype correlation, neither 
associate the 494 G allele as a disease allelic variant.  
However, in 2008 and 2009, Maximilian Muenke and co-workers reported this 
variant in probands with a vast spectrum of cardiac malformations and/or 
laterality defects (Roessler, et al., 2008). In these studies, the author confirmed 
that the H165R variation was extremely common, being present in 
heterozygosity in approximately 50% of the normal controls. Moreover, they 
also verify the effect of the variant using a NODAL luciferase assay as a 
readout of the Nodal signaling activity and calculated the relative risk 
association between conotruncal defects and the H165H, H165R and R165R 
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genotypes. Their analysis showed that the variant allele leads to a great 
decrease (50%) in the functional activity of this mutant NODAL protein 
compared to the NODAL wild-type protein and that the H165H genotype were 
associated with decrease risk of conotruncal defects as compared to the H165R 
and R165R. Nevertheless, these relative risk was not statistically significant, 
suggesting that if the variant alleles (H165R/R165R) were associated with 
disease risk, it is a very week risk or only in a subset of conotruncal defects 
(Roessler et al., 2009). Altogether, these results indicate that this variant can 
alter the function of the NODAL protein, but besides being common in the 
general population, this alteration alone appears to be neutral to selection 
pressure since it is present both in chimpanzees and humans, as shown by 
their evolutionary analysis (Roessler et al., 2009). Therefore, once this 
alteration is so common among the normal population, and since there are not 
many amino acids conserved in the pro-domain where it is located they 
proposed that this alteration may serve as modifier of variants that occur in 
others Nodal signaling pathway components, with which NODAL normally 
interact. Modifier genes is one of the mechanisms responsible for reduced 
penetrance as shown in different inherited diseases such as pancreatitis, breast 
cancer, Gaucher disease and hypertrophic cardiomyopathy among other 
(Cooper et al., 2013). This idea is also supported by the evidence that 
differences in phenotype are observed when identical gene alleles are crossed 
in different strain background mice, suggesting that these phenotypic 
differences can be attributed to specific-strain modifiers (Nadeau, 2001; 
Roessler et al., 2008).  
 
Intronic Variants 
The splicing of introns out of pre-mRNA to create mature mRNA molecule 
requires hundreds of proteins and several small ribonucleoproteins, known as 
splicing machinery, that must act together to excise precisely the right intron 
(Ward & Cooper, 2010). Due to its complexity, this process is prone to genomic 
alteration that can result in the disruption of the splicing process of certain gene. 
Indeed, ~15% of known human disease-causing alterations are thought to affect 
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splicing (Fraser & Xie, 2009). Therefore, despite exonic variants are the major 
cause of alterations in the functional activity of a mature protein due to amino 
acid substitution, the deletions, insertions, and/or intronic variants in the exon-
intron boundaries could alter the proper maturation of the mRNA and should not 
be underestimated (Cartegni, Chew, & Krainer, 2002).  
In the strategy defined for this study, the primers designed to amplify the exons 
of the genes were localized in the intronic regions near the exon-intron 
boundaries. This strategy was performed with the purpose of identify new 
potential disease intronic variants and allowed us to identify three intronic 
variants, one in the NODAL gene and two in the Nodal signaling effector 
transcription factor –  PITX2 isoform C. As shown on Chapter 3 - Part II, the 
NODAL intronic variant, which is located twelve nucleotides downstream to the 
last coding triple (c.193+12C>T), was found in a total of twenty patients. Since it 
was present in patients with a vast array of phenotypes, from a simple case of 
isolated atrial septal defect to a complex right isomerism with asplenia, 
transposition of the great arteries, atrioventricular septal defect and pulmonary 
stenosis total anomalous pulmonary venous connection and was also annotated 
in the public databases (Ensemble, NCBI and ExAC) as an extremely common 
SNP – rs10999338 – with a heterozygosity of 45% and a minor allele frequency 
(T) of 44% in the European population sequenced in the 1000 genomes project, 
we  cannot  conclude  that  this variant is a disease allele neither establish a 
genotypic-phenotype correlation. However, and because this alteration is 
located very close to a splice site, we cannot discard the hypothesis that this 
c.193+12 C>T variant can be affecting the process of splicing, namely the 
interaction between the proteins of spliceosome and the RNA. In fact, an 
intronic alteration 12 nucleotides after the end of one exon of the BRCA2 gene 
was identified and related to splicing aberrations in a breast cancer study 
(Whiley et al., 2011). The in silico analysis presented in the Chapter 3, Part II, 
showed that c.193+12 C>T alteration may lead to the creation of an important 
enhancer motif for the ligation of the SF2/ASF splicing factor and a creation of a 
motif that allows the biding of the SRp55 protein with more affinity. SF2/ASF 
and SRp55 protein facilitates and promotes 5´ and 3´ splice sites recognition 
and exon definition by interacting and recruiting other spliceosome proteins 
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(Richardson et al., 2011). Thus, the creation of new motifs for the biding of 
these proteins may alter the definition of the exons, resulting in abnormal mRNA 
transcripts and ultimately the final protein as well its functional activity. We are 
currently designing a functional splicing assay in order to elucidate if this 
alteration really alters the splicing process and to understand its functional 
effect on the NODAL final protein and their correlation with the observed 
phenotypes.  
 
The PITX2C intronic variants were found 71 and 88 nucleotides after the end of 
the coding region of the exon 1B of the PITX2 isoform C gene. As shown in 
Chapter 3, part II, both variants were classified as SNP by the NCBI and 
Ensemble databases, and so far they were not associated to any disease or risk 
for develop a certain disease. In this study, we observed both variants in our 
patients but we cannot make a genotype-phenotype correlation or associate the 
variants as disease or disease risk variants. To make such correlation we will 
perform a functional assay to verify the truly effect of the variants in the splicing 
patterns of the PITX2C gene. Nevertheless, the in silico analysis performed 
using the Human Splicing Finder software gave us a clue of what could be 
effect of these variants in the splicing process of PITX2C gene. The analysis 
presented in Chapter 3, part II, shown that the c.205+71 A>G allelic alteration 
could result in the disruption of splice site acceptor and branch point site 
sequences and could lead to the creation of a new splice donor site. In addition, 
the in silico analysis also revealed that this variant could disrupt the splicing 
enhancer motifs responsible for the ligation of SF2/ASF and 9G8 and disrupt 
the silencer motif in which the hnRNP A1 protein binds. 
The splice site acceptor, splice site donor and branch point site represent three 
core sequences elements that are essential for splicing, being recognized 
multiple times by components of the spliceosome during the processes of intron 
removal and exon joining (Ward & Cooper, 2010). Although these three 
components are essential for the splicing process, they are not sufficient for 
defining the exon-intron boundaries (Ward & Cooper, 2010). For that purpose, 
the splicing machinery requires additional cis-acting sequences, named as 
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intronic or exonic splicing enhancers (ISE or ESE) or silencers (ISS or ESS) 
and located within exons and introns, that recruit trans-acting splicing factors to 
ensure inclusion of constitutive exons or modulate the efficiency of splice site 
recognition, promoting alternative splicing (Ward & Cooper, 2010). Enhancer 
elements are bound by positive regulators that increase exon inclusion, such as 
the SR protein family, in contrast, silencer elements are bound by negative 
regulators that decrease exon inclusion, such as the abundant hnRNP proteins 
(Ward & Cooper, 2010). Therefore, if one of these sites could be potentially 
broken or newly created, it was reasonable to consider that the normal process 
of splicing could be alternated, either by exon skipping, activation of a cryptic 
splice site, or intron retention (Baralle & Baralle, 2005), all resulting in an 
abnormal mRNA molecule and an abnormal final PITX2C protein, ultimately 
leading to expression of different mRNA variants that affect disease 
susceptibility and severity. A more detailed analysis using functional assays is 
needed in order to elucidate the effect of this alterations in the isoform C of the 
PITX2 final protein and their correlation with the phenotypes of the patients. 
 
The experimental and in silico analysis for the variants identified in this study 
were performed taking into the account each variant isolated. However, many of 
the patients presented more than one of the variant alleles in their genomes, as 
shown in table S2 (Supplementary Material 7). For instance, the patients that 
presented the DAND5 variant also carry two more alterations in the NODAL 
gene, the c.193+12 C>T and the p.H165R, and one in the PITX2C gene. These 
NODAL alterations may also be interfering with the interaction between NODAL 
and DAND5 proteins and if we consider that the common polymorphism 
NODAL p.H165R, which decreases the bioactivity of NODAL to 50%, acts as a 
modifier, as proposed by Roessler et al. 2009  (Roessler et al., 2009), the 
genetic interaction between the two allelic variants (NODAL (p.H165R) and 
DAND5 (p.R152H)) might increase even more the risk of disease. Moreover, 
the intronic alterations in NODAL and PITX2C may have a cumulative effect in 
the imbalance of the proper levels of the NODAL signaling. Therefore, it is 
important to appraise that the cumulative impairment of the Nodal pathway due 
to variants in the different genes might increase the susceptibility to CHD more 
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than the contribution of a single gene. This situation was also verified in others 
studies, namely the study conducted by Ressler and colleagues, in which they 
attribute the cumulative impairment of the Nodal signaling due to alterations in 
several genes of this pathway as a possible cause for the phenotype of some 
patients (Roessler et al., 2008) and the study performed by Lowe et.al, in which 
they verify that conditional holomorphic Nodal variants shown distinct 
phenotypes, depending on the Nodal dosage (Lowe, Yamada, & Kuehn, 2001).  
Therefore, while isolated deleterious gene alterations are rare, collectively, 
common variants within a pathway of interacting genes add up to a 
considerable genetic burden. While simple heterozygosity for one of these loss-
of-function alleles might not be considered sufficient, it can be considered 
necessary for the observed phenotype(s), which explains their common 
incidence. 
Taken together, this evidences with our data from the DAND5 variant, indicate 
that the imbalanced dosage-sensitive in the Nodal signaling, due to alterations 
in several of their components, is a final remark conferring risk for laterality 
defects and related CHD.  
 
Patient iPSC line generation 
Cerl2, or its homolog in humans DAND5, is an extracellular protein belonging to 
the family of TGF-β/Nodal signaling antagonists Cerberus/DAN. Dand5/Cerl2-
mediated antagonism of Nodal signaling requires Dand5/Cerl2 binding to the 
ligand Nodal, which consequently prevents the interaction of Nodal with the 
receptor and subsequent signaling activation. In mice, Cerl2 has an important 
role in the establishment of the left-right axis, regulating the Nodal signaling at 
the node and the transmission of the LR asymmetry information to the left-
lateral plate mesoderm (LPM) in a precise time window (Inacio et al., 2013; Oki 
et al., 2009). In agreement with this, absence of Cerl2 in Cerl2 KO embryos 
leads to a wide range of asymmetry defects defined as situs ambiguus, and a 
significant mortality rate within a few hours after birth due to cardiac defects, 
being some of them laterality-associated ones (Marques et al., 2004). 
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Interestingly, it was also observed a massive increase of the ventricular 
myocardial walls in Cerl2/DAND5 KO mice that cannot be explained by laterality 
defects (Araujo et al., 2014). This increased ventricular mass is caused by 
increased cardiomyocyte mitotic index associated with increased levels of 
phospho-Smad2, suggesting prolonged TGF-β/Nodal signaling in the heart 
(Araujo et al., 2014). Since, TGF-β signaling pathways are known to influence 
growth and early cardiac specification, proliferation and differentiation (Araujo et 
al., 2014; Klaus et al., 2012), Cerl2/DAND5, the only member of this family 
expressed in the heart, seems to be specifically required in the heart to control 
cardiomyocyte proliferation through the control of TGF-β/Nodal signaling 
(Araujo et al., 2014). Therefore, and once that the DAND5 455G>A, identified in 
two of our patients cohort, lead to an increasing in the Nodal signaling, we 
hypothesized that, like Cerl2/DAND5 KO mice, this human variant most likely 
can also affect the proliferation and maturation of ventricular cardiomyocytes. 
To test this hypothesis, Patient-specific and control induced pluripotent stem 
cell lines were generated to model the disease of one of the patients that was 
identified carrying the DAND5 p.R152H variant. The iPSCs were obtained 
through a laborious protocol starting from cells isolated from urine samples of 
each individuals that were further reprogramed back to a stem cell state using 
the four Yamanaka factors, SOX2, OCT3/4, c-MYC and KLF4. The results 
obtained from the initial characterization of the iPSC lines, analyzing the 
morphology, pluripotency state and the karyotype of the iPSC derived clones, 
indicate that the cell lines were generated successfully. Nevertheless, a final 
characterization recurring to the analysis of the differentiation potential towards 
the all three germ layers from both control and patient iPSC lines is needed in 
order to really validate both cell lines as iPSC.  
As soon as this final characterization is completed, we will proceed to the 
differentiation of these iPSC into cardiomyocytes to determine whether the 
proliferation is affected by the DAND5 variant. To do that, we will perform a 
comparative analysis of the differentiation and proliferation potential of control 
and patient-derived iPSCs. Furthermore, we will perform the functional 
characterization of the differentiated cardiomyocytes, culturing these cells on a 
PDMS flexible substrate and paced by field stimulation. Single cell force 
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measurement will be performed with traction force microscopy using the 
changes in cellular dimensions and the substrate stiffness to calculate force 
generated at single cell resolution. Calcium cycling will also be concurrently 
accessed via fluorescence imaging with the calcium dye Fluo-4AM. 
Alternatively, action potential morphology will be accessed via fluorescence 
imaging with the transmembrane voltage reporter FluoVolt [28, 29]. Confocal 
imaging will be used to quantify the force generated, action potential 
morphology, and calcium cycling in these human stem cell derived CMs. If we 
observe an ectopic function or proliferation of the variant derived 
cardiomyocytes, we can functionally address and recover the cause of the 
defect(s) using drugs that may target these processes. 
 
Conclusion 
Altogether, the basic research approach with a translational medicine 
perspective presented in this thesis, allowed us to identify 5 variants in different 
genes of a pediatric unrelated CHD and/or laterality defect cohort. Although we 
cannot make a clearly genotype-phenotype correlation for each variant alone, 
we verify that the DAND5 p.R152H variant disrupts the proper levels of Nodal 
signaling in the lateral plate mesoderm and thus might function as a risk allele 
for CHDs and/laterality defects. Despite the fact that the phenotypes presented 
by the two carriers of the DAND5 variant were not exactly equal, they result 
from errors during the LR axis formation, representing a case of incomplete 
penetrance or variable expressivity. This is in agreement with the complexity of 
the CHD/ laterality trait and may reflect the action of modifier gene alterations or 
other genetic variants within the pathway that exacerbate or ameliorate the 
effect of the DAND5 alteration and the patients phenotypes. According with this 
hypothesis, it seems that the functional abnormal p.H165R NODAL variant 
could act as a modifier gene variant and thus might play a role in the 
phenotypes of the patients. Furthermore, we cannot exclude the possibility that 
the PITX2C variants and the NODAL intronic variant, which were predicted to 
alter the splicing process of the mRNA transcripts, act in the same way.  
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Therefore, the allelic variants found in this study might not function as disease 
alleles per si but probably increase the susceptibility to disease. Nevertheless, 
since most of the patients presented more than one alteration, the cumulative 
effect of each variant within the pathway seems to enhance even more the risk 
for disease. This, prompt us to evaluated the potential causes of CHDs through 
a multi-gene approach, testing several genes involved in the same pathway. 
Moreover, we start to look further, and using the currently well-established iPSC 
technology we successfully generated patient and control iPS derived cells. 
Those iPSCs will be used in the future to understand the cellular and molecular 
mechanisms of disease behind a simple nucleotide variant, allowing us to study 
the role of other interacting variants with the final purpose of developing a 
personalized medicine for each patient. 
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Supplementary Material 1 
Declaração de consentimento informado 
Para a realização de estudos genéticos 
Eu, ___________________________________________________, portador 
do Bilhete de Identidade nº ____________ do Arquivo de Identificação de 
_____________, autorizo que se faça a colheita de células bucais por esfregaço da 
parte interna da bochecha (técnica não invasiva nem dolorosa), ao meu/minha filho(a) 
________________________________________, nascido(a) em __ / ___/ ______, 
portador(a) de Cardiopatia Congénita Complexa. 
O material biológico recolhido destina-se à realização de estudos genéticos 
sobre a base molecular da Cardiopatia Congénita e Defeitos da Lateralização, no 
âmbito do projeto de investigação “Estudo Molecular dos Genes Homólogos Humanos 
Envolvidos na Definição da Assimetria do Coração “, em curso no Centro de 
Biomedicina Molecular e Estrutural, Universidade do Algarve. 
Declaro ter sido informado(a) que o material biológico assim recolhido será 
utilizado apenas para os fins atrás definidos. 
Declaro ter sido informado(a) que é assegurada, em qualquer situação, a 
confidencialidade dos dados pessoais e genéticos resultantes deste (s) estudo (s) e 
que fica salvaguardada a possibilidade de eu aceder à informação existente sempre 
que o desejar. 
Declaro autorizar / não autorizar* a recolha de imagens e a utilização dos 
resultados para fins de investigação, no âmbito deste conjunto de patologias, bem 
como a sua apresentação em reuniões científicas, desde que fique garantida a 
confidencialidade. 
 
Assinatura: __________________________________________________; Data: __ / 
__ / ______ 
Local da colheita: __________________________;   Rúbrica do técnico: 
__________________ 
* riscar o que não interessa                   Identificação da(s) amostra(s): CBME HCF 
  
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Supplementary Material 2  
Estudo Molecular dos Genes Homólogos Humanos, Envolvidos 
na Definição da Assimetria do Coração 
 
Identificação da amostra:  
 
Amostra biológica -       Data da colheita:       /       / 
 
Familiares: 
CBME            ; grau de parentesco:     ________________ Data de Nascimento:      /       
/        / 
Observações:__________________________________________________________
__________ 
CBME            ; grau de parentesco:      ______________ Data de Nascimento:      /       
/   
Observações:__________________________________________________________
__________    
Diagnóstico clínico 
Caso único:    S/N        História familiar:    S/N       
 
 
Heterotaxia   Isomerismo Esquerdo/ Direito  
   
Malformação cardíaca   
Transposição/mal posição dos 
grandes vasos 
 Atrésia da artéria pulmonary  
Ventrículo esquerdo de dupla entrada 
Ventrículo direito de dupla saída 
 Defeitos do septo atrioventricular 
DISAV* 
Coração hipoplástico 
 
  
Hipertrofia do ventrículo direito   Outra:   
   
Malformação gastrointestinal   
Estômago rodado para o lado direito   Fígado na linha média  
Anomalias do tracto biliar   Mal rotação intestinal  
Poli ou asplenia  Outra: 
__________________________ 
 
Observações:  
Assinatura da Declaração de Consentimento Informado: S/N  
Data:       /       /      Rubrica:  
nº processo origem:        CBME             
Data Nascimento:        /        /              ;   Sexo M     / F        
Instituição de origem:  
Médico de Contacto:       Telefone:  
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DNA isolation from buccal swabs samples, BIOLINE protocol 
1. Place the swab in a 1.5ml microcentrifuge tube. Add 400μl Lysis Buffer D 
and 25μl Proteinase K. Mix by vortexing vigorously for 5 seconds. Incubate at 
50ºC for 10-15 minutes. 
2. Remove the swab from the tube and scrape it against the side of the tube 
to recover as much of the liquid as possible. Discard the swab. 
3. Add 200μl Binding Buffer D to the lysed sample and mix by vortexing for 
15 seconds. 
4. Transfer the sample to Spin Column D placed in a 2ml Collection Tube. 
Centrifuge at 10,000 x g (12,000rpm) for 2 minutes. Discard the Collection Tube 
and place the Spin Column in a new Collection Tube. 
5. Add 700μl Wash Buffer D. Centrifuge at 10,000 x g (12,000rpm) for 1 
minute. Discard the filtrate and reuse the Collection Tube. 
6. Repeat step 6. 
7. Centrifuge at maximum speed for 2 minutes to remove all traces of 
ethanol. Discard the Collection Tube. 
8. Place Spin Column D in a 1.5ml Elution Tube. Add 200μl Elution Buffer 
or H2O nuclease free directly to the membrane of the column. Incubate at room 
temperature for 1 minute. Centrifuge at 6000 x g (8000rpm) for 1 minute to elute 
the DNA. 
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Ethanol precipitation protocol 
 
Ethanol and sodium acetate precipitation protocol 
1. Add 1/10 volume of sodium acetate, pH 5.2, (final concentration of 3 M) 
and mix well. 
2. Add 2 to 2.5 volumes of cold 100% ethanol. Mix well. 
3. Place on ice or at -20ºC for >20 minutes. 
4. Spin at maximum speed and 4ºC in a microfuge for 20 minutes. Carefully 
decant supernatant.  
5. Add 250 µl of cold 70% ethanol. Mix.  
6. Spin at maximum speed and 4ºC in a microfuge for 5 minutes. Carefully 
decant supernatant.  
7. Air dry or briefly vacuum dry pellet and resuspend the pellet in the 
appropriate volume of TE or nuclease-free water. 
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INFORMAÇÃO AO DADOR DE AMOSTRAS BIOLÓGICAS 
 
Título do projecto de investigação 
” Controlo da proliferação de cardiomiócitos na doença e em medicina regenerativa” 
 
Objetivo do Estudo 
Do projeto de investigação, do qual o Professor Doutor José Belo é o responsável, “Estudo 
Molecular dos Genes Homólogos Humanos Envolvidos na Definição da Assimetria do 
Coração”, protocolado anteriormente entre o CBME (Centro de Biomedicina Molecular e 
Estrutural, da Universidade do Algarve) e o Hospital de Faro (Centro Hospitalar Algarve, EPE), 
resultou a identificação de variantes genómicas em doentes. No seguimento deste projeto e 
com o objetivo da realização de um estudo mais aprofundado do mecanismo da doença, será 
criada uma linha de células estaminais pluripotentes induzidas (iPS cells) a partir de células 
somáticas isoladas dos doentes. Para tal será necessário a recolha de produto biológico (urina) 
de cada doente.  
O material biológico recolhido destina-se apenas à realização de estudos de investigação 
biomédica no âmbito da continuação dos estudos “Controlo da proliferação de cardiomiócitos na 
doença e em medicina regenerativa”, agora em curso no Centro de Estudos de Doenças 
Crónicas, Faculdade de Ciências Médicas, Universidade Nova de Lisboa. 
 
Procedimentos 
No caso de concordar continuar a participar neste projeto, ser-lhe-á apenas pedido uma amostra 
de urina (técnica não invasiva nem dolorosa). Estas colheitas serão efetuadas sem alterar os 
procedimentos médicos habituais e sem interferir com a consulta dos doentes. A amostra será 
preservada em condições apropriadas e transportada para o Laboratório de Células Estaminais 
e Desenvolvimento, localizado no CEDOC, de modo a ser processada. A partir de Células 
epiteliais isoladas da urina, estas serão reprogramadas por métodos convencionais de modo a 
criar linhas de células estaminais pluripotentes induzidas (iPS cells). Estas células poderão então 
ser utilizadas para derivação de células diferenciadas de várias linhagens somáticas 
nomeadamente cardíacas de modo a podermos estudar o papel desta mutação na 
diferenciação e função de células cardíacas. As informações clínicas relacionadas com a 
amostra serão introduzidas numa base de dados, passando a sua identificação pessoal a estar 
codificada e só acessível aos investigadores que realizam o estudo. A decisão de doar amostras 
é totalmente voluntária, pelo que o dador tem o direito de recusar. O doente é livre para 
interromper a sua colaboração no estudo, em qualquer momento, sem que com isso seja 
 152 
 
Chapter 6 Supplementary Material 
prejudicado no seu acompanhamento clínico, na instituição. Serão cumpridas todas as normas 
éticas aceites internacionalmente para o uso de materiais biológicos para fins de investigação. 
Não se antevê a utilização comercial ou benefícios financeiros que resultem diretamente das 
células obtidas do dador. 
 
Identificação das amostras e Confidencialidade 
Após a colheita, as amostras serão identificadas por um código de forma a preservar a 
privacidade. 
Os dados serão tratados confidencialmente, de acordo com a Lei (LEI 12/2005, ARTIGO Nº 19 
DIÁRIO DA REPÚBLICA – I SÉRIE A, Nº 18 DE 26 DE JANEIRO DE 2005), com os 
regulamentos e de acordo com as normas éticas aprovadas pela Comissão de Ética do Hospital 
de Faro (Centro Hospitalar Algarve). Os dados resultantes dos estudos realizados serão apenas 
alvo de publicação científica em revistas da especialidade de forma anónima. Toda a 
investigação efetuada estará sob a supervisão da Comissão de Ética do Centro Hospital Algarve 
que assegurará o cumprimento dos regulamentos mencionados. 
 
Possíveis benefícios para os participantes 
Esta é uma doação altruísta, não havendo por isso qualquer compensação para o dador. Não 
se garante que este estudo envolva quaisquer benefícios directos para o participante. No 
entanto, a sua participação proporcionará a aquisição de conhecimentos que poderão vir a 
beneficiar terceiros no futuro. Fica salvaguardada a possibilidade dos participantes acederem à 
informação existente sempre que o desejarem. 
 
Riscos físicos previsíveis 
Tendo em conta a natureza do procedimento utilizado para a recolha da amostra biológica, os 
riscos e o desconforto associados serão mínimos ou inexistentes. 
 
Se tiver qualquer dúvida, em qualquer momento, mesmo após a colheita, sobre este 
estudo poderá contactar o Responsável pelo estudo:  
José António Belo, Faculdade de Ciências Médicas, Universidade Nova de Lisboa. 
Edifício CEDOC II, Rua Câmara Pestana n.º 6, 6- A e 6- B. 1150-082 Lisboa. Portugal 
Email: jose.belo@fcm.unl.pt   Tel: +351 21 8803102 Fax: +351 21 8803010 
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DECLARAÇÃO DE CONSENTIMENTO INFORMADO 
 
 
Eu, ___________________________________________________, portador do 
Bilhete de Identidade nº/CC nº ____________ do Arquivo de Identificação de 
_____________, autorizo que se faça a colheita de amostra biológica, urina, ao 
meu/minha filho(a) ________________________________________, nascido(a) em __ 
/ ___/ ______, portador(a) de Cardiopatia Congénita Complexa. 
O material biológico recolhido destina-se à realização de estudos de investigação 
biomédica sobre a base molecular da Cardiopatia Congénita e Defeitos da Lateralização, 
no âmbito do projeto de investigação “Controlo da proliferação de cardiomiócitos na 
doença e em medicina regenerativa “, em curso no Centro de Estudos de Doenças 
Crónicas, NOVA Medical School | Faculdade de Ciências Médicas, Universidade Nova 
de Lisboa. 
Declaro ter sido informado(a) que o material biológico assim recolhido será 
utilizado apenas para os fins atrás definidos. 
Declaro ter sido informado(a) que é assegurada, em qualquer situação, a 
confidencialidade dos dados pessoais e genéticos resultantes deste (s) estudo (s) e que 
fica salvaguardada a possibilidade de eu aceder à informação existente sempre que o 
desejar. 
Declaro autorizar / não autorizar* a recolha de imagens e a utilização dos 
resultados para fins de investigação, no âmbito deste conjunto de patologias, bem como 
a sua apresentação em reuniões científicas, desde que fique garantida a 
confidencialidade. 
 
Assinatura: __________________________________________; Data: __ / __ / ______ 
Local da colheita: _____________________;Rúbrica do técnico: __________________ 
* riscar o que não interessa       Identificação da(s) amostra(s): CEDOC HCF   
(formato HCF 0000 – numeração sequencial) 
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Table S1 
 Table S1.  DAND5 c.455 G>A allele frequency according to ExAC genome project 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gene Variant Variant rs number 
DAND5 c.455 G>A / p.R152H 
 
45513495 
 
Population Allele frequency (%) Number of homozygous 
 
European (Finnish) 
 
2,4 2 
 
European (Non-Finnish) 
 
1,5 14 
 
All populations 
 
1 16 
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Table S2 
Table S2.  Genotypes of the 38 patients cohort for the variants found in this study. 
Proband DAND5 NODAL CFC1 PITX2C 
HStM001 --- 
C193+12T 
A494G 
--- --- 
HStM004 --- --- --- A205+71G 
HStM006 --- --- --- --- 
HsTC001 --- 
C193+12T 
A494G 
G523A G205+88C 
HStC002 --- A494G --- --- 
HsTC003 --- A494G --- --- 
HsTC004 --- --- --- G205+88C 
HsTC005 --- 
C193+12T 
A494G 
--- A205+71G 
HsTC006 --- 
T193+12T 
G494G 
--- G205+71G 
HsTC007 A455G 
C193+12T 
G494G 
--- G205+88C 
HsTC008 --- 
C193+12T 
A494G 
--- A205+71G 
HsTC009 --- A494G --- C205+88C 
HsTC010 --- A494G --- --- 
HsTC011 --- A494G --- --- 
HCF001 --- 
C193+12T 
A494G 
--- G205+88C 
HCF002 --- 
C193+12T 
G494G 
--- G205+88C 
HCF003 --- 
C193+12T 
A494G 
--- A205+71G 
HCF004 --- A494G --- C205+88C 
HCF005 --- A494G --- --- 
HCF006 --- --- --- A205+71G 
HCF007 --- 
C193+12T 
A494G 
--- G205+71G 
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HCF008 --- A494G --- --- 
HCF009 --- A494G --- --- 
HCF010 --- G494G --- C205+88C 
HCF011 --- 
T193+12T 
G494G 
--- C205+88C 
HCF012 --- 
C193+12T 
A494G 
--- G205+88C 
HCF013 
--- 
C193+12T 
A494G 
--- G205+88C 
 
HCF014 --- A494G --- --- 
HCF015 --- A494G --- --- 
HCF017 --- 
C193+12T 
A494G 
--- G205+88C 
HCF019 --- 
T193+12T 
G494G 
--- G205+88C 
HCF021 --- 
C193+12T 
A494G 
--- 
A205+71G 
G205+88C 
HCF023 --- 
C193+12T 
A494G 
--- --- 
HCF025 A455G 
C193+12T 
A494G 
--- --- 
HCF027 --- 
C193+12T 
A494G 
--- G205+88C 
HCF029 --- 
C193+12T 
A494G 
--- G205+88C 
HCF030 --- G494G ---  
HCF032 --- --- --- G205+88C 
 
 
